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Characterization of lung tumor-propagating cells reveals a role for CD24 and  
 
Yap/Taz in lung cancer progression and metastasis 
ABSTRACT 
 Lung cancer is the leading cause of cancer deaths worldwide. A large part of this 
high mortality rate is due to the onset of metastatic disease prior to diagnosis. Advances 
in treatment for metastatic disease may be achieved by understanding more about the 
identity of metastatic tumor cells and the mechanisms those cells employ to spread 
throughout the body. This thesis examined the relationship between cells capable of 
tumor propagation upon serial transplantation (tumor-propagating cells, or TPCs) and 
those with metastatic potential. 
 An orthotopic transplantation assay, in which tumor formation and metastatic 
growth were measured, revealed the relationship between lung TPCs and metastasis.  
First, CD24 was identified as a TPC marker in murine lung adenocarcinomas. CD24 
expression status was not sufficient to identify lung cancer cells with enhanced 
metastatic capacity. Selection of tumors cells expressing both TPC markers Sca1 and 
CD24 enabled enrichment for TPCs with metastatic potential. Knockdown of CD24 in 
murine lung adenocarcinoma cells resulted in reduced migration in vitro and less 
metastatic tumor formation in vivo, demonstrating a functional role for CD24 in lung 
cancer cell metastasis. 
 Gene expression analysis demonstrated that many genes in the Hippo pathway 
and targets of the Hippo mediators Yap and Taz were differentially expressed in lung 
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TPCs.  A gene signature of Yap/Taz targets was significantly associated with worse 
lung adenocarcinoma patient survival and metastasis. Knockdown of Yap and Taz in 
murine lung adenocarcinoma cells showed that Yap and Taz are important for lung 
cancer cell migration.  Taz was especially important for metastatic properties of these 
cells in vivo. Activation of Yap in a mouse model of lung adenocarcinoma increased 
tumor progression and number. These results show that Yap and Taz play an important 
role in lung tumor migration, progression and metastasis. 
The work described here provides insight into the relationship between TPCs and 
metastasis and identifies pathways utilized by metastatic lung cancer cells.  Future 
studies defining the detailed mechanisms by which CD24 and Yap/Taz activity affect 
lung cancer metastasis may lead to new treatment options for this deadly disease. 
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CHAPTER 1: 
 
 Introduction 
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At the time of submission of this dissertation, excerpts from the work presented in this 
chapter have been published in Molecular Therapy as a review entitled Stem cells and 
regenerative medicine in lung biology and diseases. All writing and figures in this 
chapter were created by ANL.  
 
Cancer and Metastasis 
In the United States, roughly one in three women and one in two men will 
develop cancer in his or her lifetime (Siegel et al., 2013). One in four deaths in the 
United States is due to cancer; within Hispanic and Asian Americans, cancer has 
overcome heart disease to become the most common cause of death (McCracken et 
al., 2007; Siegel et al., 2012). Despite the “war on cancer” that was declared in 1971, 
the survival of patients with metastatic disease has scarcely changed (Leaf, 2004). 
Because of the rise of cancer incidence and death in the 20th century many of us 
think of cancer as a modern disease (Jones et al., 2012). Since cancer increases with 
prevalence as we age, this increase in incidence is largely due to the fact that life 
expectancy in the U.S. has increased by about 30 years in the last century (Arias et al., 
2008). However, evidence of cancer has been around for thousands of years. The 
ancient Greek physician Hippocrates first introduced the term karkinos (or carcinos, 
carcinoma), the Greek word for crab, to describe the image of a tumor surrounded with 
its blood vessels and projections around 400 BC (Sakorafas and Safioleas, 2009). 
However, there are records and evidence of cancers dating back many thousands of 
years. The first known recording of cancer was written on what is known as The Edwin 
Smith Papyrus in the seventeenth century BC, and is thought to be the teachings of 
	  	  	   3	  
Imhotep, an Egyptian physician who lived around 2635 BC (Sakorafas and Safioleas, 
2009). Scientists have uncovered mummified remains of malignant tissue dating to 
around 400 AD, as well as skeletons with signs of metastatic tumors growing in the 
bones from much more ancient relics (Aufderheide, 2003; Prates et al., 2011; Schultz et 
al., 2007). In fact, cancer may be one of the oldest human diseases.  
There are several properties or “hallmarks” that all cancers are purported to 
share. These include genome instability and mutation, resisting cell death, deregulating 
cellular energetics, sustaining proliferative signaling, evading growth suppressors, 
avoiding immune destruction, enabling replicative immortality, tumor-promoting 
inflammation, inducing angiogenesis, and activating invasion and metastasis (Hanahan 
and Weinberg, 2011). 
This thesis will focus on the last hallmark of cancer: invasion and metastasis. 
Metastasis is estimated to be responsible for 90% of cancer-associated mortality 
(Chaffer and Weinberg, 2011). The term “metastasis” for the spread of cancer was 
coined by the French physician Joseph Recamier in 1829 (Carr and Carr, 2005). In 
1889, Stephen Paget was the first to attempt to identify which organs that breast 
cancers metastasized to, and developed what is known as the “seed and soil” 
hypothesis (Paget, 1989; Talmadge and Fidler, 2010). Paget wrote, “When a plant goes 
to seed, its seeds are carried in all directions, but they can only live and grow if they fall 
on congenial soil” (Paget, 1989). Ewing later challenged this hypothesis, proposing that 
mechanical forces and circulatory patterns were responsible for organ specificity in 
metastasis (Ewing, 1928). Fidler and colleagues later showed using parabiosis 
experiments that the pattern of metastasis formation was dependent on tumor cell 
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properties and host factors, further supporting the seed and soil hypothesis (Hart and 
Fidler, 1980). 
Today, it is understood that metastasis is made up of a “cascade”, or sequence 
of events (Chaffer and Weinberg, 2011; Hanahan and Weinberg, 2011). This cascade 
can also be thought of as two distinct phases: dissemination and colonization. First, 
cancer cells must locally invade the surrounding tissue and intravasate into the 
vasculature of the blood vessels or lymph. Next, cells must survive and migrate through 
the vessels and then extravasate into the new metastatic site. Finally, the tumor cells 
must be able to survive and grow in the new microenvironment to form a new tumor.  
 
Lung Cancer 
Lung cancer is an ideal system to study metastasis since ~85% of patients 
present with metastatic disease; the five year survival rate for lung cancer is ~15% 
(Siegel et al., 2013). Lung cancer is the leading cause of cancer-related death for both 
men and women worldwide; over 1.3 million people die of this disease every year 
(Ferlay et al., 2010; Siegel et al., 2013). This is largely due to the carcinogenic affects of 
cigarette smoke, yet about 10-25% of lung cancer cases worldwide occur in never-
smokers (Ferlay et al., 2010). Air pollution such as radon, household fumes such as 
coal and wood burning fumes or cooking oil vapors, as well as industrial hazards such 
as asbestos and radiation exposure are also known to play a role in lung cancer risk 
(Hammond et al., 1979; Mumford et al., 1987; National Research Council, 1999; Neugut 
et al., 1994). There are two histological subtypes of lung cancer: small cell lung cancer 
(SCLC) making up about 20% of lung cancer cases, and non-small cell lung cancer 
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(NSCLC), 80% of cases. Non-small cell lung cancer is further subdivided into three 
groups: large cell carcinoma, squamous cell carcinoma, and adenocarcinoma (Travis et 
al., 1999).  
Lung adenocarcinoma is characterized by glandular differentiation and mucin 
production, as well as formation in the peripheral lung (Travis et al., 1999). 
Adenocarcinoma is the most prevalent subtype of lung cancer overall and is the most 
common form of lung cancer seen in never-smokers (Toh et al., 2006). Conversely, 
smoking has historically been associated with small cell lung cancer and squamous cell 
carcinoma, although more smokers are now developing adenocarcinoma, thought to be 
due to the changes in cigarettes over the past few decades (Hoffmann et al., 2001). 
Common mutations in lung adenocarcinoma are activating mutations in the genes 
KRAS (~30%), BRAF, ERBB2 (HER2), and PIK3CA, and loss of function mutations in 
TP53 (~50%), STK11 (LKB1) (over 15%), RB1, NF1, CDKN2A, SMARCA4, and KEAP1 
(Ding et al., 2008; Imielinski et al., 2012). Other common mutations include alterations 
in EGFR (over 15%) and ALK (Ding et al., 2008; Imielinski et al., 2012). There are now 
mouse models of lung adenocarcinoma that incorporate mutations in many of these 
genes as oncogenic drivers. 
 KRAS is member of the Ras family of proto-oncogenes that encode a 
membrane- bound GTPase signaling protein important for proliferation, differentiation, 
and survival (Karnoub and Weinberg, 2008). When bound to GDP, Ras proteins are 
inactive. Activation of upstream growth factor receptors results in a switch to a GTP-
bound Ras protein, which then activates downstream pathways such as MAPK or PI3-
K. Oncogenic mutations in Ras proteins can affect the GTPase activity of the proteins, 
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blocking inactivation of the protein back to its GDP-bound state. The mouse model of 
adenocarcinoma developed by Tyler Jacks and colleagues carries a knock-in allele at 
the endogenous Kras locus, allowing for endogenous expression levels of a mutant 
Kras protein (Jackson et al., 2001). The sequence contains a stop cassette flanked on 
either side by LoxP sites followed by an activating mutation in Kras at amino acid 12, a 
glycine to aspartic acid substitution (LSL-KrasG12D, Kras hereafter). This Kras mutation 
results in decreased GTPase activity and therefore constitutive signaling. 
Tumorigenesis can be initiated in a lung specific manner by delivering an adenovirus or 
lentivirus expressing Cre recombinase to the lungs via either intranasal or intratracheal 
administration. In the Kras model, tumors develop 6-8 months after Cre administration, 
and metastases have not been reported in these mice by us or others. 
 This Kras lung tumor model can also be combined with loss of the cell cycle 
regulator and tumor suppressor gene Tp53 to yield more aggressive lung tumors. TP53 
is the most commonly mutated gene in human lung cancer, and is mutated in over 50% 
of lung adenocarcinomas (Imielinski et al., 2012). In these mice, the LSL-KrasG12D 
knock-in is combined with two floxed p53 alleles: loxP sites flank exons 2 and 10 of the 
Tp53 gene, Kras;p53-flox hereafter (Jackson et al., 2005). Advanced adenocarcinomas 
form within 15-19 weeks after Cre administration, and approximately 50% of mice 
develop metastases (between 30-50% in our hands). 
 Studies of mouse models of lung adenocarcinoma have been used to help 
further identify genes important for lung cancer metastasis. Loss of the tumor 
suppressor Lkb1 in Kras-driven lung cancers was found to confer metastatic ability as 
well as squamous differentiation (Carretero et al., 2010; Ji et al., 2007). A study using 
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lentiviral Cre integration sites to track metastatic tumors the Kras;p53-flox model found 
that tumors that metastasized downregulated the transcription factor Nkx2-1 (Winslow 
et al., 2011). In addition to identification of genes and pathways important for lung 
cancer metastasis, another main focus of cancer research has been to study the 
heterogeneity present in lung tumors to identify tumor subsets with enhanced 
tumorigenic properties, often referred to as cancer stem cells. 
 
Tumor Heterogeneity and Cancer Stem Cells 
Current cancer stem cell hypotheses propose that a subpopulation of cells within 
a tumor possesses characteristics of stem cells and can give rise to the heterogeneity of 
cell types often found in many tumor types. Cancer stem cells are typically identified by 
dissociating tumor cells, using fluorescence-activated cell sorting to select tumor 
subpopulations, and transplanting these cells in vivo. In some cases, the cancer stem 
cell population shares marker expression with normal tissue-specific stem cells.  
Importantly, cancer stem cells are thought to be resistant to available treatment 
strategies including radiation and chemotherapeutics. 
The idea that tumors were made up of cells with stem cell-like properties has 
been around for over 150 years, postulated in the early-mid 1800s by Recamier and 
Virchow (Sell, 2004; Wicha et al., 2006). This theory was then formalized by Durante 
and Virchow’s student Conheim in the late 1800s as the “embryonal rest” theory of 
cancer (Sell, 2004). The embryonal rest theory held that adult tissues contained rare, 
dormant embryonic remnants that can become reactivated to form cancers. However, 
this theory fell out of favor by the early 1900s (Sell, 2010).  
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In the 1960s and 70s there was a resurgence in studies on tumor heterogeneity. 
In 1961, Till and McCulloch proposed that tissue-specific stem cells could be the cells of 
origin for cancer, and in 1967, Pierce proposed the idea that cancers were a result of 
the maturation arrest of stem cells (Till and McCulloch, 1961; Pierce, 1967). Several 
groups reported that murine and human tumor cells had low colony forming ability in 
culture, anywhere from 0.001-1% of cells (Hamburger and Salmon, 1977; Messner and 
McCulloch, 1973; Park et al., 1971); additionally, it was reported that less than 1% of 
murine lymphoma cells could generate spleen colonies in vivo (Bruce and van der 
Gaag, 1963), lending support to the idea that tumors contained heterogeneous 
populations. Possible explanations for this heterogeneity were that (1) each cell had a 
similarly low chance of colony/tumor formation, or that (2) only a certain subset of cells 
within the tumor population had this ability. However, tumor subpopulations had not 
been identified that were more or less able to form tumors. 
In the mid-late 1990s, John Dick’s laboratory performed the seminal experiments 
that for the first time prospectively isolated a subset of what are referred to today as 
“cancer stem cells.” Dick and colleagues identified a rare population of CD34+CD38- 
cells within human acute myeloid leukemias capable of tumor formation after 
transplantation, which they termed “leukemia-initiating cells” (Bonnet and Dick, 1997; 
Dick, 1996; Lapidot et al., 1994). The leukemia-initiating cells shared cell-surface 
marker expression (CD24+CD38-) with normal hematopoietic stem cells, had the ability 
to self-renew, as they had the ability to generate leukemias upon serial transplantation, 
and also had the ability to form differentiated tumor progeny.  
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Cancer stem cell populations have since been identified in a wide variety of 
cancers, including brain (Singh et al., 2004), breast (Al-Hajj et al., 2003), colon (O'Brien 
et al., 2007; Ricci-Vitiani et al., 2007), liver (Yamashita and Wang, 2013), melanoma 
(Boiko et al., 2010), ovarian (Foster et al., 2013), pancreatic (Li et al., 2009), and 
prostate (Patrawala et al., 2006) cancers. However, the cancer stem cell hypothesis has 
been frequently challenged. Much of this debate has centered on the fact that to identify 
cancer stem cell populations, human cell populations were transplanted into 
immunocompromised, mostly NOD/SCID mice to test for serial transplantation or self-
renewal ability. Criticism of the cancer stem cell hypothesis focused on the idea that this 
artificial xenotransplantation assay selects for cells that are able to survive in this 
foreign microenvironment, and is not representative of the human tumor biology.  
The first major study to test this experimentally was by Strasser and colleagues 
in 2007 (Kelly et al., 2007). Instead of using human tumor cells, they transplanted 
mouse lymphomas and leukemias into histocompatible mice and found that at least 
10% of tumor cells could propagate the disease. These results suggested that cells with 
tumor propagating ability were more abundant than previously reported, and that some 
of the differences in tumor propagation ability were due to sub-optimal transplantation 
assays. 
 Another major challenge to the cancer stem cell hypothesis came from Sean 
Morrison’s laboratory in 2008.  This study again challenged the assays that were being 
used to identify cancer stem cell populations (Quintana et al., 2008). Instead of 
NOD/SCID mice, they used a new strain of mice with a NOD/SCID background 
combined with loss of the interleukin-2 receptor gamma chain, Il2rg-/- (NSG) mice. 
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These mice are more highly immunocompromised since they lack natural killer cells, T, 
and B cells whereas NOD/SCID mice only have impaired T and B cell maturation. In 
addition to the new mouse model, Morrison and colleagues also mixed matrigel 
extracellular matrix proteins with the cells upon transplantation to increase engraftment 
rates. They found that 25% of cells from human melanoma patients could form tumors 
when transplanted using their optimized transplantation assay. Most impressively, they 
performed single cell transplantations and found that 27% of single cells were able to 
form melanomas upon transplantation. They tested many markers previously reported 
to mark cancer stem cell populations and were unable to find any subpopulations that 
lacked tumorigenic potential (Quintana et al., 2008; Quintana et al., 2010).These results 
indicated that there are cancers such as melanoma that do not follow the cancer stem 
cell hierarchy.  
Technical advances in the past few years have now made it possible to perform 
tumor clonal analysis in vivo to test cancer stem cell hypotheses. The first study 
showing evidence for cancer stem cells during unperturbed solid tumor growth was 
performed by Cedric Blanpain’s lab in 2012 in murine squamous skin tumors (Driessens 
et al., 2012). They used a CreER/Lox lineage tracing and clonal analysis strategy that 
enabled them to label ~1% of basal tumor epithelial cells by titrating a low dose of 
tamoxifen administration. The authors found that invasive squamous cell carcinomas, 
unlike benign papillomas, contained a geometric expansion of a single cancer stem cell 
population. This study was the first to demonstrate that there were tumor cells with stem 
cell-like qualities in an unperturbed solid tumor. 
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Another cell labeling study by Luis Parada’s lab identified a putative glioma stem 
cell population that was resistant to chemotherapy and responsible for tumor regrowth 
in an in vivo mouse model (Chen et al., 2012). The authors used a Nestin-TK-IRES-
GFP mouse to label endogenous glioma tumor cells, and treated the mice with the 
chemotherapeutic agent temozolomide to transiently arrest tumor growth. Tumor 
regrowth occurred in the Nestin+ GFP marked population. The TK allele then enabled 
them to treat the mice with ganciclovir in order to kill off this population and show that 
ablation of GFP+ cells impeded tumor development. This study was the first to provide 
genetic evidence that there were cells at the top of a cellular hierarchy that were left 
behind after chemotherapy treatment, and that killing off these cells could have 
therapeutic benefit. 
Another recent study of clonal analysis and tumor heterogeneity from John Dick’s 
laboratory used DNA copy-number alteration profiling, sequencing, and lentiviral lineage 
tracking to trace the fate of singe cell-derived clones from 10 different human primary 
colorectal tumors over multiple serial transplantations in mouse renal capsule 
xenografts (Kreso et al., 2013). Some xenografts remained very similar to the parent 
tumor, while in others the first transplant and the parental tumor differed drastically, 
indicating clonal selection during xenograft growth. The authors found that there were 
clones that persisted through multiple passages, clones that became extinct, clones that 
remained below the detection threshold initially but then reemerged in later 
transplantations, and clones that disappeared and later reemerged. Treatment with 
chemotherapeutic agents eliminated persistent clones and increased those dormant 
clones initially below the detection threshold.  
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This study supports the idea that cancer stem cells and non- cancer stem cells 
are not “black and white” states, but that cellular heterogeneity is more of a “shades of 
grey” phenomenon (Marusyk and Polyak, 2013). It is possible that tumor cells have a 
gradient of tumor-propagating ability, or that the cancer stem cell state is reversible 
(Meacham and Morrison, 2013). Furthermore, it is thought that cancer stem cells no 
longer need be a rare subpopulation within the tumor. It is likely that many processes 
are co-existing within tumors that contribute to tumor heterogeneity, including the 
cancer stem cell model, clonal evolution, and inherent genetic or environmental 
properties (Magee et al., 2012) (Figure 1-1). 
 
Endogenous Lung Progenitor Cells and Cells of Origin for Lung Cancers 
 
It is important to differentiate the “cancer stem cell” population from the “cell of 
origin” of cancers. While cancer stem cells refer to a self-renewing cell in the fully 
formed tumor, the cell of origin refers to the normal cell from which a tumor arises 
(Visvader, 2011). These ideas are often confused since stem cells, with their 
quiescence and self-renewal ability, are thought to be susceptible to transformation into 
cancers. However, there is also evidence that more differentiated cells are able to give 
rise to cancers as well. In the lung, cancers are hypothesized to originate from 
endogenous stem and/or progenitor cells. 
Endogenous lung stem and progenitor cells are thought to contribute to epithelial 
maintenance and injury repair. These cells can self-renew and differentiate into 
progenitors or other more differentiated cells. Since the adult lung is a tissue that has a 
very low turnover rate, murine lung injury models have been used to identify  
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Figure 1-1: Models of Tumor Heterogeneity  
A. The cancer stem cell model hypothesizes that a subpopulation of cells (blue) has the 
inherent ability to self-renew and give rise to the heterogeneity of cell types found in the 
tumor (blue, red, green). Cancer stem cells are typically identified by dissociating tumor 
cells, using fluorescence-activated cell sorting to select tumor subpopulations, and 
transplanting these cells in vivo to test serial transplantation ability. B. The clonal 
evolution model describes the process by which different tumor cell clones can acquire 
tumorigenic properties that enable them to contribute to tumor progression. Some 
clones will acquire greater tumorigenic abilities (blue), while other clones become less 
tumorigenic (red). C. Tumor heterogeneity is likely influenced by a combination of the 
cancer stem cell model, the clonal evolution model, and other environmental factors not 
depicted here. Adapted from (Magee et al., 2012). 
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Figure 1-1: (continued)
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stem/progenitor cells by inducing cellular proliferation and repopulation of the lung 
epithelium (Rawlins and Hogan, 2006). What these studies have detailed is a complex 
heterogeneity of putative endogenous stem/progenitor cells with different candidates 
located in different regions of the mouse lung.  This is depicted in schematic form in 
Figure 1-2.  
Basal epithelial cells are a stem/progenitor cell population important in tissue 
homeostasis and injury repair in the trachea and proximal airways in mice and 
throughout the airways in humans (Borthwick et al., 2001; Daniely et al., 2004; Rock et 
al., 2009; Schoch et al., 2004). Lineage tracing studies in the mouse have revealed that 
basal cells can give rise to club (Clara) cells and ciliated cells in the proximal airways 
during homeostasis as well as after sulfur dioxide injury in mice (Hong et al., 2004a; 
Hong et al., 2004b). Basal cells are hypothesized to be the cells of origin for lung 
squamous cell carcinoma, since squamous cell carcinomas more frequently occur in the 
proximal lung and often express basal cell markers (Davidson et al., 2013). 
The distal bronchiolar epithelium includes non-ciliated columnar club cells which 
produce surfactants (Massaro et al., 1994) and ciliated cells which propel these 
surfactants across the bronchiolar wall (van der Schans, 1997). In the airways, the 
areas surrounding neuroepithelial bodies (NEB) and the bronchioalveolar duct junction 
(BADJ) represent two different stem/progenitor cell niches. Variant club cells resistant to 
naphthalene injury were identified near the NEB in the proximal airways and at the 
BADJ in distal airways (Giangreco et al., 2002; Hong et al., 2001; Reynolds et al., 
2000).  These cells survive severe injury and can re-epithelialize the airways. As 
demonstrated by a lineage-tracing study, club cells are stem/progenitor cells that have 
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Figure 1-2: Schematic of putative lung stem/progenitor cells in the mouse lung.  
1) Basal cells in the tracheobronchial region; 2) variant club cells associated with 
pulmonary neuroendocrine cell bodies; 3) variant club cells/BASCs present at the 
bronchioalveolar duct junction; 4) alveolar type II (AT2) cells present in the alveolar 
space. (Lau et al., 2012) originally adapted from (Randell, 2006).
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long-term self-renewal ability and can also generate ciliated cells during epithelial 
homeostasis (Rawlins et al., 2009).  
The epithelium at the air interface of the alveoli consists of flat alveolar type I 
(AT1) cells and cuboidal alveolar type II (AT2) cells, which produce surfactant to lower 
surface tension and aid in AT1 cell-mediated gas exchange (Fehrenbach, 2001; Herzog 
et al., 2008). In the alveolar epithelium, repopulation after bleomycin injury is due to 
proliferation of AT2 cells, which act as stem/progenitor cells for AT1 cells (Aso et al., 
1976; Barkauskas et al., 2013; Desai et al., 2014; Isakson et al., 2001; Kawamoto and 
Fukuda, 1990). 
Bronchioalveolar stem cells (BASCs) are another naphthalene-resistant 
progenitor cell population located at the BADJ, identified based on their co-expression 
of the club cell marker, club cell secretory protein (CCSP), and the alveolar type II (AT2) 
cell marker, pro-surfactant protein C (pro-SP-C) (Kim et al., 2005).  BASCs can be 
isolated using FACS to select for cell expression of the stem cell marker Sca1 after 
elimination of hematopoietic cells and endothelial cells (CD45-CD31-Sca1+). 
Importantly, more recent studies have shown that the CD45-CD31-Sca1+ population is 
more heterogeneous than previously appreciated (Raiser and Kim, 2009; McQualter et 
al., 2010). Based on our own observations that BASCs are contained in the Sca1low 
population and express low levels of CD24, a robust marker profile for enriching for 
BASCs utilizes CD45-CD31-EpCAM+Sca1lowCD24low (Zacharek et al., 2011).  
BASCs can self-renew in a 3-dimensional (3D) co-culture matrigel assay with 
primary lung endothelial cells and differentiate into colonies expressing airway and/or 
alveolar lineage markers and morphology (Lee et al., 2014). Importantly, single murine 
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CD45- CD31- EpCAM+ Sca1+ cells were able to form both bronchiolar and alveolar 
colonies in vitro, supporting the hypothesis that BASCs represent a true lung stem cell 
population. BASCs have also been implicated in injury repair after bleomycin-induced 
injury due to their proliferation after treatment and the in vitro data showing their ability 
to differentiate into alveolar cells in culture (Kim et al., 2005; Lee et al., 2014). A lineage-
tracing study using CCSP-CreER mice showed that the percentage of lineage-labeled 
cells did not increase in the alveolar space during homeostasis or following hyperoxia 
injury, suggesting that CCSP-expressing cells did not give rise to alveolar cells (Rawlins 
et al., 2009).. However, other lineage-tracing studies using the same CCSP-CreER mice 
found that CCSP+ cells can give rise to both AT1 and AT2 cells following bleomycin 
injury (Rock et al., 2011; Tropea et al., 2012). These studies suggest that bronchiolar 
cells may be able to form alveolar structures under certain conditions.  
BASCs have been proposed as a cell of origin in murine models of lung 
adenocarcinoma, as BASC expansion has been observed after oncogenic Kras 
induction, and increased tumor number and area was also observed in these mice after 
injury-induced BASC expansion (Kim et al., 2005). In addition to oncogenic Kras, BASC 
expansion has been observed after oncogenic stimulation or loss of tumor suppression 
in other adenocarcinoma models (Besson et al., 2007; Pei et al., 2007). BASC-like cells 
co-expressing SPC and CCSP can be found within murine lung adenocarcinomas 
(Curtis et al., 2010; Kim et al., 2005). 
Others have proposed that AT2 cells are cells of origin for lung adenocarcinoma 
(Desai et al., 2014; Mainardi et al., 2014; Xu et al., 2012). Hogan and colleagues used 
CCSP-CreER and SPC-CreER knock-in mice in combination with the LSL-KrasG12D 
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allele to drive tumorigenesis in CCSP-expressing (club or BASC, low levels in AT2) or 
SPC-expressing (BASC or AT2) cells (Xu et al., 2012). They found that both cells near 
the BADJ and in the alveoli proliferate after KrasG12D induction by either driver, but 
that adenocarcinomas preferentially formed in the alveoli versus hyperplasia near the 
BADJ. Similar results were found by Krasnow and colleagues (Desai et al., 2014). 
These results suggest that AT2 cells can serve as the cells of origin for 
adenocarcinomas, but due to expression of SPC and CCSP in other cell types does not 
definitely show that they are the only cell type to be able to do so.  
Another study by Barbacid and colleagues supports the AT2 cell being the cell of 
origin of adenocarcinomas (Mainardi et al., 2014). In this study, Kras-G12V was driven 
by RERT mice, a knock in strain that expresses Cre-ER under the control of the locus 
encoding the large subunit of RNA polymerase II. It was found that large clusters of 
cells that led to adenocarcinomas were only found in the alveolar region.  At 4 weeks 
after treatment, they identified large clusters that were SPC+, as well as some BADJ 
clusters that were CCSP+ and SPC+, suggesting their origin from BASCs. However, at 
8 weeks, all of the lesions were located in the alveoli and were SPC+ suggesting that 
the advanced lesions originated from SPC+ AT2 cells. The authors also looked at 
intratracheal infection with AdCre in the LSL-KrasG12V mice and found similar results; 
bronchiolar or BADJ lesions never progressed to high-grade lesions, while those in the 
alveoli progressed to large stage adenocarcinomas.  
A recent study by Berns and colleagues supports the idea that there are multiple 
cells of origin for lung adenocarcinoma (Sutherland et al., 2014). Using Ad-CCSP-Cre 
and Ad-SPC-Cre viruses to drive Kras and delete p53 in club cells, BASCs, or AT2 
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cells, the authors concluded that both CCSP+ (club or BASC) cells and SPC+ (AT2 or 
BASC) cells can form adenocarcinomas. They also used a confetti reporter mouse to 
show that after infection with Ad-CCSP-Cre, lesions arise from CCSP+ cells in the 
BADJ, suggesting their origin from BASCs. Without drivers that are more cell-type 
restricted, it is difficult to rule out contribution of multiple cell types to tumor initiation. A 
main issue in the lung field is the lack of restrictive markers for each cell type, as CCSP 
and SPC are expressed in both BASCs and other epithelial cells.  
The above studies demonstrate a rich network of endogenous stem and 
progenitor populations in mouse lungs. Although there may be overlap between cells 
identified in different investigations, an important concept is that there appears to be 
regional specificity of the progenitors. Overall, the available literature demonstrates a 
complex hierarchy of endogenous progenitors that appear specific to different lung 
regions. In addition to lineage tracing and other techniques to better identify and study 
the homeostasis of these cells, other in vivo assays such as cell transplantation are 
needed to assess the ability of putative lung stem/progenitor cells to reconstitute lung 
epithelial cell lineages within damaged or diseased tissue. To conclusively show which 
cells are true stem cell populations and which are cells of origin for lung cancers, cell 
type-restricted promoters are needed. In this way oncogenic Kras can be driven in 
various lung epithelial cell types proposed to be cells of origin for lung adenocarcinoma 
including club cells, BASCs, AT2, and AT1 cells.  
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Evidence for Lung Cancer Stem Cells 
In addition to cells of origin, accumulating data has provided evidence for the 
existence of cancer stem cells in some lung cancers. The first study to look at stem cell 
characteristics in lung cancer cells was performed over 30 years ago by Carney and 
colleagues, describing a rare population of cells in patient lung cancer samples with the 
ability to form colonies in soft agar which could recapitulate the original tumor 
phenotype when transplanted into nude mice (Carney et al., 1982). 
Since then, many studies have been done, largely looking at potential cancer 
stem cell populations in human lung cancer cell lines or cultured cells. Side population 
cells, which efflux Hoechst dye, have been shown to be resistant to chemotherapy, 
express increased levels of drug transporters, and show increased invasiveness in vitro 
(Ho et al., 2007). This study of six human non-small cell lung cancer cell lines also 
showed that side population cells were tumorigenic in a subcutaneous transplant assay 
in mice (Ho et al., 2007). CD133, originally a cell surface marker of brain and colon 
cancer stem cells, has also been used to identify lung cancer cells with tumorigenic 
properties. CD133+ cells from human lung tumors formed self-renewing spheres in vitro 
that could propagate tumors when transplanted subcutaneously in mice, and CD133+ 
cells from xenografts were enriched for tumorigenicity (Bertolini et al., 2009; Eramo et 
al., 2008; Tirino et al., 2009). However, other studies looking at lung cancer cell lines 
have shown that CD133 does not mark a cancer stem cell population (Meng et al., 
2009a; 2009b). Another cell surface marker, CD44, marked tumorigenic cells in lung 
cancer cell lines transplanted subcutaneously (Leung et al., 2010).  Expression of 
aldehyde dehydrogenase (ALDH) has also been used to isolate putative cancer stem 
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cells in leukemia, brain, breast, colon, prostate, liver, bladder, pancreatic, thyroid, and 
head and neck cancers (Bar et al., 2007; Chen et al., 2009; Cheung et al., 2007; 
Ginestier et al., 2007; Huang et al., 2009; Li et al., 2010; Ma et al., 2008; Rasheed et al., 
2010; Su et al., 2010; Todaro et al., 2010).  ALDH1+ cells from primary human lung 
tumor cells and from lung cancer cells lines were enriched for tumor initiating ability in 
subcutaneous transplant assays (Jiang et al., 2009; Liang and Shi, 2012; Sullivan et al., 
2010).  
Many of these above studies were done using cell lines, cultured primary cells, 
and/or subcutaneous transplantation. Previous work in our lab has developed an 
orthotopic transplantation assay for delivering tumor cells to the murine lung. Sca1, one 
of the cell surface markers used to isolate bronchioalveolar stem cells from the normal 
mouse lung, was found to enrich for cells with tumor-propagating ability in primary 
mouse adenocarcinomas from the Kras;p53-flox mouse model using this assay (Curtis 
et al., 2010). However, in the same study Sca1 did not enrich for tumor-propagating 
cells in other mouse tumor models carrying different oncogenic mutations. This study 
using genetically distinct mouse models suggests that those seeking to identify human 
lung cancer propagating cells should consider the genotype of their human tumor 
samples. 
A recent study also using this orthotopic transplantation assay in the Kras;p53-
flox model identified a CD24+ITGB4+Notchhi tumor propagating cell population (Zheng 
et al., 2013). Although the findings of this study have some overlap with the work 
presented here, there are a few important differences in the two studies. The work of 
Sweet-Cordero and colleagues focused on the role of the Notch pathway in tumor 
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propagation, while our work focuses on the Hippo pathway. The sorting strategy used in 
the study uses mice that have a Rosa26-LSL-YFP allele as a marker of Cre-infected 
Kras;p53-flox tumor cells. Last, the metastatic capacity of the tumor propagating 
CD24+ITGB4+Notchhi population was not studied. 
Within human lung cancer, a CD166+ cancer stem cell population has been 
identified by serial transplantation of primary human NSCLC tumor cells subcutaneously 
into NSG mice (Zhang et al., 2012). The authors tested the markers CD166, CD44, 
CD133, and EpCAM and found that only CD166 was able to distinguish a population of 
tumor propagating and non-tumor propagating cells via serial transplantation. All of the 
other markers tested were able to form tumors from both positive and negative 
populations. 
However, a population of human lung cancer stem cells serially transplanted in 
the lung microenvironment that recapitulates the lung tumor phenotype is yet to be 
described. In fact, at the time this work was started, our lab was the only one to identify 
a tumor propagating cell population in	  autochthonous mouse models of lung cancer 
using an orthotopic transplantation assay. Thus, while several lung cancer stem cell 
candidates have emerged, ongoing studies to further characterize lung tumor 
propagating cells will further identify and target important lung cancer cells. 
Similarly, there has yet to be published work prospectively identifying subsets of 
metastatic lung cancer cells. The low five-year survival rate for patients diagnosed with 
lung cancer is largely due to the fact that most patients already have metastatic disease 
at time of diagnosis (Siegel et al., 2013). One way to develop therapies for metastatic 
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cancer is to examine possible links to cancer stem cells, although little has been done in 
this field.  
 
Metastasis and Cancer Stem Cells 
The first studies to examine tumor heterogeneity with regards to metastasis were 
performed by Fidler and colleagues in the mid-late 1970s. Fidler was first able to select 
for more metastatic cancer cells through repeated in vivo selection in animal models 
(Fidler, 1973). Fidler and colleagues next did a series of experiments where they first 
grew melanoma in culture and then either the parent cells or individual cell clones were 
transplanted via tail vein into mice (Fidler and Kripke, 1977). They found that in contrast 
to when bulk tumor cells were transplanted, transplanting various cell clones resulted in 
large differences in the number of resulting lung tumors that formed. The authors 
interpreted this result to mean that the parent tumor was heterogeneous and contained 
“highly metastatic tumor cell variants.” To determine whether the heterogeneity in 
tumors was preexisting or whether it was due to random differences in cell survival, they 
did another set of experiments where a parent cell line and 21 clones produced from 
this line were injected via tail vein or subcutaneously and examined at different time 
points (Kripke et al., 1978). The authors concluded that the heterogeneity was 
preexisting since clones tended to have similar metastatic capability regardless of 
transplantation type. These were the first experiments to suggest such a metastatic 
heterogeneity in cancer, and that such heterogeneity should be taken into account when 
developing cancer therapies (Fidler, 1978). 
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 The first study to demonstrate the existence of a metastatic cancer stem cell 
population was performed by Heeschen and colleagues (Hermann et al., 2007).  The 
authors identified a CD133+CXCR4+ cancer stem cell population that was essential for 
metastasis. First, the authors identified CD133+CXCR4+ cells at the leading edge of 
patient tumors, and showed that CD133+ cells from pancreatic cell lines were enriched 
for tumor propagating activity and resistant to chemotherapy. From orthotopic 
pancreatic transplants of pancreatic cancer cell lines, only CD133+CXCR4+ cells were 
found in the circulating blood and were later able to seed liver metastases, while the 
CD133+CXCR4- population was not. Treatment with a CXCR4 inhibitor reduced these 
metastases. Although this was the first study to link cancer stem cells and metastasis, 
this study used cell lines instead of primary human or mouse tumor cells. Other notable 
studies utilizing cell lines and xenograft models have been done in breast cancer, 
identifying cells with aldehyde dehydrogenase activity as metastatic cancer stem cells 
(Charafe-Jauffret et al., 2009; 2010; Croker et al., 2009; Korkaya et al., 2008). 
 Another approach to link cancer stem cells and metastasis used a lentiviral 
barcoding strategy (Dieter et al., 2011).  They grew primary human colon cancer tumors 
as spheres in culture, infected them with lentivirus, and then serially transplanted these 
spheres under the kidney capsule in immunodeficient mice. Using the lentiviral 
integration sites as “barcodes,” the authors identified three types of tumor initiating cells 
(TICs): tumor transit-amplifying cells (T-TACs) with limited self-renewal ability, delayed-
contributing tumor initiating cells (DC-TICs) with activity in secondary or tertiary mice, 
and self-renewing long-term tumor initiating cells (LT-TICs) which were responsible for 
tumor formation in serial transplants. Only the LT-TICs were responsible for metastasis. 
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 Wong and colleagues identified a CD26+ cancer stem cell population in colon 
cancer enriched for metastatic capability using primary human colorectal tumors (Pang 
et al., 2010). In patients, CD26 expression was higher in liver metastases than in 
primary tumors, and primary tumors with CD26 expression were more likely to 
metastasize. The authors then transplanted tumor subpopulations in the cecal wall of 
mice. Both CD26+ and CD26- cells were able to form primary tumors, but only CD26+ 
cells were able to form liver metastases. These results are interesting because while 
CD26 doesn’t enrich for tumor propagating ability, it does enrich for metastatic ability. 
 To date, only these few studies have shown a causal relationship between 
cancer stem cells and metastasis, the majority of which were published in the past 5 
years since this thesis work had begun. Prior to this work, a link between lung cancer 
stem cells and metastasis had yet to be shown.  
 
Summary of the Dissertation 
My thesis work will prospectively identify a population of lung tumor propagating 
cells that is enriched for metastatic potential. In Chapter 2, I will detail our work looking 
at CD24 and Sca1 as markers of a murine lung tumor-propagating cell population with 
enriched metastatic capacity. We also found that CD24 function was important for lung 
cancer cell migration and metastasis. Next, we used a microarray of TPC and non-TPC 
cells to create a TPC gene signature that is predictive of survival and metastasis in lung 
adenocarcinoma patients. Members and targets of the Hippo pathway were found to be 
enriched in this population by Gene Set Enrichment Analysis (GSEA). We found that the 
Hippo mediators Yap and Taz were important for lung cancer cell migration, metastasis, 
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and lung tumor progression. This study is the first to prospectively isolate lung tumor 
propagating cells with metastatic potential, and also highlights the utility of tumor 
propagating cells for identifying molecules contributing to metastatic lung cancer and 
potentially enabling therapeutic targeting. It is also the first to identify the importance of 
Yap/Taz in lung cancer progression in a mouse model of lung cancer in vivo. In Chapter 
3, I will further discuss the significance of these findings in the context of the field. 
Unanswered questions and future directions for this project will also be explored. My 
hope is that these studies of tumor heterogeneity and metastasis will contribute to our 
understanding and help enable targeting of metastatic lung cancer cells.
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CHAPTER 2: 
 
Tumor-propagating cells and Yap/Taz activity contribute to lung tumor 
progression and metastasis 
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Abstract 
Metastasis is the leading cause of morbidity for lung cancer patients.  Here we 
demonstrate that murine tumor propagating cells (TPCs) with the markers Sca1 and 
CD24 are enriched for metastatic potential in orthotopic transplantation assays.  In lung 
cancer patient data sets, metastatic spread and patient survival could be stratified with a 
murine lung TPC gene signature.  The TPC signature was enriched for genes in the 
Hippo signaling pathway. In cell lines resembling TPCs, knockdown of CD24 or the 
Hippo mediators Yap1 or Taz decreased in vitro cellular migration and transplantation of 
metastatic disease.  Furthermore, constitutively active Yap was sufficient to drive lung 
tumor progression in vivo.  These results demonstrate functional roles for CD24 and 
Yap/Taz in lung tumor propagation and metastasis. This study demonstrates the utility 
of TPCs to identify molecules contributing to metastatic lung cancer, potentially enabling 
the therapeutic targeting of this devastating disease.  
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Introduction 
The average five-year survival rate for patients diagnosed with lung cancer 
remains at a strikingly low 16%. The predominant contributor to this statistic is the fact 
that the vast majority (~85%) of patients are diagnosed when their cancer has already 
progressed beyond a localized state (Siegel et al., 2013). Even for those patients who 
undergo resection of localized lung cancer, 72% will later develop lethal metastatic 
disease (Pisters et al., 2000). In the absence of novel early detection modalities, it is 
essential to better understand the mechanisms that control progression and metastasis 
in order to offer new therapeutic options for lung cancer patients. 
The mucin-like cell surface adhesion molecule, CD24, has been implicated as a 
marker and a key regulator of advanced disease in multiple types of cancer, yet with 
some possibly conflicting results (Lee et al., 2011; Liu et al., 2012; Overdevest et al., 
2011).  High levels of CD24 detected by immunohistochemistry had a significantly 
increased likelihood of disease progression and cancer-related death for lung cancer 
patients (Kristiansen et al., 2003; Lee et al., 2010).  Disseminated lung tumor cells from 
malignant pleural effusions also express CD24 (Yao et al., 2013).  On the other hand, 
CD24-negative/low membrane expression was significantly correlated with poor 
differentiation and worse survival in lung cancers (Damelin et al., 2011). In breast 
cancers, the links between CD24 expression and tumor progression have also differed 
between studies (Al-Hajj et al., 2003; Shipitsin et al., 2007).   
Tumor-propagating cells (TPCs) are tumor cells capable of serially transplanting 
and recapitulating the tumor phenotype and may contribute to tumor progression and 
metastasis, yet few studies have directly tested this idea. Notable examples have 
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utilized cancer cell lines and xenograft models in breast cancer (Charafe-Jauffret et al., 
2010; Charafe-Jauffret et al., 2009; Croker et al., 2009; Korkaya et al., 2008), pancreatic 
(Hermann et al., 2007), and colorectal cancer (Pang et al., 2010) to link metastasis to 
TPCs.  Murine CD24+ CD90+ TPCs play a key role in breast cancer metastasis through 
cell autonomous and microenvironmental requirements (Malanchi et al., 2011).  
However, differentiated, non-tumor propagating cancer cells can also facilitate 
metastasis in embryonal rhabdomyosarcoma (Ignatius et al., 2012).  A CD24-
expressing population (CD24+ITGB4+Notchhi) was shown to be enriched for tumor 
propagation in a mouse model of lung cancer (Zheng et al, 2013), yet the metastatic 
potential of this CD24+ cell population has not been reported. 
The Hippo signaling cascade, most noted for its role in organ size control and 
development, has been posited to play a role in cancer progression (reviewed in Pan, 
2010), and emerging evidence supports this concept in lung cancer.  Expression of the 
canonical effector of the Hippo pathway, Yes associated protein 1 (Yap1), has been 
correlated with poor prognosis in non-small cell lung cancer patients and was shown to 
modulate the tumorigenicity of human lung cancer cell lines (Wang et al., 2010).  
Overexpression of WW domain-containing transcription regulator protein 1 (Wwtr1, 
more commonly referred to as Taz), a paralog of Yap1, was capable of transforming 
immortalized human bronchial epithelial cells, while knockdown of Taz in non-small cell 
lung cancer cell lines decreased tumorigenicity, validating Taz as an oncogene in the 
lung (Zhou et al., 2011).   
Metastatic lung adenocarcinomas, the most common form of lung cancer in 
patients, can be initiated in mice harboring Lox-Stop-Lox-KrasG12D and p53flox/flox 
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alleles (hereafter, Kras;p53-flox) upon intranasal instillation of adenovirus expressing 
Cre-recombinase (Jackson et al., 2005). Using this model, we have shown that the 
Sca1+ population of tumor cells is enriched for tumor-propagating potential (Curtis et al., 
2010). In the present study, we determined that CD24a (the mouse homolog of human 
CD24, CD24 hereafter) is an additional lung TPC marker and a key mediator of lung 
cancer cell line migration and subcutaneous tumor propagation. We also show that 
Sca1+CD24+ cells are enriched for metastatic potential after orthotopic delivery of 
tumor cells.  Lung TPCs exhibit transcriptional profiles correlating with metastatic 
potential and poor patient prognosis. Finally, our data point to a functional role for YAP 
and TAZ in lung cancer progression and metastasis. 
 
Results  
CD24 expression marks cells with tumor-propagating capacity 
We sought to identify additional cell surface markers of the Sca1+ Kras;p53-flox 
cancer cells we previously identified as lung TPCs. DAPI- CD31- CD45- Sca1+ (Sca1+ 
hereafter) and DAPI- CD31- CD45- Sca1- (Sca1- hereafter) cell populations from four 
primary Kras;p53-flox lung tumors were isolated via fluorescence activated cell sorting 
(FACS) as previously described (Curtis et al., 2010) and their transcriptional profiles 
were analyzed by Affymetrix microarray (Appendix).  
Expression levels of cell surface markers were examined followed by quantitative 
real-time PCR (qPCR) and FACS analysis to identify candidate lung TPC markers. 
Differential expression of Sca1 (LY6A) in TPCs was confirmed (fold change in Sca1+ 
vs. Sca1-, 30.77) in this data set. CD133, a putative marker of human lung cancer cells 
with increased tumorigenicity (Bertolini et al., 2009; Chen et al., 2008; Eramo et al., 
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2008; Levina et al., 2008), was highly expressed in Sca1+ TPCs by microarray and 
qPCR analysis (fold change, 23.63) (Curtis et al., 2010), yet flow cytometry for CD133 
failed to show enrichment within the Sca1+ fraction (unpublished observations). Several 
other markers of aggressive cancer stem cells in other tissues, including CD44 and 
CXCR4, were not significantly differentially expressed in Sca1+ and Sca1- cells. 
Interestingly, CD24 was upregulated in lung TPCs (fold change, 1.8). qPCR confirmed 
that CD24 was overexpressed more than 3-fold in Sca1+ TPCs from Kras;p53-flox lung 
tumors compared to Sca1- cells (p=0.0057) (Figure 2-1A). Flow cytometric analysis of 
Kras;p53-flox lung tumor cell preparations revealed that 87.1% +/- 5.44% of Sca1+ cells 
were CD24+ (Figure 2-1B, n=7).  
We utilized our orthotopic intratracheal transplantation model (Curtis et al., 2010) 
to verify that CD24 expressing cells were lung TPCs. Primary Kras;p53-flox lung tumors 
were isolated for digestion, FACS, and transplantation.  We first compared the activity of 
DAPI- CD31- CD45- CD24+ cells (hereafter CD24+) with the activity of DAPI- CD31- 
CD45- CD24- cells (CD24-). 10,000 CD24+ or CD24- cells were transplanted 
intratracheally into immunocompromised Foxn1nu/nu (nude) mice. Recipient mice were 
observed until they exhibited labored breathing, when mice were euthanized for 
analysis of lung tumors (22 ± 3 weeks for CD24+ cells, 25 ± 4 weeks for CD24- cells). 
The CD24+ and CD24- populations both propagated lung adenocarcinomas that 
accurately recapitulated primary Kras;p53-flox tumors (Figure 2-1C,D). 100% of 
recipient mice developed at least one lung tumor after transplantation of 10,000 CD24+ 
or CD24- cells (10/10 for CD24+ and 12/12 for CD24-) (Appendix). Histological  
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Figure 2-1: CD24 marks cells enriched for tumor-propagating ability. 
A. Real Time RT-PCR analysis for CD24 in sorted Sca1+ and Sca1- Kras;p53-flox lung 
tumor cells. B. A representative flow cytometry plot showing CD24 and Sca1 expression 
in Kras;p53-flox lung tumor cells. Cells shown were gated on the single, live (DAPI-
negative), CD31-negative, CD45-negative population. C and D. H&E image showing a 
secondary Kras;p53-flox lung adenocarcinoma from the transplantation of CD24+ tumor 
cells (C) or CD24- tumor cells (D). 200x magnification, scale bar = 100µm. E. and F. 
Quantification of tumors from transplantation of 10,000 CD24+ or CD24- cells. E. 
Average tumor number per recipient mouse. N = 7 for each cell type transplanted.  F. 
Average tumor burden in secondary mice calculated as the percentage of lung area 
filled with tumors. N = 6 for CD24+, N=7 for CD24-. G. Table showing tertiary tumor 
formation ability of CD24+ and CD24- Kras;p53-flox lung tumor cells from secondary 
transplants. 1,000 or 10,000 CD24+ or CD24- cells were intratracheally transplanted 
into immunocompromised mice. The percentage of recipient mice with at least one lung 
tumor after 13-28 weeks is shown.  p=0.0063, Fisher’s Exact Test, two tailed. H.  H&E 
image showing a tertiary Kras;p53-flox lung adenocarcinoma from the transplantation of 
CD24+ tumor cells.  *, p < 0.05.
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Figure 2-1: (continued)
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analysis revealed that while CD24+ recipient mice had an average of 17 tumors, CD24- 
recipients had only 4 (p=1.2x10-4), and likewise CD24+ recipients showed 72% tumor 
burden (lung area filled with tumor) in contrast to 19% tumor burden observed for CD24- 
recipients (p=8.3x10-5) (Figure 2-1E,F).  
We next tested the ability of cell populations separated by CD24 expression to 
serially passage tumors. Interestingly, lung tumors in recipient mice contained a CD24+ 
population regardless of whether CD24+ or CD24- cells were transplanted despite 
~95% cell purity at the time of tumor cell isolation (Figure 2-2A,B).  1,000 or 10,000 
CD24+ or CD24- cells from secondary tumors were FACS-sorted and transplanted 
orthotopically to test for serial tumor formation ability. Recipients of CD24- cells from 
secondary tumors did not develop lung tumors (0/9 and 0/15 for 1,000 and 10,000 cells, 
respectively). In contrast, CD24+ cells from secondary tumors could form tertiary 
tumors. CD24+ cells from secondary tumors yielded tumors in 1/7 mice after 
transplantation of 1,000 cells and in 6/14 mice after transplantation of 10,000 cells, 
p=0.0063) (Figure 2-1G,H, Figure 2-2C,D, Appendix). These data supported our 
hypothesis that CD24 is a marker of lung cancer cells with tumor-propagating capacity. 
We next used the combination of Sca1 and CD24 to further delineate Kras;p53-
flox TPCs.  Limiting dilution transplantation experiments were used to compare TPC 
activity in the Sca1+CD24+, Sca1-CD24+, Sca1+CD24- and Sca1-CD24- fractions.  
Recipients of Sca1+CD24+ and Sca1-CD24+ tumor cells had higher rates of tumor 
formation than Sca1-CD24- and Sca1+CD24- recipients, further showing CD24 is a 
TPC marker (Sca1-CD24+ vs Sca1-CD24-, p=0.0429, Sca1-CD24+ vs Sca1+CD24-, 
p=0.0290) (Figure 2-3A, Appendix). 
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Figure 2-2: Characterization of CD24+ TPCs. A-B. Representative FACS plot of a 
lung tumor from a secondary mouse transplanted with CD24+ cells (A) or CD24- cells 
(B). Cells shown were gated on the single, live (DAPI-negative), CD31-negative, CD45-
negative population. C-D. Tables showing tertiary tumor formation ability of CD24+ and 
CD24- Kras;p53-flox lung tumor cells from CD24+ (C) or CD24- (D) secondary 
transplants. 1,000 or 10,000 CD24+ or CD24- cells were intratracheally transplanted 
into immunocompromised mice. The percentage of recipient mice with at least one lung 
tumor after 28 weeks is shown. CD24+ CD24- p=0.0108, Fisher’s Exact Test, two tailed. 
E. Table of metastatic incidence in secondary mice from transplantation of 10,000 
CD24+ or CD24- cells. The number and (percentage) of recipient mice with at least one 
metastatic lesion are shown in the first column. Location columns show the number and 
(percentage) of recipient mice with metastases in the noted site. F. H&E images 
showing metastases from the transplantation of CD24+ tumor cells (left column images) 
or CD24- tumor cells (right column images).  Top, chest cavity metastases; Middle, 
lymph node metastases; Bottom, heart metastasis from CD24+ recipient, normal heart 
from CD24- recipient. All H&E images 200x magnification. Scale bars represent 100µm. 
G. The average tumor size of secondary tumors from transplantation of CD24+ (N=8) or 
CD24- (N=10) cells. H. The percentage of recipient mice bearing lung tumors from 
transplantation of CD24+ (N=10) or CD24- (N=10) cells with the indicated tumor grade 
(Scale 1-4) is shown. Grade 1 lesions were not observed in recipient mice
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Figure 2-2: (continued) 
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Figure 2-3: Sca1 and CD24 mark cells in Kras;p53-flox tumors with metastatic 
potential after orthotopic transplantation. A. Table showing tumor propagation ability 
of Sca1+CD24+, Sca1-CD24+, Sca1+CD24- and Sca1-CD24- Kras;p53-flox lung tumor 
cells. 100-10,000 cells were intratracheally transplanted into immunocompromised 
mice. The percentage of recipient mice with at least one lung tumor after 17-33 weeks is 
shown. B. Table showing tertiary tumor formation ability of Sca1+CD24+, Sca1-
CD24+,and Sca1-CD24- Kras;p53-flox lung tumor cells from secondary transplants. 
10,000 cells were intratracheally transplanted into immunocompromised mice. The 
percentage of recipient mice with at least one lung tumor after 20-29 weeks is shown. 
C. H&E images showing a lung tumor (left) and kidney metastasis (right) from the 
transplantation of Sca1+CD24+ tumor cells. 200x magnification, scale bars = 100µm. D. 
H&E images showing a lung tumor (left) and chest cavity metastasis (right) from the 
transplantation of Sca1-CD24+ tumor cells. 200x magnification, scale bars = 100µm. E. 
Table of metastatic incidence in secondary mice from transplantation of 6000-10,000 
Sca1+CD24+, Sca1-CD24+, Sca1+CD24- and Sca1-CD24- Kras;p53-flox lung tumor 
cells. The number and (percentage) of recipient mice with at least one metastatic lesion 
are shown in the first column. Location columns show the number and (percentage) of 
recipient mice with metastases in the noted site. F. The percentage of recipient mice 
bearing lung tumors from transplantation of Sca1+CD24+ (N=7) or Sca1-CD24+ (N=9) 
cells with the indicated tumor grade (Scale 1-4) is shown. Grade 1 or 2 lesions were not 
observed in recipient mice.
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Figure 2-3: (continued) 
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Similar to our results using CD24 alone, Sca1+CD24+ and Sca1-CD24+ also had 
higher rates of tumor propagation in secondary transplantation (Figure 2-3B).  
Importantly, cytospin and qPCR showed the four Sca1/CD24-sorted populations had 
similar epithelial cell content (Figure 2-4A,B,C,D).  Thus, Sca1+CD24+ and Sca1-
CD24+ cells are enriched for Kras;p53-flox TPCs.   
Sca1+ CD24+ status correlates with metastatic potential 
Orthotopically transplanted Kras;p53-flox tumor cell populations also produced 
metastases in recipient mice, allowing us to also test the role of TPCs in metastasis. 
First, a cohort of CD24+ and CD24- cell recipients were euthanized for collection of 
tissues from common metastatic sites for lung cancer, including connective tissue in the 
pleural cavity, lymph nodes, heart, liver, spleen and adrenal glands. To more fairly 
compare metastatic capacity, we analyzed CD24- cell recipients 26-29 weeks after 
transplantation, when they had primary tumors of similar size and grade as tumors in 
CD24+ cell recipients analyzed at 22 weeks (Figure 2-2G,H).  With these parameters, 
there was no significant difference in metastasis in recipients of CD24+ cells versus 
CD24- cells (Figure 2-2E). CD24+ cell recipients developed metastatic lesions in the 
chest wall, local lymph nodes, and the heart (Figure 2-2E, F). Similarly, mice that 
received CD24- cells developed small chest cavity lesions and local lymph node 
metastases yet did not have metastatic lesions in the heart.  Thus, CD24 status alone is 
not sufficient as a metastatic marker. 
Sca1+ and Sca1- cells from Kras;p53-flox tumors were also transplanted via 
intratracheal transplantation to test for metastatic potential, since previous studies only 
examined the role of Sca1 in tumor propagation (Curtis et al., 2010) (Figure 2-5A,B,
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Figure 2-4: Characterization of Sca1+CD24+ TPCs 
A. Percent of Kras;p53-flox lung tumors cells with SPC expression determined after 
cytospin and staining.  Representative images of SPC+ and SPC- cells are shown. N= 3 
mice.  B. qPCR analysis of Vimentin expression in Sca1+CD24+, Sca1-CD24+, 
Sca1+CD24- and Sca1-CD24- Kras;p53-flox lung tumor cells. Normal lung EpCAM+ 
and EpCAM- cells were used as negative and positive controls. C. qPCR analysis of 
SMA (Acta2) expression in Sca1+CD24+, Sca1-CD24+, Sca1+CD24- and Sca1-CD24- 
Kras;p53-flox lung tumor cells. D. qPCR analysis of ECadherin (ECad) expression in 
Sca1+CD24+, Sca1-CD24+, Sca1+CD24- and Sca1-CD24- Kras;p53-flox lung tumor 
cells. E. Average tumor size in Sca1+CD24+ (N=4) and Sca1-CD24+ recipients. (N =8).
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Figure 2-4: (continued) 
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Figure 2-5: Tumor transplants using Sca1. A. Table showing tumor propagation 
ability of Sca1+ and Sca1- Kras;p53-flox lung tumor cells. 1,000-10,000 cells were 
intratracheally transplanted into immunocompromised mice. The percentage of recipient 
mice with at least one lung tumor after 17-29 weeks is shown. B. Table of metastatic 
incidence in secondary mice from transplantation of 6,000-10,000 Sca1+ or Sca1- 
Kras;p53-flox lung tumor cells. The number and (percentage) of recipient mice with at 
least one metastatic lesion are shown in the first column. Location columns show the 
number and (percentage) of recipient mice with metastases in the noted site.
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Figure 2-5: (continued) 
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Appendix). More mice are needed to make definitive conclusions about the role of Sca1 
as a metastatic marker (2/3 mice developed metastases in Sca1+ transplants vs. 1/2 
mice in Sca1- transplants) (Figure 2-5B). 
Having identified the Sca1+CD24+ and Sca1-CD24+ populations as TPC-
enriched, we tested their relative metastatic capability.  Recipients of Sca1+CD24+ or 
Sca1-CD24+ populations developed high-grade lung tumors and metastases (Figure 2-
3C,D).  When we compared mice bearing lung tumors of equal size and comparable 
grades that arose from either of the TPC populations, recipients of Sca1+CD24+ cells 
(6/7) were significantly more likely to have metastases than the Sca1-CD24+ recipients 
(3/10) (p=0.0498, Figure 2-3E, F, Figure 2-4E). Thus, at least two TPC populations can 
be identified with Sca1 and CD24 staining, and the Sca1+CD24+ phenotype is most 
highly associated with metastatic activity. 
CD24 plays a functional role in metastatic activity 
To further probe the role of CD24 in the metastatic spread of lung cancer, we 
generated a series of cell lines from the Kras;p53-flox lung adenocarcinoma model. The 
CK1750 and SC241 cell lines exhibit many properties of metastatic lung tumor cells. 
Firstly, CK1750 cells robustly formed adenocarcinomas when transplanted 
intratracheally (10/12 recipients formed tumors when 1,000-10,000 cells were injected) 
(Figure 2-6A). Furthermore, these recipient animals developed metastases in multiple 
sites including the chest wall (5/10), lymph nodes (4/10), adrenal glands (2/10), and liver 
(1/10), with approximately 50% of recipients exhibiting metastasis to one or more sites 
(Figure 2-6A). Nearly all CK1750 and SC241 cells expressed CD24 and Sca1 (Figure 2-
	   60	  
Figure 2-6: CD24 expression is required for migration and ectopic growth of 
murine lung adenocarcinoma cells. A. H&E images of a lung tumor (left) and adrenal 
gland metastasis (right) from intratracheal transplantation from the Kras;p53-flox 
CK1750 cell line. Images are 200x magnification, scale bars represent 100µM. B. FACS 
plot from CK1750 cells showing expression of CD24 and Sca1. Cells shown were gated 
on the single, live (DAPI-negative), CD31-negative, CD45-negative population. C. 
Analysis of  cellular migration from in vitro transwell migration assays, determined by 
scoring cells migrating towards serum-containing (10% FBS) media with CK1750 CD24 
knockdown cells (shCD24-Low-1 & Low-5, n=3) or control CK1750 shGFP cells (shGFP 
n=6,).  Results shown are the average of three independent experiments.  D. Average 
number of lung metastases after tail vein injection of CK1750 shGFP cells (circles), 
CK1750 shCD24-Low-1 cells (squares), or CK1750 shCD24-Low-5 cells (triangles). 
Lungs were analyzed for metastases two weeks after injection of 500,000 cells. Each 
symbol represents an individual mouse analyzed.  E. Table showing the number of 
recipient mice with lung tumor formation after intratracheal injection with 100,000 
shGFP cells or shCD24-Low-1 cells out of the total injected mice (percentage).  *, p < 
0.05.  
	   61	  
Figure 2-6: (continued) 
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6B). Thus, the cell lines functionally and phenotypically resembled the most metastatic 
Kras;p53-flox lung TPCs. 
Utilizing two different shRNA constructs against CD24 (shCD24-1 targets the 
3’UTR, while shCD24-5 targets the coding region) we diminished CD24 expression to 
~20-30% of normal transcript levels compared to shGFP control cells after selection for  
CK1750 and SC241 cells expressing the lowest levels of CD24 (termed “Low”) (Figure 
2-7A). Importantly, knockdown of CD24 in the CK1750 cell line did not affect the growth 
of the cells in standard cell culture conditions (Figure 2-7B). However, in transwell in 
vitro migration assays, the CD24 knockdown lines showed markedly less migration 
compared with control shGFP cells (Figure 2-6C); the shCD24-Low-1 and shCD24-Low-
5 lines showed a 3-fold and 4-fold reductions in migration, respectively (p=0.033 & 
p=0.015). CD24 knockdown in SC241 cells showed similar results; the shCD24-Low-1 
and shCD24-Low-5 lines also showed 3-fold and 4-fold reductions in migration, 
respectively (p=0.013 & p=0.0024) (Figure 2-6C). To assess metastatic capacity in vivo, 
shGFP and shCD24 cells were injected into the tail vein of nude mice. Transplantation 
of the shCD24-Low-1 and shCD24-Low-5 lines resulted in a significantly lower number 
of lung metastases (p = 0.7x10-4, & p=0.027) and smaller tumor burden for shCD24-
Low-1 transplants (Figure 2-6D, Figure 2-7D,E). However, average tumor size was not 
significantly different between the shGFP control and shCD24 groups, suggesting 
engraftment rather than proliferation is affected by knockdown of CD24 in this tail vein 
assay (Figure 2-7F). Intratracheal injections showed that shCD24 cells were devoid of 
TPC activity compared with shGFP controls; shCD24-Low-1 cells produced lung tumors 
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Figure 2-7:  CD24 knockdown in CK1750 and SC241 cells. A. qPCR for CD24 
expression levels after knockdown of of CD24 in CK1750 (see also Figure 3) B. A 
growth curve analysis of CD24 knockdown and control (shGFP) CK1750 cell line 
derivatives. No time points showed significant differences. C. The average number of 
migratory cells observed in transwell migration assays, determined by the number of 
cells migrating towards serum-containing (10% FBS) media in control or CD24 
knockdown SC241 cells. *p= 0.013 shCD24-Low-1, p= 0.0024, shCD24-Low-5. Results 
shown are from one representative experiment. D. H&E images of lung metastasis after 
tail vein injection of 500,000 CK170 shGFP, shCD24-Low-1, and shCD24-Low-5 cells.  
Images are 40x magnification, scale bars represent 1000µM. E.  Average tumor burden 
in tumors from tail vein transplantation of shGFP or shCD24 CK1750 cells calculated as 
the percentage of lung area filled with tumors. N = 6 mice for shGFP, N=3 for shCD24-
Low-1, N=6 for shCD24-Low-5. *, shCD24-Low-1 p=0.048.  F. Average tumor area in 
tumors from tail vein transplantation shGFP or shCD24 CK1750 cells. N = 6 mice for 
shGFP, N=3 for shCD24-Low-1, N=6 for shCD24-Low-5. G. Cell line derivatives (10,000 
cells) were transplanted subcutaneously and resulting tumors were measured.  
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Figure 2-7:  (continued) 
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after IT administration in 0/5 recipients whereas shGFP cells yielded tumors in 4/6 
recipients (p= 0.04, Figure 2-6E). While CD24 knockdown cells were capable of 
subcutaneous tumor formation, the shCD24-Low-1 line showed a longer latency to first 
palpable tumor (p=0.04) and yielded smaller tumors 3 weeks post-transplant (p=0.001) 
(Figure 2-7G). These findings strongly suggest that CD24 plays a functional role in TPC 
activity and in promoting lung cancer metastasis. 
To further probe the mechanism of CD24 function in metastasis, we bred CD24 
knockout mice to the Kras;p53-flox mice and we have started to compare tumor 
development and metastasis in Kras;p53-flox CD24 KO/KO and CD24 WT/WT mice 
(Figure 2-8A,B).  To date, the percentage of Kras;p53; CD24 KO mice with metastasis 
was not significantly different compared to wild-type controls (8/29=28% of CD24KO 
mice had metastasis and 7/15=47% of CD24WT/WT mice developed metastases, 
Figure 2-8B). Interestingly, we observed a trend for reduced metastases in the pleural 
lining or chest cavity in CD24 KO mice (3/8=38%) compared to CD24 WT mice 
(5/7=71%).  These data are still preliminary due to low numbers of WT/WT mice, yet 
they do demonstrate that CD24 is not required for metastasis per se.  CD24 may prove 
to have a role in metastatic development in particular locations.  It is also important to 
note that CD24 is deleted in these mice from development and at the time of tumor 
initiation, so that any CD24-dependent activity that may occur specifically during the 
course of tumor progression and metastasis cannot be assessed.   
Murine lung TPCs exhibit clinically relevant, metastatic gene expression profiles  
To better understand the connections between TPCs and metastatic potential, 
we next took an unbiased gene expression profiling approach. Microarray data from the
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Figure 2-8: Kras;p53-flox CD24WT and CD24KO mice have similar rates of tumor 
formation and metastases. Tumor development and metastasis formation was 
examined 17 weeks following Cre administration, unless mice exhibited signs of distress 
earlier. A. The number and percentage of mice with that developed lung tumors are 
shown. B. The number and percentage of mice with at least one metastatic lesion are 
shown in the first column. Location columns show the number and percentage of mice 
with metastases in the noted site.  
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Figure 2-8: (continued) 
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Kras;p53-flox TPCs were further interrogated by bioinformatics. 278 differentially 
expressed, upregulated probes corresponding to 250 unique genes (log2 fold-change > 
1.53 and p-value <= 0.02) were used in this analysis (Figure 2-9A) (Appendix). Gene 
set enrichment analysis (GSEA) on the expression data revealed that gene sets 
involved in processes such as cytoskeletal rearrangement, cell motility/migration, and 
invasion, all of which are associated with metastatic capacity, were significantly 
overrepresented in TPCs (Figure 2-9B). Sca1+ and Sca1- populations had equally low 
levels of vimentin (Vim) expression and high levels of E-cadherin (Cdh1) (Figure 2-
10A,B), confirming that enrichment for these gene sets was not a result of stromal 
contamination. These results supported the idea that lung TPCs are involved in 
metastatic spread of Kras;p53-flox lung tumors, and that this activity is not related to an 
epithelial-to-mesenchymal transition as observed in other tumor types (Cordenonsi et 
al., 2011).  
As we had found increasing evidence that TPCs contributed to metastasis, we 
sought to determine a relationship between murine TPCs and lung adenocarcinoma 
patient data.  We generated a gene signature consisting of 126 human orthologs 
corresponding to the significantly upregulated genes in Kras;p53-flox TPCs (Appendix). 
The TPC gene signature was examined in the Director’s Challenge cohort of lung 
adenocarcinoma patients and was found to be significantly associated with decreased 
overall survival (p=0.0006) and with metastasis (p=0.049) (Figure 2-9C). These data 
indicated that our results using murine models to study tumor propagation and 
metastasis are applicable to human lung cancer.  
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Figure 2-9: Lung tumor-propagating cells exhibit clinically relevant gene 
expression profiles that suggest metastatic potential.  A. Heatmap showing the 250 
genes significantly upregulated in Sca1+ TPCs compared to Sca1- non-TPCs from 
Kras;p53-flox lung tumors as assessed by Affymetrix Mouse 430 2.0 gene expression 
microarray. Red indicates upregulated expression, green is downregulated expression. 
B. Table of the top 5 most significantly enriched gene sets (based on GSEA enrichment 
and False Discovery Rate (FDR) q-value less than 0.25) in the TPC cell population.  
Hippo conserved signature genes found in the indicated gene set are listed in the last 
column.  C. The Director’s Challenge collection of lung cancer data sets was 
interrogated for expression of a gene signature upregulated in murine TPCs.  Higher 
expression of the TPC signature (red) versus lower expression of the TPC signature 
(blue) was compared for patient metastasis (left) and overall survival (right). D-G. 
Expression of indicated genes by qPCR in sorted TPC or non-TPC cells from Kras;p53-
flox lung tumors.  N=8 samples each. D. Yap1 expression, E. Taz (Wwtr1) expression, 
F. Nf2 expression, G. Cyr61 expression.  H.  The Director’s Challenge collection of lung 
cancer data sets was interrogated for expression of the Hippo conserved signature.  
Higher expression of the Hippo signature (red) versus lower expression of the Hippo 
signature (blue) was compared for patient metastasis (left) and overall survival (right).  
*, p < 0.05
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Figure 2-9: (continued) 
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Figure 2-10. Kras;p53-flox Sca1+ TPCs and Sca1- non-TPCs. A. qPCR analysis of 
Vimentin (Vim) expression in lung TPCs and non-TPC cells. B. qPCR analysis of 
expression of E-Cadherin (Cdh1) in lung TPCs and non-TPC cells.  C. Enrichment plot 
from GSEA of Yap/Taz Signature enrichment in TPCs. NES = Normalized Enrichment 
score, P value = nominal P value.  
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Figure 2-10: (continued) 
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Yap/Taz in metastatic lung TPCs 
We next used the gene expression analyses to identify molecules other than 
CD24 that may be crucial for lung tumor propagation and metastatic potential.  The 
gene sets enriched in lung TPCs, including Actin Filament Based Processes, Actin 
Cytoskeleton Organization and Biogenesis, and Regulation of Cell Migration, included 
members of the Hippo signaling cascade (Figure 2-9B). Furthermore, GSEA with a 
Yap/Taz Gene Signature (Cordenonsi et al., 2011) revealed that Sca1+ TPCs were 
significantly enriched for this gene set; 25 out of 52 genes in the Yap/Taz gene set 
exhibited core enrichment in lung TPCs (Figure 2-10C).  
We validated expression differences in Hippo pathway components in lung 
TPCs.  Yap1 was not significantly differentially expressed between the Sca1+ and 
Sca1- cells by Real Time RT-PCR analysis (Figure 2-9D, p=0.10). However, Wwtr1 
(Taz), which has been shown to be important in lung development (Mitani et al., 2009), 
was over 2-fold overexpressed in the Sca1+ TPCs compared to Sca1- cells (Figure 2-
9E, p=0.0087). Importantly, the potent negative regulator of the Hippo pathway, Nf2, 
was greater than 15-fold down-regulated in the Sca1+ cell population (Figure 2-9F, 
p=0.0001), while a known downstream target of activated Hippo signaling, cysteine-rich 
angiogenic inducer 61 (Cyr61), was over 2-fold up-regulated in the Sca1+ cell 
population (Figure 2-9G, p=0.021).  In the Director’s Challenge cohort of lung 
adenocarcinoma patients, the Yap/Taz signature was significantly associated with 
worse overall survival (p=0.00001) and with metastasis (p=0.009) (Figure 2-9H). We 
have also stained a human lung tumor tissue microarray for YAP (Figure 2-11). Slides  
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Figure 2-11: Human Lung Tumor Tissue Microarray Stained for YAP. Slides were 
stained for YAP and scored for both nuclear and cytoplasmic expression level scores 
(1-3) and percentages of positive cells (0-100%). H-Score is the score x percent tumor 
nuclei (0-300). A. Kaplan-Meier survival curve using H-Score, patients grouped into 
terciles. B. Kaplan-Meier Survival curve using YAP nuclear percentage, patients 
grouped by nuclear score and nuclear percent. C. Median YAP Nuclear Percent by N-
stage. D. Median YAP Nuclear Percent by T-stage. E. Median YAP Nuclear Percent by 
Final Stage.  F. MedianYAP H-Score by N-stage. G. Median YAP H-Score by T-stage.  
H. Median YAP H-Score by Final Stage. 
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Figure 2-11: (continued) 
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were stained for YAP and scored for both nuclear and cytoplasmic expression level 
scores (1-3) and percentages of positive cells (0-100%). There was a trend of higher 
YAP nuclear percentage with higher T stage (Figure 2-11D). Although no significant 
associations with survival or stage were found, this could be due to staining difficulties 
(one slide of samples could not be scored due to poor staining) or to insufficient sample 
size. These data implicated Yap/Taz in TPCs and human lung cancer progression. 
We next examined Yap1/Taz protein levels in tissue sections from murine lung 
cancer models, since differences in protein levels and localization of the Hippo 
transcriptional controllers may be more important than overall expression levels 
detected at the RNA level.  Yap1/Taz activity is tightly controlled at the protein level: 
phosphorylated Yap1/Taz is sequestered in the cytoplasm and inactive, but 
dephosphorylated Yap1/Taz can translocate into the nucleus to activate target gene 
transcription. Using an antibody that recognizes both Yap1 and Taz proteins, we 
performed immunostaining of tumors from the non-metastatic Kras model (Jackson et 
al., 2001) and the Kras;p53-flox metastatic tumors. Interestingly, Yap1/Taz expression 
in Kras tumors was very weak and almost exclusively cytoplasmic (Figure 2-12A, n=4). 
In stark contrast, in Kras;p53-flox tumors (n=4) ~30-50% of tumor cells expressed 
nuclear Yap1/Taz, and in lymph node metastases from Kras;p53-flox mice, almost all 
cells expressed nuclear Yap1/Taz (n=3) (Figure 2-12A). These results supported the 
concept that Yap1/Taz expression and activity is correlated with more aggressive 
disease in lung cancer.  
To determine if Yap activity is sufficient to affect lung tumor progression, we used 
a doxycycline-inducible, constitutively active allele of Yap1 in combination with 
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Figure 2-12: Yap/Taz function contributes to lung tumor progression and 
metastatic potential. A. Representative Yap1/Taz IHC (brown staining) in a Kras 
primary lung tumor (top), Kras;p53-flox tumor (middle), and Kras;p53-flox lymph node 
metastasis (bottom). 400x magnification, with zoom as shown, approximately 75 µm. B. 
Percentage of mice of each genotype with tumors of grade 0-4 scored from paraffin 
sections. Grade shown is the highest tumor grade present in each mouse. Grade 0 
indicates no tumors present.  C. Number of lung tumors per mouse was scored from 
paraffin sections and averaged for each genotype. N = 15 Kras mice, 14 Kras;Yap mice. 
D. Tumor burden was measured as the percentage of lung filled with tumors.  *p<0.05.  
Mice were euthanized 7 months after Cre or earlier if symptoms of lung tumors were 
apparent.  N = 15 Kras mice, 14 Kras;Yap mice. E. Percentage of Ki67+ cells per 200x 
field. F. The average number of migratory cells observed in transwell migration assays, 
determined by the number of cells migrating towards serum-containing (10% FBS) 
media in control, Yap1 or Taz knockdown CK1750 cells.  Results shown are the 
average of three independent experiments.  G. Average number of lung metastases 
after tail vein injection of CK1750 shGFP cells (circles), CK1750 shYap1 cells (squares, 
up triangles), or CK1750 shTaz cells (down triangles, diamonds). Lungs were analyzed 
for metastases two weeks after injection of 100,000 cells. Each symbol represents an 
individual mouse analyzed.  Data shown are the combination of two independent 
experiments.  *p < 0.05, one tailed t test, n=6. 
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Figure 2-12: (continued) 
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oncogenic Kras in vivo.  In tetO-YapS127A mice, a mutated version of Yap1 exhibits 
enhanced nuclear localization of Yap1 and constitutive signaling activity (Schlegelmilch 
et al, 2011).  In a binary genetic approach, we activated Yap1 activity in lung tumor cells 
by treating Kras; LSL-rtTA; tetO-YapS127A mice with Adeno-Cre to initiate lung 
tumorigenesis, followed by treatment with doxycycline to activate Yap signaling 
concomitant with tumor initiation.  Mice were euthanized when they showed signs of 
distress, seven months after Adeno-Cre and doxycycline administration. Histological 
analysis showed that tumors of Kras; LSL-rtTA; tetO-YapS127A mice were significantly 
higher grade than those in Kras controls (Cochran-Armitage test, p =0.04, Figure 2-
12B). Kras; LSL-rtTA; tetO-YapS127A mice had significantly more tumors than Kras 
controls (Figure 2-12C), but no difference in overall tumor burden, average tumor size, 
or Ki67 staining index (Figure 2-12D,E, Figure 2-13A,B,C). These results indicated that 
Yap activation is sufficient to promote lung tumor progression in vivo.  
We interrogated the role of Yap/Taz in metastatic capacity using in vitro migration 
and in vivo tail vein assays in the Kras;p53-flox cell lines after knockdown of Yap1/Taz.  
Two different shRNAs were used to reduce Yap1 or Taz levels to 40-80% of control 
levels (Figure 2-13D,E). A significant reduction (1.5-3-fold compared to shGFP) in 
migration was observed in the shYap1 or shTaz cells exhibiting knockdown (p < 0.05) 
compared with the negative control shGFP (Figure 2-12F). To examine whether YAP 
knockdown in the human lung cancer cell line A549 would yield similar results, we 
interrogated the ability of two different doxycycline-inducible YAP shRNAs to affect cell 
migration. Dox-induced YAP knockdown resulted in significantly fewer migrated cells 
using both hairpins (p=0.023 and p=0.020); migration was over 2-fold decreased in 
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Figure 2-13: Yap/Taz knockdown and CK1750, SC241, Tmet, and A549 cells. A. 
qPCR analysis of human Yap1 levels in Kras;LSL-rtTA; tetO-YapS127A (Kras; Yap) 
mice and littermate controls B. Average tumor size in Kras;Yap mice and Kras controls. 
N = 6 Kras mice, 11 Kras;Yap mice. C. Representative images of Ki67 staining in a 
Kras;Yap tumor (top) and a Kras tumor (bottom). Images are 200x magnification. D. 
qPCR analysis of Yap1 levels after knockdown of Yap1 in CK1750 cells. E. qPCR 
analysis of Taz levels after knockdown of Taz in CK1750 cells. F. The average number 
of migratory cells observed in transwell migration assays, determined by the number of 
cells migrating towards serum-containing (10% FBS) media in control or YAP1 
knockdown A549 cells. +DOX cells were treated with 1ug/mL doxycycline for two days 
prior to migration experiment to induce knockdown. A and B are two different YAP1 
shRNAs. Results shown are the average of two independent experiments.  *, p = 0.023, 
shYAPA, p= 0.020, shYAPB. G. H&E images of lung metastasis after tail vein injection 
of 100,000 CK170 shGFP, shYap1 or shTaz cells.  Images are 40x magnification, scale 
bars represent 1000µM. H. Average tumor burden in tumors from tail vein 
transplantation of shGFP or shTaz CK1750 cells calculated as the percentage of lung 
area filled with tumors. N=6 mice. shTaz1616, p=0.0096. I. Average tumor size in 
tumors from shGFP or shTaz CK1750 cells. N=6 mice. p= 0.00031 shTaz 771, 
p=5.9x10-5 shTaz16
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Figure 2-13: (continued) 
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A549 YAP knockdown cells (Figure 2-13F). Finally, tail vein injection was performed to 
assess the impact of knockdown on metastatic capacity in vivo. Lung metastases were 
significantly less frequent in recipients of shTaz cell lines compared to shGFP or shYap 
cells (shYap1108 p=0.061, shYap1824 p=0.18, shTaz771 p=0.029, shTaz1616 
p=0.0029), and recipients of shTaz1616 cell lines in particular showed very few or no 
metastases or tumor burden (Figure 2-12G, Figure 2-13G,H). Average tumor size was 
also smaller in shTaz recipients (Figure 2-13I).  These data indicated that Yap/Taz is 
necessary and sufficient to drive key steps in advanced lung tumorigenesis, including 
progression, migration, and metastasis.   
To investigate the mechanism of Yap/Taz activity and to discover potential Taz 
targets in lung cancer cells, gene expression microarray analysis was performed.  3 
paired shGFP or shTaz Kras;p53-flox murine lung tumor cell lines (CK1750, SC241, 
and Tmet) were compared; differentially expressed genes are listed in the Appendix 
(Figure 2-14A).  Gene Set Enrichment Analysis of the shTaz vs shGFP data was used 
to identify gene sets with negative enrichment scores, indicating cellular processes 
possibly impacted by Taz knockdown (Figure 2-14B). The Yap/Taz gene signature 
(Cordenonsi et al., 2011) and genes differentially expressed in the Taz knockout mouse 
lungs (Mitani et al, 2009) were significantly enriched in the shTaz data set, validating 
our approach.  qPCR confirmed differential expression of Cyr61, a known Yap/Taz 
target, and Ltbp4, a mediator of the TGF-β pathway and possible Yap/Taz target, in 
SC241 shGFP and shTaz cells (Figure 2-14C), further validating our gene expression 
data set.  Published data sets connected to migration and metastasis (Lung Cancer  
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Figure 2-14: Gene Set Enrichment Analysis in shGFP vs shTaz cells A. qPCR 
analysis of Taz levels after knockdown of Taz in CK1750, SC241, and Tmet cells used 
for microarray analysis. B. Enrichment plots from GSEA showing enrichment in shGFP 
vs shTaz cells. NES = Normalized Enrichment score, P value = nominal P value. See 
manuscript text for references. C. qPCR analysis of Ltbp4 levels after knockdown of Taz 
in SC241 cells. D. qPCR analysis of Cyr61 levels after knockdown of Taz in SC241 
cells. E. qPCR analysis of Bcl2 levels after knockdown of Taz in SC241 cells. 
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Figure 2-14: (continued) 
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Metastasis- Nguyen et al., 2009, Breast Cancer Invasion- Patsialou et al., 2012, Breast 
Cancer Migration- Gunawardane et al., 2005, Bladder Cancer Migration- Wu et al., 
2008) were also enriched, validating the metastatic capacity associated with Yap/Taz 
activity.  
Gene sets of interest that were significantly enriched in shTaz cells revealed 
several pathways and activities that may be critical for Yap/Taz function in lung cancer 
progression and metastasis.  Several gene sets associated with NF Kappa B signaling 
were significantly enriched: I KappaB Kinase NF KappaB Cascade, Regulation of I 
KappaB Kinase NF KappaB Cascade, and Positive Regulation of I KappaB Kinase NF 
KappaB Cascade (Appendix).  Expression of Bcl2, an NF-KB target that inhibits 
apoptosis, was validated for significantly decreased expression in shTaz cells (Figure 2-
14E).  Gene sets corresponding to actin cytoskeletal processes were also highly 
decreased after Taz knockdown, including Actin Cytoskeleton, Cytoskeletal Protein 
Binding, Actin Binding, Actin Filament Binding, and Actin Filament Based Processes.  
These pathways and activities may be critical for cancer progression and metastasis. 
 
Discussion 
Our results provide novel insight into the cells and pathways that drive the 
progression and metastasis of lung adenocarcinoma using TPCs as a discovery 
platform.  TPCs expressing Sca1 and CD24 were enriched for metastatic activity after 
orthotopic transplantation.  CD24 knockdown impaired metastatic processes including 
migration and ectopic tumor growth.  Our findings also implicate a role for the Hippo 
signaling mediators Yap and Taz in lung TPCs and the progression and metastasis of 
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lung cancer. Importantly, expression of TPC and Yap/Taz gene signatures predicted 
metastasis and patient survival, demonstrating the relevance of our findings in mouse 
models to human disease.  These results delineate new ways to uncover clinically 
relevant mechanisms in advanced lung cancer.  
Our data provide new understanding of the links between tumor-propagating 
cells and metastasis, an idea that has been postulated for at least a decade with limited 
experimental backing (reviewed in (Adhikari et al., 2011)). The significant correlation of 
our TPC gene expression signature with both metastasis and patient survival adds new 
support for this proposition. Lung TPCs also exhibited downregulation of Nkx2.1, a 
mechanism known to correspond with increased metastatic potential (Curtis et al., 2010;  
Winslow et al., 2011). We show that several TPC populations can produce metastatic 
lesions, albeit with differing degrees of activity; Sca1+CD24+ cells were more metastatic 
than Sca1-CD24+ cells.  Differing from our work, tumor cell barcoding studies in colon 
cancer showed that only one TPC fraction, long-term TPCs, contributed to metastases 
(Dieter et al., 2011).  Therefore, in some tumor types one unique metastasis-
propagating cell population may exist, whereas our data suggest a gradient of 
metastatic capacity exists within lung tumors. 
CD24 appears to be required for lung TPCs to propagate tumors and possibly to 
drive a metastatic cascade. CD24 expression levels were similar in lung tumors arising 
in recipient mice after transplantation of CD24+ or CD24- cells; it is possible that 
activation of CD24 expression is critical during a particular stage of tumorigenesis or 
metastatic progression.  Furthermore, results in bladder (Overdevest et al., 2011) and 
liver (Lee et al., 2011) cancer, in combination with the present study, make a strong 
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argument for CD24 being a marker and functional mediator of metastatic potential in 
multiple tumor types.  As proliferation and apoptosis were not significantly altered in 
CD24 knockdown cells, the mechanism by which CD24 affects tumorigenesis remains 
to be determined.   
We demonstrate for the first time that Yap/Taz are active in lung-tumor 
propagating cells with metastatic potential, and that Yap activation affects lung tumor 
progression in a mouse model in vivo.  Interestingly, the Yap/Taz gene signature 
predicted lung cancer patient metastasis and survival.  Taz expression was also found 
to be significantly associated with poor differentiation, poor survival, and metastasis in 
patients with non-small cell lung cancer (Xie et al., 2012).  Previously, Yap1 and Taz 
have both been implicated in different processes of lung development and disease (see 
also Introduction).  Taz interacts with the master transcription factor Nkx2.1 during 
mouse lung development to promote alveolarization (Mitani et al., 2009). These and our 
own observations of elevated Taz expression in TPCs and decreased lung metastases 
from tail vein injections after knockdown of Taz tempt us to speculate that Taz, rather 
than Yap1, is primarily utilized by lung tumors to promote metastasis. Supporting this 
idea, Taz may regulate the cancer stem cell phenotype in breast cancers (Cordenonsi 
et al., 2011).  In our studies, constitutive mutant Yap was sufficient to significantly 
impact Kras-driven lung tumor progression, yet metastasis did not develop in Kras;Yap 
mice.  Notably, the presence of more high grade tumors in Kras;Yap mice required 
euthanasia and may have precluded our ability to assess later metastatic progression. It 
is also possible that further activation of Yap1 through mutation at more than one site is 
	   88	  
necessary to drive metastases. It remains possible that both Yap1 and Taz play 
important and complementary roles in lung TPC function and metastatic potential.   
Yap/Taz may control lung cancer cell migration and metastasis through a number of 
mechanisms implicated in this study.  In tail vein assays, the average tumor size was 
significantly less in recipients of shTaz cells vs shGFP cells, pointing to the potential 
importance of Taz regulation of proliferation in advanced lung tumors.  Supporting this idea, 
we found many gene sets enriched for cell growth in shTaz cells.  GSEA also suggested a 
role for Taz regulation of the NF-KappaB pathway, which has been shown to be required for 
Kras;p53-flox lung tumorigenesis (Meylan et al, 2009; Xue et al., 2011). Further studies are 
needed to which, if any, of the cellular activities identified in our expression analyses are 
critical for Yap/Taz contribution to aggressive lung cancer. 
It will be important to understand the cellular markers and mechanistic drivers of 
metastatic cancer cells in each tumor type of interest. In bladder cancer, CD24+ cells 
rely on the STAT3/NANOG network to promote metastasis (Lee et al., 2011), whereas 
CD24+ cells utilize the SRC-family kinase YES in metastatic melanoma (Liu et al., 
2012).  Additionally, we show here that Yap/Taz activity may mediate lung cancer 
metastasis in lung TPCs. It remains to be determined if there is a direct interaction 
between CD24 and Yap1/Taz regulation in lung tumorigenesis, since we found that 
these molecules were all required for lung cancer cell metastatic behavior. Interestingly, 
Hippo signaling has been implicated in regulation of expression of CD44, another 
surface marker of tissue-specific TPCs such as in breast cancer (Cordenonsi et al., 
2011; Xu et al., 2010). Although there may be overlap between the markers and 
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pathways responsible for metastasis in different tumor types, many combinations are 
likely utilized by aggressive cancer cells. Synergistic investigations into the phenotype 
of cells that are responsible for metastatic spread of lung cancer and the pathways that 
mediate this progression should ultimately lead to new ways to target the most 
functionally important and deadly lung cancer cells.  
 
Materials and Methods  
Generation of Cell Lines and in vitro Assays 
CK1750 and SC241 cells were generated by culturing tumor cells from a 
Kras;p53-flox donor mouse in DMEM+10%FBS. Tmet cells were obtained from Monte 
Winslow (Winslow et al, 2011). These cells were infected with lentiviral constructs from 
The RNAi Consortium, pLKO.1 based system. The two hairpins directed at CD24a were 
TRCN0000077028 (shCD24a-1) and TRCN0000077032 (shCD24a-5), the two hairpins 
directed at Yap1 were TRCN0000095866 (Yap1108) and TRCN0000095864 
(Yap1824), the two hairpins directed at Taz were TRCN0000095949 (Taz1616) and 
TRCN0000095951 (Taz771), with a non-targeting hairpin directed against GFP (Sigma 
SHC005) as a control. Transduced cells were selected with 3µg/ml puromycin for 1-2 
weeks. Knockdown was confirmed by quantitative RT-PCR and flow cytometry. To 
generate shCD24-Low-1 and shcD24-Low-5 cell lines, sorts for the lowest CD24 
expressing cells were completed. All lines were maintained in DMEM+10%FBS. 24-well 
format cell migration assays (Corning) were performed as per the manufacturer’s 
instructions. Briefly, cells were serum-starved overnight, harvested with Accutase 
(Millipore) and counted. Cells were plated in serum-free conditions (30,000 cells per 
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well) on the top chambers and the bottom chambers contained either serum-free DMEM 
or DMEM+10%FBS. After a 24 hour incubation, non-migratory cells were removed 
using a cotton swab, migratory cells were stained with DAPI for imaging and nuclei were 
counted using ImageJ. All conditions were completed with three to four replicates and 
averaged. 
Mice and Tissues 
Lox-Stop-Lox-KrasG12D;p53fl/fl and Lox-Stop-Lox-KrasG12D mice (Jackson et al., 
2005; Jackson et al., 2001) were maintained in virus-free conditions on 129 SvJae 
background. Lox-Stop-Lox-KrasG12D;Lox-Stop-Lox-rtTA;tetO-YapS127A mice were 
maintained in virus-free conditions on a mixed 129/C57Bl6 background. All mouse 
experiments were approved by the BCH Animal Care and Use Committee and by the 
Dana-Farber Cancer Institute Institutional Animal Care and Use Committee, both 
accredited by AAALAC, and were performed in accordance with relevant institutional 
and national guidelines and regulations. Lung tissue preparation was as described 
(Curtis et al., 2010) and sections were analyzed for tumors by at least two investigators 
including a pathologist with expertise in murine lung cancer.  Tumor burden, the 
percentage of lung filled with tumor, was calculated using ImageJ to measure total lung 
and tumor area from H&E stained paraffin sections from each mouse.  Tumor size was 
measured using ImageJ to quantify tumor area from paraffin sections and the average 
area of all lung tumors per mouse was calculated.  For metastases, heart, liver, spleen, 
kidneys, lymph nodes, and chest wall were also analyzed. Immunohistochemistry was 
performed as described (Schlegelmilch et al., 2011) with anti- Yap1 (1:50, Cell Signaling 
#4912) or anti-Ki67 (1:10,000, Novocastra) antibodies and developed using Vectastain 
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Elite ABC kit (Vector Labs). Immunofluorescent staining for pro-SPC was performed 
with anti-pro-SPC (1:500, Chemicon). Imaging was performed with a Nikon 90i camera 
and NIS-Elements software and processed with NIS-Elements and Adobe Photoshop.  
FACS Analysis and Sorting 
Mice were euthanized with avertin overdose and lungs were dissected and 
examined grossly for tumor formation. Tumors were dissected from the lungs of 
primary mice and tumor tissue was prepared as described (Curtis et al., 2010). Briefly, 
tumors were isolated, minced, digested rotating for 1h at 37°C with 2mg/ml 
Collagenase/Dispase (Roche) and then filtered twice (100 µm, then 40 µm) after a 5 
minute incubation with 0.025 mg/mL DNase. Cell lines were trypsinized and then 
filtered (40 µm). Single cell suspensions were stained using Sca1-FITC, –PE, or APC-
Cy7, CD45-APC, CD31-APC, CD24-Biotin (with Streptavidin-APC/Cy7) or –FITC (BD 
Pharmingen) with 7AAD (Molecular Probes) or DAPI (Sigma) staining to visualize dead 
cells. All antibodies were incubated for 15-20 minutes at 1:100 dilutions for primaries 
and 1:200 for secondaries. Cell sorting was performed with a Beckman 
Coulter/Cytomation MoFlo or a BD FACS Aria, and data were analyzed with FloJo 
software (Tree Star, Inc.). 
Tumor Transplants 
Intratracheal transplants were performed as described (Curtis et al., 2010). Mice 
were monitored for signs of lung tumor onset and euthanized for gross and histological 
analysis upon signs of distress. Cells for tail vein injections were resuspended in PBS 
and mice were sacrificed two weeks after injection for analysis of lung metastasis. Cells 
for subcutaneous injections were resuspended in a 1:1 mixture of PBS and matrigel (BD 
	   92	  
Biosciences), and subcutaneous tumor volume was measured (volume = length x width 
x depth).  
Quantitative RT-PCR Gene Expression Analysis 
RNA from sorted cell populations was extracted from 8-12 tumors using the 
Stratagene Absolutely RNA Nanoprep Kit. cDNA was made using the SuperScript III kit 
(Invitrogen) and analyzed using TaqMan Assays (Applied Biosystems) for Acta2 
(Mm00725412_s1), Bcl2 (Mm00477631_m1), Cd24a (Mm00782538_sH), Cdh1 
(Mm01247357_m1), Cyr61 (Mm00487498_m1), Ltbp4 (Mm00723631_m1), Nf2 
(Mm00477771_m1), Vim (Mm01333430_m1), Wwtr1 (Mm01289583_m1), Yap1 
(Mm01143263_m1), or YAP1 (Hs00902712_g1), with a BioRad iQ5 iCycler or 
StepOnePlus™ Real-Time PCR System (Applied Biosystems) and software as per the 
manufacturer’s recommendations. Mouse Actb (B-actin, 4352341E) or Gapdh 
(4352339E) was used as an endogenous control for normalization. 
Microarray Analysis 
For Sca1+/Sca1- arrays, four primary tumors from Kras;p53-flox mice were 
dissociated and sorted into CD31-/CD45-/Sca1- and CD31-/CD45-/Sca1+ populations. 
RNA was isolated as above and subsequently amplified using the WT-Ovation Pico kit 
(NuGEN). The amplified cDNA was fragmented and biotin labeled using the FL-Ovation 
Biotin V2 kit (NuGEN). The Children’s Hospital Boston Molecular Genetics Core Facility 
performed the hybridization and data acquisition using an Affymetrix Mouse Genome 
430 2.0 expression array. Array normalization, expression value calculation
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and clustering analysis were performed using DNA-Chip Analyzer (www.dchip.org, 
Schadt et al., 2001). The Invariant Set Normalization method was used to normalize 
arrays at probe cell level to make them comparable, and the model-based method was 
used for probe-selection and computing expression values. These expression levels 
were attached with standard errors as measurement accuracy, which were 
subsequently used to compute 90% confidence intervals of fold changes between the 
Sca1+ and Sca1- groups. The lower confidence bounds of fold changes were 
conservative estimate of the real fold changes. Genes with more than 2 fold increased 
expression in Sca1+ cells relative to Sca1- cells and an associated p value of 0.02 were 
selected for further study (Sca1+ up gene signature, Appendix). The Affymetrix probe 
match tool was used for matching the Sca1+ up gene list to human U133A probes. 
Gene set enrichment analysis (GSEA) was performed by the Center for Computational 
Cancer Biology at the Dana Farber Cancer Institute with the pre-ranked implementation 
of the GSEA software package (Subramanian et al., 2005) using the moderated t-
statistic from limma to determine rank order (Smyth, 2004).  
shGFP/shTaz Arrays were performed in the Boston Children’s Hospital Molecular 
Genetics Core facility on Affymetrix mouse Gene2.0ST slides. Array quality was 
assessed using the R/Bioconductor package (http://www.bioconductor.org/).  Raw CEL 
files from U133A Affymetrix arrays were processed using the robust multi-array average 
(RMA) algorithm (Irizarry et al., 2003).  To identify genes correlating with the phenotypic 
groups, we used limma (Smyth, 2004) to fit a statistical linear model to the data and 
then tested for differential gene expression in the two groups: shTaz (SC241, CK1750 
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and Tmet) vs shGFP (SC241, CK1750 and Tmet).  GSEA (Subramanian et al., 2005) 
was performed using the javaGSEA desktop application on pre-ranked gene lists 
constructed from RMA normalized expression data. 
Human tumor data Kaplan-Meier analysis 
Raw gene expression data from human lung adenocarcinoma samples were 
obtained from publications (Director’s Challenge, 2008, Chitale et al., 2009, 
http://cbio.mskcc.org/Public/lung_array_data/). Among these datasets, 3 are annotated 
for survival post biopsy while 1 dataset is annotated for both survival and metastatic 
spread of disease. Probes intensities from the Affymetrix U133A platform used in these 
studies were normalized and modeled using dChip software. Kaplan-Meier survival 
analyses were implemented after the samples were hierarchically clustered using 
centroid linkage into two risk groups using either the human orthologues of the Sca1+ 
up gene set or the Yap/Taz conserved gene set (Cordenonsi et al., 2011).  Differences 
of the survival risk between the two risk groups were assessed using the Mantel-
Haenszel log rank test. The larger area between the two risk groups and its associated 
smaller p value from the Mantel-Haenszel log rank test implicate a better classification 
model.  For the dataset for which metastatic spread was annotated, both survival and 
metastatic spread of the two risk groups were queried. 
Statistical Analysis 
Except where indicated, Student’s t-test was used to compare measurements 
between 2 conditions. For tumor cell transplants, data organized in tables was analyzed 
using Fisher’s exact test. GraphPad Prism (GraphPad Software, Inc.), Excel and Mstat 
(McArdle Laboratory for Cancer Research, University of Wisconsin) were used for 
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graphing and statistical analyses. Unless noted otherwise, pooled data is represented 
by the mean and standard deviation. p-values less than 0.05 with a one-tailed 
distribution were considered significant. 
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Summary 
  The work presented in this thesis identifies key molecules and pathways 
important for lung cancer metastasis. These findings are summarized in Figure 3-1. 
First, studies of murine lung adenocarcinoma tumors led to prospective isolation of TPC 
populations with metastatic potential. When fractionating murine lung tumors into four 
populations based on expression of the TPC markers Sca1 and CD24, two populations 
were capable of tumor propagation and metastasis, Sca1+CD24+ and Sca1-CD24+. 
However, metastatic capability was enriched in the Sca1+CD24+ population. CD24 
function was also found to be important for migration and metastatic properties of 
murine lung adenocarcinoma cells. In addition to identification of CD24 as a molecule 
important for metastasis, further study of the double positive population will be valuable 
in understanding more about metastatic lung cancer cells. Gene expression analysis of 
murine lung TPCs identified the Hippo pathway as an important pathway involved in 
lung cancer metastasis. Mediators of their signaling mechanism, Yap and Taz, were 
found to be important for tumor progression and metastases of lung adenocarcinoma 
cells. The advances described here will lead to future studies regarding the mechanism 
of CD24 and Yap/Taz in metastatic lung cancer, which will hopefully lead to treatments 
for this deadly disease.
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Figure 3-1: Model of murine lung TPCs and metastasis. Murine lung 
adenocarcinoma tumors were fractionated into four populations based on expression of 
the TPC markers Sca1 and CD24. Two populations were capable of tumor propagation, 
Sca1+CD24+ and Sca1-CD24+, but metastatic ability was enriched in the Sca1+CD24+ 
population.
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Lung TPCs and Metastasis 
 Although a few previous studies have linked TPCs with metastasis in other 
cancer types, the work presented here is the first to link lung TPCs and metastasis. The 
results of this study bring up several intriguing questions regarding the relationship 
between tumor propagating ability and metastatic ability. First, our work provides 
evidence that there are multiple TPC populations within murine Kras;p53-flox lung 
adenocarcinomas, and that these various TPCs have different degrees of metastatic 
capacity. Second, our work highlights differences in TPC frequency based on tumor 
subfractionation using single markers or combinations of markers to enrich for different 
populations. 
Many studies of CSCs, clonal evolution, and metastasis raise the issue of 
whether metastatic potential is limited to one population of tumorigenic cells or whether 
it can arise through genetic or epigenetic changes in many populations of cancer cells 
(Magee et al., 2012). Today, it is generally thought within the field that some 
combination of the cancer stem cell hypothesis, clonal evolution, and 
microenvironmental influence is at work within tumors, with different tumor types leaning 
more towards a hierarchy than others (Magee et al., 2012; Meacham and Morrison, 
2013). Our results support the idea that multiple populations within lung 
adenocarcinoma may be capable of tumor propagation and metastasis. It would be 
interesting to test whether multiple tumor clones within Kras-driven lung tumors have 
different tumor propagating and metastatic abilities at various time points during tumor 
progression or after therapy. Ongoing work in our lab is examining this hypothesis using 
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a LSL-YFP lineage tag to sort and transplant tumor cells at various time points (K 
Bellaria, SJ Curtis, C Kriegel, CF Kim, unpublished data). 
 Others have suggested that there are multiple TPC clones within a tumor and 
that these TPCs compete with each other for tumor repopulation or metastatic ability 
(Baccelli and Trumpp, 2012; Magee et al., 2012; Visvader and Lindeman, 2012). Our 
results support this hypothesis, showing that Sca1+CD24+ TPCs are best able to seed 
metastases, but that Sca1-CD24+ TPCs are also able to metastasize at a lower 
frequency.  While some studies have identified one TPC population that is capable of 
metastasis (Dieter et al., 2011; Hermann et al., 2007; Pang et al., 2010), other studies 
show that there are multiple tumor clones (not necessarily TPCs) that are responsible 
for metastasis (Campbell et al., 2010; Gerlinger et al., 2012; 2014; Wu et al., 2012; 
Yachida et al., 2010). 
 Two studies by Iacobuzio-Donahue, Futreal and colleages showed that there are 
clonal populations within pancreatic tumors that give rise to distant metastases, but that 
these metastatic clones are distinct and evolve from the original parental clones which 
are non-metastatic (Campbell et al., 2010; Yachida et al., 2010). Similar work in renal 
cell carcinoma and medulloblastoma found that there were metastatic clones which 
branched off from the parental tumor clone  (Gerlinger et al., 2012;  2014; Wu et al., 
2012). These studies provide evidence for parallel evolution of multiple mutations in 
different tumor subclones. In contrast, a study of tumor clones in breast cancer showed 
evidence for a single metastatic clone that arose late in tumor development (Navin et 
al., 2011). Similar to our findings, two studies of acute lymphoblastic leukemia (ALL) 
showed that there were several CSC clones that existed in patients (Anderson et al., 
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2011; Notta et al., 2011).  During progression, after therapy, and in serial 
xenotransplantation different clones could take over and initiate new tumors (Anderson 
et al., 2011; Notta et al., 2011).  
 Another interesting implication of the work presented here is that the TPC 
frequency was lower when comparing more purified populations than it was for bulk 
populations (Table 3-1) (Chapter 2) (Curtis et al., 2010). TPC frequency was similar in 
the total epithelial tumor cell population (CD31-CD45-) and in Sca1+ TPCs (~1/ 1,400), 
whereas TPC frequency in Sca1+CD24+ and Sca1-CD24+ was much lower (~1/ 8,000-
10,000).  
This raises the interesting idea that tumor cell populations influence each other’s 
tumor propagation ability, and more importantly, regulate each other’s role in driving 
tumor maintenance or progression. Little has been studied about the effect of 
separating smaller and smaller subfractions of tumor cells from their surrounding 
microenvironment. It is possible that there are supporting cells in more heterogeneous 
TPCs that are lost upon further selection of Sca1+CD24+ cells, and this explains the 
difference in TPC frequency in these populations. In the normal lung, Sca1 has been 
shown to also mark fibroblasts and other stromal cells (McQualter et al., 2009), while 
CD24 marks epithelial populations such as ciliated cells, BASCs, and other lung 
progenitors (McQualter et al., 2010; Zacharek et al., 2011). It is possible that either 
stromal cells and/or other epithelial cells within Kras;p53-flox tumors are present within 
the Sca1+ TPC population and interact with tumor propagating cells to enhance their 
function, and that further selection of Sca1+CD24+ and Sca1-CD24+ cells reduces the  
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Table 3-1. Frequency of tumor-propagating cells in multiple populations of 
Kras;p53-flox lung tumors. TPC frequency was determined by limiting dilution 
analysis of tumor transplants and calculated using the L-CALC software. 
Kras; p53-flox tumor cells transplanted 
Population TPC Frequency Source 
CD31-CD45- 1/ 1,400  (Curtis et al., 2010) 
Sca1+ 1/ 1,489  (Curtis et al., 2010) 
Sca1- 1/ 7,567  (Curtis et al., 2010) 
Sca1+ CD24+ 1/ 10,284  (Lau et al., 2014) 
Sca1- CD24+ 1/ 8,153  (Lau et al., 2014) 
Sca1+ CD24- 1/ 37,838  (Lau et al., 2014) 
Sca1- CD24- 1/ 22,289  (Lau et al., 2014) 
	  	   109	  
ability of these cells to interact. For example, the non-TPC tumor cells such as the 
CD24- and Sca1- populations may produce paracrine signaling molecules that support 
TPCs. Work in breast cancer has shown that paracrine factors produced by non-cancer 
stem cells can influence and expand cancer stem cell populations (Fillmore et al., 2010; 
Harrison et al., 2013; Scheel et al., 2011; Yamamoto et al., 2013). 
Other work in our lab has shown that interaction with endothelial cells enhances 
both bronchioalveolar stem cell function (Lee et al., 2014), as well as Kras lung tumor 
cell growth in subcutaneous transplants (JH Lee and CF Kim, unpublished data). It is 
known that Kras;p53-flox tumors contain a significant amount of desmoplastic stroma 
(Jackson et al., 2005). Studies in other cancers such as brain, colorectal, and head and 
neck cancers have shown that stromal cells such as endothelial cells or myofibroblasts 
within the tumor can enhance CSC numbers or function (Borovski et al., 2009; 
Calabrese et al., 2007; Krishnamurthy et al., 2010; Lu et al.,  2013; Vermeulen et al., 
2010). In trying to sort out the most purified, enriched TPC population, it is possible that 
we have abrogated important interactions of these TPCs with their stromal cell and non-
TPC partners.  
Cancer stem cell therapies have focused on targeting the cancer stem cells 
themselves. However, if the signals regulating cancer stem cell function are originating 
in the microenvironment, then disrupting the cancer stem cell niche may be an 
important strategy for cancer therapy. The work of several groups suggests that anti-
angiogenic therapies aimed at disrupting the vascular niche of cancer stem cells could 
be used to treat brain tumors (Borovski et al., 2009; Calabrese et al., 2007; Folkins et 
al., 2007). Targeting secreted factors produced by stromal cells or other tumor cells that 
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induce cancer stemness could also be an important strategy for cancer stem cell 
therapy. 
It would be interesting to see if transplanting the Sca1+CD24+ and Sca1-CD24+ 
populations along with different tumor stromal cell types such as endothelial cells or 
fibroblasts would enhance their tumor propagating ability. Another interesting 
experiment would be to isolate tumor cell subpopulations, uniquely label each, and then 
transplant mixed populations to determine how they influence each other. We could also 
perform lineage tracing experiments within unperturbed tumors to track different tumor 
cell subpopulations simultaneously and watch how they influence tumor progression. 
 
The Role of CD24 in Lung Cancer Metastasis 
Although the CD24 gene has been cloned for over 20 years, the function of 
CD24 is still being elucidated. CD24 is a glycosyl phosphatidylinositol (GPI) –linked cell 
surface adhesion molecule with multiple N- and O- glycosylation sites (Fang et al., 
2010). CD24 was first identified in 1978 as part of screen to identify leukocyte 
differentiation antigens and was first named “heat-stable antigen,” or HSA, due to its 
heat resistance ability (Springer et al., 1978). Mouse CD24 was cloned in 1990, and the 
human CD24 was identified in 1991 (Kay et al., 1990; Kay et al., 1991). Unlike the 
mouse protein, human CD24 also contains additional serine and threonine residues, 
making the molecule more mucin-like (Kay et al., 1991).  This difference in structure 
could possibly lead to differences in mouse CD24 versus human CD24 function, as will 
be further discussed.  
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CD24 knockout mice have a defect in B cell maturation (Wenger et al., 1995; 
Nielsen et al., 1997). In B cells, CD24 acts as a co-stimulatory molecule that activates T 
cells (Hubbe and Altevogt, 1994; Liu et al., 1997). In other contexts and in cancer cells, 
CD24 has been shown to bind to P-selectin to mediate cell rolling along endothelial cells 
(Aigner et al., 1997; Friederichs et al., 2000; Sammar et al., 1994). CD24 has also been 
shown to signal through the Src family kinases (SFKs) to activate mitogen-activated 
protein kinase (MAPK) signaling (Bretz et al., 2012a; 2012b; Liu et al., 2012; Mierke et 
al., 2011; Sammar et al., 1997; Wang et al., 2010a; Zarn et al., 1996). 
In addition to hematopoietic cells, CD24 is expressed on a wide variety of 
epithelial cells and cancers, and has been well studied in mammary stem cells and 
breast cancer stem cells. Murine mammary stem cells are found in the 
CD49fhiCD29hiCD24+Sca1- population, while in human breast cancer, the cancer stem 
cell phenotype is thought to be CD44+CD24-/low (Al-Hajj et al., 2003; Shackleton et al., 
2006; Stingl et al., 2006). Murine CD24+ CD90+ breast cancer cells were shown to be 
TPCs that also played a role in metastasis (Malanchi et al., 2012). 
In the lung, the CD24 high expressing population is thought to contain ciliated 
cells, while BASCs or other lung progenitors are CD24low (McQualter et al., 2010; 
(Zacharek et al., 2011). In lung cancer, patients with high expression of CD24 by 
immunohistochemistry had more advanced disease progression and cancer-related 
death (Kristiansen et al., 2003a; Lee et al., 2010). Malignant pleural effusions from lung 
cancers have also been shown to express CD24 (Yao et al., 2013). However, another 
study showed that lung cancers with CD24-negative/low expression were associated 
with worse survival and poor differentiation (Damelin et al., 2011). A recent study in the 
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Kras;p53-flox model showed that the CD24+ITGB4+Notchhi population was enriched for 
tumor propagation, but metastatic potential in this population was not examined (Zheng 
et al., 2013). 
Since Src phosphorylation is one mechanism by which CD24 controls cell 
migration and invasion, total Src levels and phosphorylation status of Src family kinases 
were measured by Western blot in CK1750 shGFP and shCD24 cells in three murine 
Kras;p53-flox lung tumor cell lines, CK1750, Tmet and SC241 (Figure 3-2). While Src 
levels were similar, phospho-SFK levels decreased after CD24 knockdown in all three 
cell lines; decreased SFK activity may impair tumor propagation in CD24 knockdown 
cells. Further experiments such as immunoprecipitation and western blots for specific 
SFK members will be needed to identify which SFK member is responsible for the effect 
on migration and invasion. In addition, treatment of shGFP and shCD24 cells with 
dasatinib, a SFK inhibitor, would further show that SFK activity is important for migration 
of CD24-expressing lung cancer cells. 
Recent studies also showed that CD24 acts through Src to affect the contractility 
of cancer cells, leading to their increased invasiveness (Bretz et al., 2012b; Mierke et 
al., 2011). Contractile forces are one of many physical forces such as hydrostatic 
pressure, shear stress, and compression and tension forces that cells are exposed to in 
their microenvironment (Butcher et al., 2009; Halder et al., 2012). Cells respond to 
these mechanical properties of their environment, including stiffness of the extracellular 
matrix (ECM) as well as traction or compression forces exerted by other cells. The cells 
then use these cues to change the stiffness of their cytoskeletons, and actomyosin 
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Figure 3-2: p-SFK levels decrease after CD24 knockdown. Phospho-Src Family 
Kinase and total Src levels are shown in shGFP vs shCD24 whole-cell lysates from 
three Kras;p53-flox lung cancer cell lines. p-SFK and Src blots were stripped and re-
probed with a pan-Actin antibody as a loading control. Similar results were obtained in 
repeat experiments.
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Figure 3-2: (continued) 
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contractility and cytoskeletal remodeling then transmits forces back to the ECM and 
other cells to induce microenvironmental changes. The disruption of this process of 
“mechanoreciprocity” has been shown to promote tumorigenesis (Butcher et al., 2009). 
We tested whether knockdown of CD24 in CK1750 cells affected cell contractility 
and found that CD24 knockdown decreased the traction force, net contractile moment, 
and the contractile strain energy of individual cells (Figure 3-3). Apart from contractility, 
other cell mechanical properties can be tested such as testing the dynamics of cell 
spreading. Our current focus is to test whether CD24 (and Taz, discussed later) affects 
the spreading of cell aggregates on a solid fibronectin-coated substrate in 3 dimensions 
(Douezan et al., 2011). This spreading is dependent on integrin binding to fibronectin 
and is thought to mimic in vitro the process of EMT observed in metastatic tumors in 
vivo. In this assay, the cells are measured as a population instead of on an individual 
cell basis as in the contractility experiments. This may be beneficial to rule out variability 
in single cell experiments based on CD24 knockdown levels. In the future, we also plan 
to perform these cell spreading experiments on primary Kras;p53-flox CD24+ or CD24- 
lung tumor cells. 
CD24 has been therapeutically targeted in many other studies. In bladder cancer, 
treatment of mice with an anti-CD24 antibody decreased tumor formation in xenograft 
models (Overdevest et al., 2011). Anti-CD24 antibody treatment has also been used in 
models of colorectal and pancreatic cancers (Sagiv et al., 2008). There have also been 
anti-CD24 clinical treatments for hematopoietic cancers (Benkerrou et al., 1998; Fischer 
et al., 1991). Treating mice with an anti-CD24 antibody either in Kras;p53-flox mice or in 
our transplant assay for TPC ability could be useful in terms of testing effectiveness of
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Figure 3-3: Contractility measurements in CD24 knockdown cells.  A. Root mean 
squared traction measurements of CK1750 shGFP and shCD24 cells. Cells are plated 
sparsely on collagen 1-coated gels. N = 39-46 cells per group. Statistical comparisons 
to control were made using the Kruskal-Wallis nonparametric one-way analysis of 
variance by ranks. p= 0.0146. B. Median traction measurements of CK1750 shGFP and 
shCD24 cells. p= 0.0224 C. Net contractile moment measurements of CK1750 shGFP 
and shCD24 cells p=0.0300 D. Contractile strain energy measurements of CK1750 
shGFP and shCD24 cells. p= 0.00300 E-F. Example measurement of traction forces 
exerted by a single shCD24 cell in Pa.
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Figure 3-3: (continued) 
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anti-CD24 treatments in lung adenocarcinoma. These experiments would provide a 
complement to our studies of Kras;p53-flox; CD24 KO mice. 
We have also examined the role of CD24 in human lung cancer. By qPCR, CD24 
expression in human lung tumors did not differ across tumor stage (Figure 3-4A).  In 
fact, perhaps opposite of what was expected, tumors with higher CD24 mRNA 
expression were more differentiated (Figure 3-4B). Similarly, immunohistochemistry for 
CD24 on human lung tumor sections showed that staining was highest in more 
differentiated cells as determined by a pathologist (Figure 3-4C) (L Chirieac, AN Lau, L 
Sholl, KW Sinkevicius, CF Kim, unpublished data). In contrast to what has been 
reported by other studies (Kristiansen et al., 2003a; Lee et al., 2010), staining of a 
human lung tissue microarray of more than 60 samples failed to show a correlation with 
patient prognosis (L Chirieac, KW Sinkevicius, CF Kim, unpublished data).  
It is possible that the different structure of CD24 in humans compared to mice is 
responsible for these differences; or, another possibility is that CD24 localization is 
important to consider in these experiments. It has been reported in breast cancer that 
CD24 has both apical membranous and membrano-cytoplasmic expression patterns 
(Abraham et al., 2005; Kristiansen et al., 2003b; Park et al., 2010). Apical membranous 
expression patterns were found in more differentiated cells, while membrano-
cytoplasmic expression was found in more aggressive tumor cells (Park et al., 2010).  
In lung cancer, it has been reported that intracellular CD24 is most correlated 
with patient prognosis (Lee et al., 2010). We noticed that CD24 expression in human 
matched sets of human lung tumors and metastases also displayed both apical and  
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Figure 3-4: Human CD24 expression is higher in more differentiated lung tumor 
cells. A. Quantitative real-time PCR analysis of relative CD24 mRNA levels in human 
lung tumor samples grouped by tumor stage. N = 25 samples B. Quantitative real-time 
PCR analysis of relative CD24 mRNA levels in human lung tumor samples grouped by 
tumor differentiation status. N = 25 samples. C. Example of CD24 staining in human 
lung adenocarcinoma tissue.
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Figure 3-4: (continued) 
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cytoplasmic expression patterns (KW Sinkevicius, CF Kim, unpublished data). Similar to 
the report in breast cancer, tumors with membrano-cytoplasmic CD24 staining were 
more poorly differentiated than those with apical CD24 staining. Also, the majority of 
lymph node metastases had higher CD24 levels than the primary tumors. It is possible 
that CD24 has dual roles: one to mark EMT/stem-like cells (membrano-cytoplasmic) 
and the other to mark more differentiated cells (apical membranous).  Further staining 
and analysis of CD24 expression patterns in human tumors will be needed to validate 
this hypothesis. 
 
The Role of Yap/Taz in Lung Cancer Metastasis 
 Yap and its paralog Taz are best known as mediators of the Hippo signaling 
pathway, a pathway first identified in Drosophila melanogaster and known for its role in 
organ size determination, stem cell activity, and tumorigenesis (reviewed in (Johnson 
and Halder, 2014)). Like other signaling pathways, the Hippo pathway carries signals 
from the plasma membrane to the nucleus, but unlike other pathways, the Hippo 
pathway is not known to have specific extracellular signaling proteins. Instead, the 
pathway is regulated by a large, ever-expanding network of cell adhesion, cytoskeletal, 
and cell polarity proteins. Like their upstream regulators, additional transcription factor 
binding partners of Yap and Taz as well as their downstream targets are still being 
elucidated. 
The core Hippo pathway consists of serine threonine kinases Mst1/2 and 
Lats1/2, the scaffolding proteins Sav1 and Mob1a/1b, and the transcriptional 
coactivators Yap and Taz. Mst kinases form a complex with Sav1 and then 
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phosphorylate and activate Lats kinases and Mob1 proteins, which then phosphorylate 
Yap and Taz. When phosphorylated, Yap and Taz are sequestered in the cytoplasm by 
14-3-3 or are degraded. When non-phosphorylated, Yap and Taz translocate into the 
nucleus where they bind to transcription factors such as the TEAD family of transcription 
factors to mediate transcription of target genes important for survival, anti-apoptosis, 
and tumorigenesis. 
Higher levels and nuclear localization of Yap and Taz have been found in many 
human cancers, including breast, colon, liver, lung, ovarian, and skin cancers (Camargo 
et al., 2007; Chan et al., 2008; Dong et al., 2007; Fernandez-L et al., 2009; Overholtzer 
et al., 2006; Steinhardt et al., 2008; Xu et al., 2009; Zender et al., 2006; Zhao et al., 
2007). Yap expression has been correlated with poor prognosis in non-small cell lung 
cancer patients and was shown to be tumorigenic in human lung cancer cell lines 
(Wang et al., 2010b). Overexpression of Taz was able to transform immortalized human 
bronchial epithelial cells while knockdown in lung cancer cell lines decreased their 
tumorigenicity (Zhou et al., 2011). Taz expression was found to be significantly 
associated with poor differentiation, poor survival, and metastasis in lung cancer 
patients (Xie et al., 2012). Interestingly, although deregulation of Yap and Taz 
expression levels and nuclear localization have been reported, the mechanism 
regulating these changes is unknown. Mutations in Hippo pathway members are rare in 
cancers, as are activating mutations in Yap and Taz. Yap and Taz are amplified in 
several types of cancer (Baldwin et al., 2005; Fernandez-L et al., 2009; Modena et al., 
2006; Overholtzer et al., 2006; Snijders et al., 2005; Zender et al., 2006), while Mst and 
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Lats kinases have been reported to be silenced via promoter methylation and epigenetic 
silencing (Jiang et al., 2006; Seidel et al., 2007; Takahashi et al., 2005). 
We found that knockdown of either Yap or Taz was able to decrease migration of 
CK1750 murine lung adenocarcinoma cells in transwell migration assays (Chapter 2). 
We were able to obtain LSL-rtTA; tetO-YapS127A mice and breed them to our Kras 
lung adenocarcinoma mouse model (Schlegelmilch et al., 2011). The resulting Kras; 
LSL-rtTA; tetO-YapS127A (Kras;Yap) mice had more and higher grade tumors than 
Kras controls (Chapter 2). The LSL-rtTA; tetO-YapS127A mice were also bred to 
Kras;p53-flox mice to generate Kras;p53-flox;LSL-rtTA;tetO-YapS127A mice; however, 
these mice died within one month after AdCre administration (AN Lau, CF Kim, 
unpublished data). Cause of death was unknown, but increased upper airway 
hyperplasia was observed in these mice, suggesting that loss of p53 in combination with 
Kras and Yap activation causes overproliferation of airway cells. In the future, 
intratracheal administration of AdCre could be used to infect only the distal lung, 
however airway cells will also be targeted with this method. Diluting the AdCre further 
could also be of use to try and get around this issue, as could driving Cre only in BASCs 
and alveolar cells with the SPC-CreER mouse (Xu et al., 2012). Conversely, we have 
also bred Yap fl/fl mice to the Kras;p53-flox mouse model and have infected these mice 
as well as Kras;p53-flox;Yap WT littermate control mice with AdCre. Mice will be 
euthanized at 17 weeks post-AdCre administration and the number and size of lung 
tumors will be measured, as will number and location of metastases. Based on our 
results from the Kras;Yap mice, we expect that Yap deletion in Kras;p53-flox tumors will 
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result in decreased numbers of lung tumors, lower grade tumors, and possibly 
decreased numbers of metastases. 
However, knockdown of Taz, and not Yap, led to decreased lung tumor formation 
after tail vein injection, suggesting that Taz may be the more important factor for 
metastasis in vivo (Chapter 2). Transwell invasion assays also revealed that shTaz cells 
had significantly fewer invaded cells compared to shGFP cells (p=0.016) (Figure 3-5).  
Therefore, Taz may affect metastasis by regulating invasion as well as migration.  Taz, 
also known as Wwtr1, or WW-domain containing transcription regulator-1, was identified 
in 2000 as a 14-3-3 interacting protein and shares 45% amino acid identity with Yap 
(Kanai et al., 2000). Interestingly, Taz knockout mice have partial embryonic lethality, 
but those that do survive are characterized by a lung developmental phenotype; the 
adult lungs display enlarged airspaces reminiscent of emphysematous lungs (Mitani et 
al., 2009). Taz has been shown to directly interact with the master lung transcription 
factor TTF-1 (Nkx2-1) to regulate differentiation of lung epithelial cells (Park et al., 
2004). These data, in combination with our results pointing to Taz as the more important 
protein in terms of metastatic capability, suggest that perhaps Taz, rather than Yap, is 
more important for lung cancer metastasis. Similarly, in breast cancer stem cells, Taz 
was shown to play an important role in metastasis (Cordenonsi et al., 2011).  
Since our data suggest a role for Taz in metastasis, Taz deletion in Kras;p53-flox mice 
would be an important experiment to show that Taz affects tumor progression and 
metastasis in a mouse model of lung cancer. Since Taz KO/KO mice are difficult to 
obtain and breed, breeding Taz fl/fl mice which have recently been published (Xin et al., 
2013) to our Kras;p53-flox model would be ideal.  In lieu of testing the affects of Yap 
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Figure 3-5: Invasion Assay with CK1750 shTaz cells. The average number of 
invasive cells observed in transwell invasion assays, determined by the number of cells 
invading through a matrigel-coated membrane towards serum-containing (10% FBS) 
media in control or Taz knockdown CK1750 cells. *p=0.016. Results shown are from 
one independent experiment.
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Figure 3-5: (continued) 
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and Taz directly in these mouse models, another future direction will be to determine 
the more detailed mechanism of Yap and Taz action in lung adenocarcinoma cells. 
Since Nkx2-1 (Ttf-1) and Hmga2 expression levels have been shown to correlate with 
metastatic disease, we examined expression levels of these genes in both CD24 and 
Yap/Taz knockdown cells. Nkx2-1 was found to be down-regulated in tumor progression 
and not expressed in metastases, while Hmga2 was found to be more highly expressed 
in metastatic tumors (Winslow et al., 2011). Hmga2 expression decreased after 
knockdown of CD24 with one out of two hairpins (p=0.026), but not after Taz 
knockdown (Figure 3-6A, B). Nkx2-1 increased after knockdown of Yap with one of two 
hairpins (p=0.045) but was not altered after CD24 or Taz knockdown (Figure 3-6C,D). 
This indicates that CD24 and Yap/Taz may be affecting migration and metastasis 
through a mechanism that does not rely on Hmga2/Nkx2-1 regulation.   
To address whether CD24 regulated migration and invasion by activating Yap 
and Taz activity (or vice versa), we used qPCR, FACS, Western blot, and luciferase 
reporter assays. We have found no consistent changes in the levels of Yap, Taz, or the 
Yap/Taz targets Cyr61 and Ctgf in CD24 knockdown cells nor vice versa; CD24 was not 
altered in Yap/Taz knockdown cells (Figure 3-7A,B,C,E). CD24 knockdown did not alter 
Yap/Taz phosphorylation levels (Figure 3-7D). CK1750 cells overexpressing wildtype 
human YAP, YAPS127A, or TAZS89A (Figure 3-8A,B) were made to assess the affect 
on CD24 levels as well as to examine migration and metastatic properties.  YAP or TAZ 
overexpression had no affect on CD24 levels by FACS (Figure 3-8C) and did not have a 
significant affect on cell migration or tail vein metastases (Figure 3-8D,E). However, 
CK1750 cells are already highly migratory/metastatic and express very high levels of  
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Figure 3-6: Hmga2 and Nkx2-1 levels in CD24 and Yap/Taz knockdown cells. A. 
qPCR analysis of Hmga2 expression levels after CD24 knockdown. shCD24-Low-1 p = 
0.026. B. qPCR analysis of Hmga2 expression levels after Taz knockdown. C. qPCR 
analysis of Nkx2-1 expression levels after CD24 knockdown. D. qPCR analysis of Nkx2-
1 expression levels after Taz knockdown. shYap1824 p=0.045. 
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Figure 3-6: (continued) 
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Figure 3-7: Analysis of CD24 and Yap/Taz reciprocal expression levels. A. 
Quantitative real-time PCR analysis of relative Yap1 and Taz mRNA levels in shCD24 
cell lines normalized to expression in shGFP cells. Data represent the mean of four 
independent experiments, error bars represent the standard deviation of the mean. B. 
Quantitative real-time PCR analysis of relative CD24 mRNA levels in shYap1 and shTaz 
cell lines normalized to levels in shGFP cells. Data represent the mean of four 
independent experiments, error bars represent the standard deviation of the mean. C. 
Quantitative real-time PCR analysis of relative mRNA levels of Yap1/Taz targets Cyr61 
and CTGF mRNA in shCD24 cell lines normalized to expression in shGFP cells. Data 
represent the mean of four independent experiments, error bars represent the standard 
deviation of the mean. D. Whole-cell lysate serial dilutions from shGFP and shCD24 
cells immunoblotted with the indicated antibodies. Similar results were obtained in 
repeat experiments. E. FACS analysis of CD24 levels in shYap1 and shTaz cell lines 
compared to levels in shGFP cells.
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Figure 3-7: (continued) 
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Figure 3-8: YAP and TAZ overexpression in CK1750 cells. A. qPCR analysis of 
human YAP expression levels in CK1750 cells made to overexpress empty vector, 
YAP,YAPS127A, or TAZ. B. qPCR analysis of human TAZ expression levels in CK1750 
cells made to overexpress empty vector, YAP,YAPS127A, or TAZ.  C. FACS analysis of 
CD24 levels in CK1750 cell lines overexpressing YAP or TAZ compared to levels in 
cells expressing empty vector. D. The average number of migratory cells observed in 
transwell migration assays, determined by the number of cells migrating towards serum-
containing (10% FBS) media in control or YAP or TAZ overexpressing- CK1750 cells. 
Results shown are the average of three independent experiments. E. Average number 
of lung metastases after tail vein injection of CK1750 cells expressing empty vector 
(circles), YAP (squares), YAPS127A (up triangles), or TAZS89A (down triangles). Lungs 
were analyzed for metastases two weeks after injection of 5000 cells. Each symbol 
represents an individual mouse analyzed.  F. Average number of lung metastases after 
tail vein injection of CK1750 cells expressing empty vector (circles), YAP (squares) or 
TAZS89A (up triangles). Lungs were analyzed for metastases two weeks after injection 
of 50,000 cells. Each symbol represents an individual mouse analyzed. 
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Figure 3-8: (continued) 
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CD24 at baseline and therefore it may be difficult to observe an increase in these 
properties. Another possibility is that the human version of YAP or TAZ has different 
effects on migration or metastasis as compared to murine Yap/Taz in these cells. 
Two different TEAD-reporter systems were used to measure Yap/Taz activity 
(Figure 3-9A,B). In one set of experiments, CK1750 shGFP or shCD24 cells were 
transfected with a plasmid containing a TEAD-binding site cassette 5’ of luciferase.  In a 
second set of experiments, CK1750 shGFP or shCD24 cells were infected with a virus 
containing a TEAD-binding site cassette 5’ of an mCherry reporter (Mohseni et al., 
2014).  shYap/shTaz CK1750 cells were used as controls (Figure 3-9A,B). We observed 
a decrease in reporter activity after CD24 knockdown using the mCherry TEAD reporter 
(p=0.010 shCD24-Low-1, p= 0.0064 shCD24-Low-5).  However, with the luciferase 
TEAD reporter, a decrease in reporter activity was only seen with one of two CD24 
hairpins (shCD24-Low-1, p =0.0038).  Therefore, there is no clear relationship between 
CD24 and Yap/Taz expression that we can establish with these methods, yet further 
studies may reveal a connection, possibly through the regulation of the actin 
cytoskeleton.   
As discussed in Chapter 2, we also performed a microarray gene expression 
comparison of three Kras;p53 murine lung cancer cell lines with shTaz versus a control 
hairpin (shGFP). Gene sets of interest that were significantly enriched in shTaz cells 
included several sets associated with NF Kappa B signaling, mitochondria, as well as 
gene sets corresponding to actin cytoskeletal processes (Appendix). NF Kappa B 
signaling is known to be required in lung adenocarcinoma (Meylan et al, 2009; Xue et 
al., 2011), so the genes in this gene set could be interesting to follow up on in TPCs and  
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Figure 3-9: TEAD-binding site- (TBS)-reporter assays in CD24 and Yap/Taz 
knockdown cells. A. Relative luciferase units of control, shCD24, or shYap/Yaz 
CK1750 cells transfected with a TBS-luciferase reporter. Luciferase was measured two 
days after transfection. Results shown are from three independent experiments. 
shCD24-Low-1 p =0.0038, shYap1108 p=0.0031, shYap1824 p=0.0078, shTaz771 
p=3.6x10-5. B. Relative mCherry expression of control or shCD24 CK1750 cells infected 
with a lentivirus containing a TBS-mCherry reporter. Results shown are from two 
independent experiments shCD24-Low-1 p=0.010, shCD24-Low-5 p= 0.0064, 
shYap1824 p= 0.046 , shTaz771 p= 0.0010. 
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Figure 3-9: (continued) 
R
el
at
iv
e 
m
C
he
rr
y 
E
xp
re
ss
io
n 
A!
B!
* 
* * 
* 
R
el
at
iv
e 
Lu
ci
fe
ra
se
 U
ni
t 
0.0 
0.5 
1.0 
1.5 
2.0 
sh
GF
P 
sh
CD
24
-Lo
w-
1 
sh
CD
24
-Lo
w-
5 
sh
GF
P 
sh
Ya
p1
10
8 
sh
Ya
p1
82
4 
sh
Ta
z7
71
 
sh
Ta
z1
61
6 
* 
* 
* 
* 
0.0 
0.5 
1.0 
1.5 
sh
GF
P 
sh
CD
24
-Lo
w-
1 
sh
CD
24
-Lo
w-
5 
sh
GF
P 
sh
Ya
p1
10
8 
sh
Ya
p1
82
4 
sh
Ta
z7
71
 
sh
Ta
z1
61
6 
	  	   137	  
Taz deficient lung cells. In Drosophila, Yap was found to regulate mitochondrial 
structure (Nagaraj et al., 2012), and mitochondrial dysfunction was shown to cooperate 
with Ras activation to inactivate the Hippo pathway and drive tumor progression 
(Ohsawa et al., 2012). Mitochodrial dysfunction and metabolism could also be an 
attractive target to study in lung TPCs and Taz knockdown cells. 
Gene sets corresponding to actin cytoskeletal processes were highly decreased 
after Taz knockdown, including Actin Cytoskeleton, Cytoskeletal Protein Binding, Actin 
Binding, Actin Filament Binding, and Actin Filament Based Processes. F-actin staining 
was performed in the CK1750 cell lines to determine if Taz knockdown altered the 
arrangement of the actin cytoskeleton.  Knockdown of Taz significantly decreased 
anisotropy and alignment indices, two measures of F-actin orientation (Figure 3-10) (Xu 
et al., 2012). CK1750 cells with Taz knockdown also had fewer lamellapodia and 
fillipodia, another indicator of migratory potential (AN Lau, DE Wagner, unpublished 
observations). An intact cytoskeleton is needed to generate sufficient contractile forces 
for cell movement, therefore disruption of the F-actin network may have contributed to 
the decreased migration and metastatic capacity of shTaz cells.  Previous work in 
ovarian cancer has shown the degree of actin-alignment was highly correlated to cell 
stiffness (Xu et al., 2012). 
Similar to our work with CD24, we also tested whether contractile forces were 
affected in measurements of single CK1750 cells after Taz knockdown (Figure 3-11). 
Taz knockdown did not significantly affect measures of cell contractility in these assays. 
We also plan to test whether Taz knockdown affects cell spreading dynamics in the 3-D 
fibronectin-coated substrate assay (Douezan et al., 2011). There is published evidence  
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Figure 3-10: Actin alignment is altered following knockdown of Taz in CK1750 
cells. A, B. Summary of F-actin orientation analysis. The anisotropic and alignment 
indices were extracted for each cell line (n= at least 6 for each cell line; all experiments 
performed in replicate). Bars represent means and error bars are standard deviation of 
the mean. A. Alignment index in CK1750 shGFP vs shTaz cells. p = 0.027. B. 
Anisotropy index in CK1750 shGFP vs shTaz cells. The anisotropy index is a measure 
of how much the cell deviates from isotropy (where there would be no actin alignment). 
A value of one is isotropic; the closer to one this value is, the less aligned the cells are. 
p = 0.035. C. Representative fluorescent images for F-actin stained with phalloidin in 
CK1750 shGFP cells. Original images taken at 1000x. D. Representative fluorescent 
images for F-actin stained with phalloidin in CK1750 shTaz1616 cells.
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Figure 3-10: (continued) 
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Figure 3-11: Contractility measurements in Taz knockdown cells.  A. Root mean 
squared traction measurements of CK1750 shGFP and shTaz cells. Cells are plated 
sparsely on collagen 1-coated gels. N = 45-46 cells per group. Statistical comparisons 
to control were made using the Kruskal-Wallis nonparametric one-way analysis of 
variance by ranks. p= 0.918. B. Median traction measurements of CK1750 shGFP and 
shTaz cells. p= 0.818 C. Net contractile moment measurements of CK1750 shGFP and 
shTaz cells p=0.611 D. Contractile strain energy measurements of CK1750 shGFP and 
shTaz cells. p= 0.721  
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Figure 3-11: (continued) 
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that Yap and Taz both respond to mechanical cues and also mediate 
mechanotransduction (Halder et al., 2012). Nuclear Yap/Taz localization is regulated by 
cell spreading; on stiff surfaces, Yap/Taz is nuclear, whereas on soft surfaces, Yap/Taz 
is cytoplasmic (Dupont et al., 2011). Similarly, when cells are grown on large fibronectin 
islands and cells spread out, Yap and Taz are nuclear, whereas cells grown on small 
islands have cytoplasmic and inactive Yap/Taz (Dupont et al., 2011). When F-actin or 
Rho are inhibited, Yap and Taz are inactivated, and conversely, F-actin polmerization 
promotes increased Yap/Taz activity (Dupont et al., 2011; Sansores-Garcia et al., 2011; 
Wada et al., 2011). Inhibition of myosin regulators also inactivates Yap and Taz  
(Dupont et al., 2011; Wada et al., 2011). Since defects in mechanotransduction are 
implicated in tumorigenesis and metastasis, future study of the effect of Taz on this 
process in lung adenocarcinoma should be informative. Further studies are needed to 
determine which, if any, of the cellular activities identified in our expression analyses are 
critical for Yap/Taz contribution to aggressive lung cancer. 
 
Conclusions 
 The work presented in this thesis makes important conclusions about the 
relationship between lung TPCs and metastasis. We found that there were multiple TPC 
populations with metastatic ability, but that using two TPC markers enriched for TPCs 
with metastatic capability. Additionally, cell-cell interactions between TPCs, non-TPCs, 
and tumor stroma are likely to affect TPC and metastatic ability. 
 This work opens up many avenues for future study. More work will be necessary 
to determine if both CD24 and Yap/Taz are important regulators of (or are being acted 
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upon by) actin dynamics and mechanotransduction in lung adenocarcinoma cells. Our 
gene expression studies point to the importance of the actin cytoskeleton, and more 
functional studies of cell spreading dynamics and cellular forces exerted in metastatic 
cells will be performed to confirm these findings. While our data suggest a role for Taz 
in lung cancer metastasis, further experiments are needed to elucidate the specific 
transcription factors and target genes that are mediating Taz function. 
 Identification of lung tumor cells important for metastatic disease is important for 
understanding more about the mechanisms of metastasis. The genes and pathways 
discovered in murine lung TPCs were also shown to be important for lung 
adenocarcinoma patient survival, and it is my hope that by studying these pathways we 
can develop targeted therapies to treat metastatic lung cancer. 
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Mice Used in Tumor Transplants 
 
Table A1: CD24 primary transplants 
 
 
 
Table A2: CD24 secondary transplants 
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Table A3: Sca1/CD24 primary transplants 
 
 
 
Table A4: Sca1/CD24 secondary transplants 
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Table A5: Sca1 Gene Signature 
Human Orthologues of Sca1+ up genes - U133a probe list 
Probe Set ID Gene Symbol 
219693_at AGPAT4 
228667_at AGPAT4 
1553734_at AK7 
1569699_at AK7 
1569700_s_at AK7 
241326_at AK7 
202759_s_at AKAP2 /// PALM2-AKAP2 
202760_s_at AKAP2 /// PALM2-AKAP2 
226694_at AKAP2 /// PALM2-AKAP2 
205633_s_at ALAS1 
212224_at ALDH1A1 
228817_at ALG9 
219374_s_at ALG9 /// FDXACB1 
243151_at ANKRD42 
201012_at ANXA1 
233011_at ANXA1 
1568126_at ANXA2 
201590_x_at ANXA2 
210427_x_at ANXA2 
213503_x_at ANXA2 
201686_x_at API5 
201687_s_at API5 
214959_s_at API5 
214960_at API5 
233078_at API5 
218218_at APPL2 
210066_s_at AQP4 
210067_at AQP4 
210068_s_at AQP4 
210906_x_at AQP4 
226228_at AQP4 
205239_at AREG 
215564_at AREG 
1557285_at AREGB 
206030_at ASPA 
228807_at ASPA 
1568743_at ATP10A 
214255_at ATP10A 
214256_at ATP10A 
221484_at B4GALT5 
221485_at B4GALT5 
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206232_s_at B4GALT6 
206233_at B4GALT6 
235333_at B4GALT6 
222643_s_at BBS1 /// DPP3 
204378_at BCAS1 
234221_at BCAS1 
234780_at BCAS1 
224435_at C10orf58 
228155_at C10orf58 
232662_x_at C10orf58 
218925_s_at C11orf1 
222785_x_at C11orf1 
231530_s_at C11orf1 
231538_at C11orf1 
1552950_at C15orf26 
229238_at C17orf97 
1555111_at C1orf114 
1555112_a_at C1orf114 
206721_at C1orf114 
231077_at C1orf192 
237131_at C1orf230 
228100_at C1orf88 
218123_at C21orf59 
244369_at C21orf59 
1553761_at C22orf30 
1558097_at C22orf30 
216555_at C22orf30 
236941_at C22orf30 
231133_at C2orf39 
220149_at C2orf54 
230273_at C6orf165 
1554919_s_at C7orf63 
219455_at C7orf63 
221946_at C9orf116 
59437_at C9orf116 
229012_at C9orf24 
1553433_at C9orf93 
1556516_at C9orf93 
1558082_at C9orf93 
1558160_at C9orf93 
1559672_a_at C9orf93 
236945_at C9orf93 
239712_at C9orf93 
242821_at C9orf93 
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1566149_at CALML4 
1566150_at CALML4 
1568600_at CALML4 
221879_at CALML4 
64408_s_at CALML4 
236085_at CAPSL 
1553886_at CCDC108 
1556969_at CCDC108 
239508_x_at CCDC108 
222890_at CCDC113 
230807_at CCDC151 
240293_at CCDC153 
1563563_at CCDC40 
220592_at CCDC40 
220593_s_at CCDC40 
229918_at CCDC40 
239254_at CCDC40 
219644_at CCDC41 
239282_at CCDC41 
211173_at CCKAR 
211174_s_at CCKAR 
203593_at CD2AP 
236257_at CD2AP 
205288_at CDC14A 
210440_s_at CDC14A 
210441_at CDC14A 
210742_at CDC14A 
210743_s_at CDC14A 
225081_s_at CDCA7L 
227742_at CLIC6 
242913_at CLIC6 
221900_at COL8A2 
52651_at COL8A2 
1558034_s_at CP 
204846_at CP 
227253_at CP 
228143_at CP 
202551_s_at CRIM1 
202552_s_at CRIM1 
228496_s_at CRIM1 
205081_at CRIP1 
207030_s_at CSRP2 
211126_s_at CSRP2 
200661_at CTSA 
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223454_at CXCL16 
226960_at CXCL17 
223294_at CXorf26 
224177_s_at CXorf26 
206755_at CYP2B6 
217133_x_at CYP2B6 
206754_s_at CYP2B6 /// CYP2B7P1 
207913_at CYP2F1 
223385_at CYP2S1 
1555497_a_at CYP4B1 
210096_at CYP4B1 
1007_s_at DDR1 
207169_x_at DDR1 
208779_x_at DDR1 
210749_x_at DDR1 
202480_s_at DEDD 
211255_x_at DEDD 
215158_s_at DEDD 
208250_s_at DMBT1 
205186_at DNALI1 
227081_at DNALI1 
1553976_a_at DPCD 
226009_at DPCD 
218567_x_at DPP3 
232510_s_at DPP3 
1553105_s_at DSG2 
217901_at DSG2 
238116_at DYNLRB2 
201999_s_at DYNLT1 
1564630_at EDN1 
218995_s_at EDN1 
222802_at EDN1 
1568930_at EFCAB1 
220156_at EFCAB1 
239500_at EFCAB1 
201842_s_at EFEMP1 
201843_s_at EFEMP1 
228421_s_at EFEMP1 
219833_s_at EFHC1 
225656_at EFHC1 
231026_at EFHC1 
219850_s_at EHF 
222932_at EHF 
224189_x_at EHF 
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225645_at EHF 
232360_at EHF 
232361_s_at EHF 
201510_at ELF3 
210827_s_at ELF3 
229842_at ELF3 
225156_at ELOF1 
204975_at EMP2 
225078_at EMP2 
225079_at EMP2 
238500_at EMP2 
237314_at ENKUR 
204160_s_at ENPP4 
204161_s_at ENPP4 
208156_x_at EPPK1 
232164_s_at EPPK1 
232165_at EPPK1 
234552_at EPPK1 
234555_at EPPK1 
202609_at EPS8 
208621_s_at EZR 
208622_s_at EZR 
208623_s_at EZR 
217230_at EZR 
217234_s_at EZR 
204363_at F3 
223058_at FAM107B 
223059_s_at FAM107B 
1557385_at FAM161A 
1564467_at FAM161A 
239090_at FAM161A 
242584_at FAM161A 
232968_at FANK1 
1557771_at FHAD1 
1560097_at FHAD1 
1563639_a_at FHAD1 
1563830_a_at FHAD1 
1563961_at FHAD1 
1564635_a_at FHAD1 
201539_s_at FHL1 
201540_at FHL1 
210298_x_at FHL1 
210299_s_at FHL1 
214505_s_at FHL1 
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205906_at FOXJ1 
239275_at FRMPD2 /// FRMPD2P1 /// FRMPDP2 
205044_at GABRP 
203397_s_at GALNT3 
203398_s_at GALNT3 
204224_s_at GCH1 
211020_at GCNT2 
230788_at GCNT2 
206917_at GNA13 
224761_at GNA13 
227539_at GNA13 
206681_x_at GP2 
208473_s_at GP2 
214324_at GP2 
214325_at GP2 
240856_at GPR120 
202831_at GPX2 
239595_at GPX2 
205770_at GSR 
225609_at GSR 
205752_s_at GSTM5 
1557915_s_at GSTO1 
201470_at GSTO1 
1552515_at HIPK1 
1552516_a_at HIPK1 
212291_at HIPK1 
212293_at HIPK1 
207764_s_at HIPK3 
210148_at HIPK3 
213697_at HIPK3 
226297_at HIPK3 
208429_x_at HNF4A 
214832_at HNF4A 
214851_at HNF4A 
216889_s_at HNF4A 
230914_at HNF4A 
205543_at HSPA4L 
202438_x_at IDS 
202439_s_at IDS 
206342_x_at IDS 
210666_at IDS 
211782_at IDS 
212221_x_at IDS 
212223_at IDS 
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213821_s_at IDS 
217432_s_at IDS 
236823_at IDS 
218100_s_at IFT57 
222519_s_at IFT57 
222520_s_at IFT57 
218516_s_at IMPAD1 
222654_at IMPAD1 
222655_s_at IMPAD1 
224743_at IMPAD1 
224744_at IMPAD1 
227774_s_at IMPAD1 
204989_s_at ITGB4 
204990_s_at ITGB4 
211905_s_at ITGB4 
214292_at ITGB4 
230704_s_at ITGB4 
201124_at ITGB5 
201125_s_at ITGB5 
214020_x_at ITGB5 
214021_x_at ITGB5 
1568619_s_at ITPRIPL2 
227514_at ITPRIPL2 
227792_at ITPRIPL2 
227954_at ITPRIPL2 
227956_at ITPRIPL2 
228074_at ITPRIPL2 
226003_at KIF21A 
231875_at KIF21A 
212101_at KPNA6 
212102_s_at KPNA6 
212103_at KPNA6 
226976_at KPNA6 
224534_at KREMEN1 
227250_at KREMEN1 
234843_s_at KREMEN1 
235370_at KREMEN1 
243029_at KREMEN1 
200923_at LGALS3BP 
204272_at LGALS4 
217892_s_at LIMA1 
222456_s_at LIMA1 
222457_s_at LIMA1 
1558469_at LPP 
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202821_s_at LPP 
202822_at LPP 
224811_at LPP 
230996_at LPP 
235000_at LPP 
241879_at LPP 
243874_at LPP 
206076_at LRRC23 
217609_at LRRC23 
1554584_at LRRC48 
208140_s_at LRRC48 
215173_at LRRC50 
222068_s_at LRRC50 
202018_s_at LTF 
206276_at LY6D 
212233_at MAP1B 
214577_at MAP1B 
226084_at MAP1B 
201668_x_at MARCKS 
201669_s_at MARCKS 
201670_s_at MARCKS 
213002_at MARCKS 
225897_at MARCKS 
213045_at MAST3 
226238_at MCEE 
220990_s_at MIR21 /// TMEM49 
204783_at MLF1 
204784_s_at MLF1 
207565_s_at MR1 
207566_at MR1 
210223_s_at MR1 
210224_at MR1 
210528_at MR1 
235352_at MR1 
1552364_s_at MSI2 
225233_at MSI2 
225237_s_at MSI2 
225238_at MSI2 
225240_s_at MSI2 
239232_at MSI2 
243010_at MSI2 
243579_at MSI2 
220953_s_at MTMR12 
225232_at MTMR12 
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202180_s_at MVP 
204798_at MYB 
215152_at MYB 
206197_at NME5 
1553994_at NT5E 
1553995_a_at NT5E 
203939_at NT5E 
227486_at NT5E 
201173_x_at NUDC 
210574_s_at NUDC 
210575_at NUDC 
209925_at OCLN 
227492_at OCLN 
231022_at OCLN 
235937_at OCLN 
228577_x_at ODF2L 
230926_s_at ODF2L 
231909_x_at ODF2L 
237420_at ODF2L 
209626_s_at OSBPL3 
209627_s_at OSBPL3 
202780_at OXCT1 
244134_at OXCT1 
215823_x_at PABPC1 /// RLIM 
214204_at PACRG 
215472_at PACRG 
218736_s_at PALMD 
222725_s_at PALMD 
232187_at PALMD 
202336_s_at PAM 
212958_x_at PAM 
214620_x_at PAM 
203242_s_at PDLIM5 
203243_s_at PDLIM5 
211680_at PDLIM5 
211681_s_at PDLIM5 
212412_at PDLIM5 
213684_s_at PDLIM5 
216803_at PDLIM5 
216804_s_at PDLIM5 
221994_at PDLIM5 
241208_at PDLIM5 
215718_s_at PHF3 
217951_s_at PHF3 
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217952_x_at PHF3 
217953_at PHF3 
217954_s_at PHF3 
204213_at PIGR 
226147_s_at PIGR 
207469_s_at PIR 
202430_s_at PLSCR1 
202446_s_at PLSCR1 
244315_at PLSCR1 
202075_s_at PLTP 
233454_at POLN 
242804_at POLN 
204304_s_at PROM1 
1554997_a_at PTGS2 
204748_at PTGS2 
203223_at RABEP1 
214552_s_at RABEP1 
225064_at RABEP1 
225092_at RABEP1 
231002_s_at RABEP1 
210335_at RASSF9 
1554003_at RGNEF 
1554004_a_at RGNEF 
1559706_at RGNEF 
1560348_at RGNEF 
219610_at RGNEF 
232994_s_at RGNEF 
1553318_at RIBC1 
235946_at RIBC1 
222815_at RLIM 
225416_at RLIM 
244470_at RLIM 
221523_s_at RRAGD 
221524_s_at RRAGD 
230093_at RSPH1 
1556049_at RTN4 
210968_s_at RTN4 
211509_s_at RTN4 
214629_x_at RTN4 
219684_at RTP4 
1569433_at SAMD5 
228653_at SAMD5 
242626_at SAMD5 
205725_at SCGB1A1 
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230378_at SCGB3A1 
202082_s_at SEC14L1 
202083_s_at SEC14L1 
202084_s_at SEC14L1 
240036_at SEC14L1 
206941_x_at SEMA3E 
210083_at SEMA7A 
230345_at SEMA7A 
200986_at SERPING1 
209090_s_at SH3GLB1 
209091_s_at SH3GLB1 
210101_x_at SH3GLB1 
203123_s_at SLC11A2 
203124_s_at SLC11A2 
203125_x_at SLC11A2 
210047_at SLC11A2 
237106_at SLC11A2 
219911_s_at SLCO4A1 
229239_x_at SLCO4A1 
206874_s_at SLK 
206875_s_at SLK 
208127_s_at SOCS5 
209647_s_at SOCS5 
209648_x_at SOCS5 
205406_s_at SPA17 
216119_s_at SPEF1 
1552716_at SPEF2 
232745_x_at SPEF2 
233429_at SPEF2 
1552630_a_at SRCAP 
1569138_a_at SRCAP 
212275_s_at SRCAP 
213667_at SRCAP 
215053_at SRCAP 
38766_at SRCAP 
1555427_s_at SYNCRIP 
209024_s_at SYNCRIP 
209025_s_at SYNCRIP 
217832_at SYNCRIP 
217833_at SYNCRIP 
217834_s_at SYNCRIP 
236146_at SYNCRIP 
202796_at SYNPO 
235128_at SYNPO 
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235914_at SYNPO 
206161_s_at SYT5 
206162_x_at SYT5 
207662_at TBX1 
211273_s_at TBX1 
211274_at TBX1 
236926_at TBX1 
242941_x_at TBX1 
202396_at TCERG1 
205217_at TIMM8A 
210800_at TIMM8A 
209386_at TM4SF1 
209387_s_at TM4SF1 
215033_at TM4SF1 
215034_s_at TM4SF1 
238168_at TM4SF1 
217016_x_at TMEM212 
1558177_at TMEM229B 
227544_at TMEM229B 
238820_at TMEM229B 
219503_s_at TMEM40 
222892_s_at TMEM40 
1569003_at TMEM49 
1556116_s_at TNPO1 
1557278_s_at TNPO1 
207657_x_at TNPO1 
209225_x_at TNPO1 
209226_s_at TNPO1 
212635_at TNPO1 
221829_s_at TNPO1 
225765_at TNPO1 
225766_s_at TNPO1 
243324_x_at TNPO1 
217853_at TNS3 
234257_at TNS3 
218876_at TPPP3 
215111_s_at TSC22D1 
235315_at TSC22D1 
243133_at TSC22D1 
222220_s_at TSNAXIP1 
209114_at TSPAN1 
230997_at TTC21A 
232308_at TTC21A 
205854_at TULP3 
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221964_at TULP3 
200930_s_at VCL 
200931_s_at VCL 
237755_s_at WDR16 
239916_at WDR16 
217734_s_at WDR6 
233573_s_at WDR6 
218173_s_at WHSC1L1 
221248_s_at WHSC1L1 
222544_s_at WHSC1L1 
224076_s_at WHSC1L1 
224077_at WHSC1L1 
201020_at YWHAH 
236559_at YWHAH 
242325_at YWHAH 
1557953_at ZKSCAN1 
214670_at ZKSCAN1 
214900_at ZKSCAN1 
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Table A6: Genes Down in Sca1+ Cells	  
Probe set Gene Symbol Gene Name 
1423523_at Aass aminoadipate-semialdehyde synthase 
1420157_s_at Abcf1 
ATP-binding cassette, sub-family F (GCN20), 
member 1 
1416947_s_at Acaa1a  
acetyl-Coenzyme A acyltransferase 1A /// 
acetyl-Coenzyme A acyltransferase 1B 
1428146_s_at Acaa2 
acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
1428145_at Acaa2 
acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
1434185_at Acaca acetyl-Coenzyme A carboxylase alpha 
1424183_at Acat1 acetyl-Coenzyme A acetyltransferase 1 
1456728_x_at Aco1 aconitase 1 
1449065_at Acot1 acyl-CoA thioesterase 1 
1439478_at Acot2 acyl-CoA thioesterase 2 
1424654_at Acp2 acid phosphatase 2, lysosomal 
1418402_at Adam19 
a disintegrin and metallopeptidase domain 19 
(meltrin beta) 
1418403_at Adam19 
a disintegrin and metallopeptidase domain 19 
(meltrin beta) 
1456307_s_at Adcy7 adenylate cyclase 7 
1440801_s_at Adrbk2 adrenergic receptor kinase, beta 2 
1449383_at Adssl1 adenylosuccinate synthetase like 1 
1420428_at Ager 
advanced glycosylation end product-specific 
receptor 
1441958_s_at Ager 
advanced glycosylation end product-specific 
receptor 
1425354_a_at Aggf1 
angiogenic factor with G patch and FHA 
domains 1 
1422184_a_at Ak1 adenylate kinase 1 
1456590_x_at Akr1b3 
aldo-keto reductase family 1, member B3 
(aldose reductase) 
1421324_a_at Akt2 thymoma viral proto-oncogene 2 
1455247_at Amotl1 angiomotin-like 1 
1416906_at Anapc5 anaphase-promoting complex subunit 5 
1428063_at Ankrd46 ankyrin repeat domain 46 
1438090_x_at Ankrd54 ankyrin repeat domain 54 
1418858_at Aox3 aldehyde oxidase 3 
1418847_at Arg2 arginase type II 
1438841_s_at Arg2 arginase type II 
1426027_a_at Arhgap10 Rho GTPase activating protein 10 
1455166_at Arl5b ADP-ribosylation factor-like 5B 
1428138_s_at Arl8b ADP-ribosylation factor-like 8B 
1428137_at Arl8b ADP-ribosylation factor-like 8B 
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1423511_at Asf1a 
ASF1 anti-silencing function 1 homolog A (S. 
cerevisiae) 
1434014_at Atg4c autophagy-related 4C (yeast) 
1460639_a_at Atox1 ATX1 (antioxidant protein 1) homolog 1 (yeast) 
1428340_s_at Atp13a2 ATPase type 13A2 
1433562_s_at Atp5f1 
ATP synthase, H+ transporting, mitochondrial 
F0 complex, subunit B1 
1417632_at Atp6v0a1 
ATPase, H+ transporting, lysosomal V0 subunit 
A1 
1450634_at Atp6v1a 
ATPase, H+ transporting, lysosomal V1 subunit 
A 
1422508_at Atp6v1a 
ATPase, H+ transporting, lysosomal V1 subunit 
A 
1430306_a_at Atp6v1c2 
ATPase, H+ transporting, lysosomal V1 subunit 
C2 
1449712_s_at Atp6v1e1 
ATPase, H+ transporting, lysosomal V1 subunit 
E1 
1420038_at Atp6v1e1 
ATPase, H+ transporting, lysosomal V1 subunit 
E1 
1421166_at Atrn attractin 
1449435_at B4galt3 
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 3 
1429432_at Bat2l2 HLA-B associated transcript 2-like 2 
1419004_s_at Bcl2a1a  
B-cell leukemia/lymphoma 2 related protein A1a 
/// B-cell leukemia/lymphoma 2 related protein 
A1b /// B-cell leukemia/lymphoma 2 related 
protein A1d 
1420631_a_at Blcap 
bladder cancer associated protein homolog 
(human) 
1436960_at Brd3 bromodomain containing 3 
1448521_at Brd7 bromodomain containing 7 
1437345_a_at Bscl2 
Bernardinelli-Seip congenital lipodystrophy 2 
homolog (human) 
1449007_at Btg3  
B-cell translocation gene 3 /// B-cell 
translocation gene 3 pseudogene 
1459900_at C79468 expressed sequence C79468 
1436489_x_at C85492 expressed sequence C85492 
1437537_at Casp9 caspase 9 
1419803_s_at Ccdc12 coiled-coil domain containing 12 
1429150_at Ccdc77 coiled-coil domain containing 77 
1448919_at Cd302 CD302 antigen 
1425519_a_at Cd74 
CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
1428092_at Cdc5l cell division cycle 5-like (S. pombe) 
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1425262_at Cebpg 
CCAAT/enhancer binding protein (C/EBP), 
gamma 
1420579_s_at Cftr 
cystic fibrosis transmembrane conductance 
regulator homolog 
1428466_at Chd3 chromodomain helicase DNA binding protein 3 
1433684_at Chmp6 chromatin modifying protein 6 
1425455_a_at Churc1 churchill domain containing 1 
1417458_s_at Cks2 CDC28 protein kinase regulatory subunit 2 
1416616_s_at Clpp 
caseinolytic peptidase, ATP-dependent, 
proteolytic subunit homolog (E. coli) 
1421861_at Clstn1 calsyntenin 1 
1451052_at Cog8  
component of oligomeric golgi complex 8 /// 
peptide deformylase (mitochondrial) 
1440911_at Col23a1 collagen, type XXIII, alpha 1 
1423245_at Cops7a 
COP9 (constitutive photomorphogenic) 
homolog, subunit 7a (Arabidopsis thaliana) 
1451825_a_at Copz1 coatomer protein complex, subunit zeta 1 
1428134_at Coq9 coenzyme Q9 homolog (yeast) 
1450895_a_at Cox16 
COX16 cytochrome c oxidase assembly 
homolog (S. cerevisiae) 
1417607_at Cox6a2 
cytochrome c oxidase, subunit VI a, polypeptide 
2 
1423095_s_at Crbn cereblon 
1452901_at Creb1 cAMP responsive element binding protein 1 
1436983_at Crebbp CREB binding protein 
1450667_a_at Cs citrate synthase 
1422510_at Ctdspl 
CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small 
phosphatase-like 
1416382_at Ctsc cathepsin C 
1431145_a_at Cuedc2 CUE domain containing 2 
1451153_a_at Cyhr1 cysteine and histidine rich 1 
1419070_at Cys1 cystin 1 
1420129_s_at D10Wsu52e 
DNA segment, Chr 10, Wayne State University 
52, expressed 
1449118_at Dbt 
dihydrolipoamide branched chain transacylase 
E2 
1436680_s_at Ddb2 damage specific DNA binding protein 2 
1417516_at Ddit3 DNA-damage inducible transcript 3 
1415915_at Ddx1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 
1426832_at Ddx26b 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 
26B 
1417875_at Ddx50 DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 
1428728_at Ddx51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 
1451363_a_at Dennd2d DENN/MADD domain containing 2D 
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1435927_at Dennd3 DENN/MADD domain containing 3 
1425228_a_at Dguok deoxyguanosine kinase 
1453487_at Dhdh dihydrodiol dehydrogenase (dimeric) 
1416144_a_at Dhx15 DEAH (Asp-Glu-Ala-His) box polypeptide 15 
1438969_x_at Dhx30 DEAH (Asp-Glu-Ala-His) box polypeptide 30 
1416918_at Dlg3 discs, large homolog 3 (Drosophila) 
1449939_s_at Dlk1 delta-like 1 homolog (Drosophila) 
1434944_at Dmpk dystrophia myotonica-protein kinase 
1421032_a_at Dnajb12 
DnaJ (Hsp40) homolog, subfamily B, member 
12 
1425135_a_at Dnm2 dynamin 2 
1425136_x_at Dnm2 dynamin 2 
1437437_x_at Dnpep aspartyl aminopeptidase 
1439452_x_at Dnpep aspartyl aminopeptidase 
1438557_x_at Dnpep aspartyl aminopeptidase 
1416697_at Dpp4 dipeptidylpeptidase 4 
1453731_a_at Dram2 
VDNA-damage regulated autophagy modulator 
2 
1449929_at Dynlt3 dynein light chain Tctex-type 3 
1418286_a_at Efnb1 ephrin B1 
1460432_a_at Eif3e 
eukaryotic translation initiation factor 3, subunit 
E 
1439268_x_at Eif3e 
eukaryotic translation initiation factor 3, subunit 
E 
1423220_at Eif4e eukaryotic translation initiation factor 4E 
1419556_at Elf5 E74-like factor 5 
1450208_a_at Elmo1 
engulfment and cell motility 1, ced-12 homolog 
(C. elegans) 
1452157_at Eprs glutamyl-prolyl-tRNA synthetase 
1433514_at Etnk1 ethanolamine kinase 1 
1437712_x_at Exosc4 exosome component 4 
1416888_at Fadd Fas (TNFRSF6)-associated via death domain 
1431002_x_at Fahd2a 
fumarylacetoacetate hydrolase domain 
containing 2A 
1431189_a_at Fahd2a 
fumarylacetoacetate hydrolase domain 
containing 2A 
1431190_x_at Fahd2a 
fumarylacetoacetate hydrolase domain 
containing 2A 
1428540_at Fam115a family with sequence similarity 115, member A 
1434010_at Fam117b family with sequence similarity 117, member B 
1418474_at Fam158a family with sequence similarity 158, member A 
1425323_a_at Fam173a family with sequence similarity 173, member A 
1451668_at Fam20b family with sequence similarity 20, member B 
1454621_s_at Fam73b family with sequence similarity 73, member B 
1438036_x_at Fam82a1 family with sequence similarity 82, member A1 
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1430986_at Farsb phenylalanyl-tRNA synthetase, beta subunit 
1423828_at Fasn fatty acid synthase 
1447878_s_at Fgfrl1 fibroblast growth factor receptor-like 1 
1444075_at Filip1 filamin A interacting protein 1 
1454935_at Fitm2 fat storage-inducing transmembrane protein 2 
1435221_at Foxp1 forkhead box P1 
1455843_at Fut4 fucosyltransferase 4 
1449410_a_at Gas5 growth arrest specific 5 
1423271_at Gjb2 gap junction protein, beta 2 
1424108_at Glo1 glyoxalase 1 
1451121_a_at Gltscr2 
glioma tumor suppressor candidate region gene 
2 
1435335_a_at Gnptab 
N-acetylglucosamine-1-phosphate transferase, 
alpha and beta subunits 
1449390_at Gpatch4 G patch domain containing 4 
1437436_s_at Grk6 G protein-coupled receptor kinase 6 
1433824_x_at Grsf1 G-rich RNA sequence binding factor 1 
1438858_x_at H2-Aa histocompatibility 2, class II antigen A, alpha 
1435290_x_at H2-Aa histocompatibility 2, class II antigen A, alpha 
1450648_s_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 
1451721_a_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 
1425477_x_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 
1449580_s_at H2-DMb1  
histocompatibility 2, class II, locus Mb1 /// 
histocompatibility 2, class II, locus Mb2 
1418638_at H2-DMb1  
histocompatibility 2, class II, locus Mb1 /// 
histocompatibility 2, class II, locus Mb2 
1417025_at H2-Eb1 histocompatibility 2, class II antigen E beta 
1415743_at Hdac5 histone deacetylase 5 
1424522_at Heatr1 HEAT repeat containing 1 
1425937_a_at Hexim1 hexamethylene bis-acetamide inducible 1 
1435967_s_at Hibadh 3-hydroxyisobutyrate dehydrogenase 
1448183_a_at Hif1a hypoxia inducible factor 1, alpha subunit   
1455014_at Hint3 histidine triad nucleotide binding protein 3 
1448239_at Hmox1 heme oxygenase (decycling) 1 
1416399_a_at Hmox2 heme oxygenase (decycling) 2 
1454898_s_at Iah1 
isoamyl acetate-hydrolyzing esterase 1 homolog 
(S. cerevisiae) 
1429119_at Iah1 
isoamyl acetate-hydrolyzing esterase 1 homolog 
(S. cerevisiae) 
1451412_a_at Ift20 
intraflagellar transport 20 homolog 
(Chlamydomonas) 
1455048_at Igsf3 immunoglobulin superfamily, member 3 
1448496_a_at Ing1 inhibitor of growth family, member 1 
1450760_a_at Ing3 inhibitor of growth family, member 3 
1433464_at Ipo13 importin 13 
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1451983_at Irx1 Iroquois related homeobox 1 (Drosophila) 
1420860_at Itga9 integrin alpha 9 
1450029_s_at Itga9 integrin alpha 9 
1422157_a_at Itgb1bp1 integrin beta 1 binding protein 1 
1431808_a_at Itih4 inter alpha-trypsin inhibitor, heavy chain 4 
1415961_at Itm2c integral membrane protein 2C 
1426900_at Jmjd1c jumonji domain containing 1C 
1420056_s_at Jmjd6 jumonji domain containing 6 
1450185_a_at Kcnj15 
potassium inwardly-rectifying channel, subfamily 
J, member 15 
1426810_at Kdm3a lysine (K)-specific demethylase 3A 
1436056_at Kif13b kinesin family member 13B 
1416350_at Klf16 Kruppel-like factor 16 
1435086_s_at Klhdc2 kelch domain containing 2 
1448269_a_at Klhl13 kelch-like 13 (Drosophila) 
1417812_a_at Lamb3 laminin, beta 3 
1417057_a_at Lamp3  
lysosomal-associated membrane protein 3 /// 
peptidylprolyl isomerase D (cyclophilin D) 
1427011_a_at Lancl1 
LanC (bacterial lantibiotic synthetase 
component C)-like 1 
1434418_at Lass6 LAG1 homolog, ceramide synthase 6 
1440246_at Lass6 LAG1 homolog, ceramide synthase 6 
1460546_at Lgi3 leucine-rich repeat LGI family, member 3 
1456377_x_at Limd2 LIM domain containing 2 
1429104_at Limd2 LIM domain containing 2 
1417627_a_at Limk1 LIM-domain containing, protein kinase 
1418232_s_at Lims1 LIM and senescent cell antigen-like domains 1 
1450872_s_at Lipa lysosomal acid lipase A 
1451359_at Lpcat1 lysophosphatidylcholine acyltransferase 1 
1431394_a_at Lrrk2 leucine-rich repeat kinase 2 
1438312_s_at Ltbp3 
latent transforming growth factor beta binding 
protein 3 
1451490_at Lyplal1 lysophospholipase-like 1 
1455928_x_at Lztr1 leucine-zipper-like transcriptional regulator, 1 
1426409_at Lzts2 leucine zipper, putative tumor suppressor 2 
1416212_at Magoh 
mago-nashi homolog, proliferation-associated 
(Drosophila) 
1434354_at Maob monoamine oxidase B 
1423667_at Mat2a methionine adenosyltransferase II, alpha 
1433576_at Mat2a methionine adenosyltransferase II, alpha 
1427040_at Mdfic MyoD family inhibitor domain containing 
1421528_a_at Med22 mediator complex subunit 22 
1417844_at Med4 
mediator of RNA polymerase II transcription, 
subunit 4 homolog (yeast) 
1419377_at Med9 mediator of RNA polymerase II transcription, 
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subunit 9 homolog (yeast) 
1439380_x_at Meg3 maternally expressed 3 
1452905_at Meg3 maternally expressed 3 
1460050_x_at Mettl13 Methyltransferase like 13 
1456736_x_at Mff mitochondrial fission factor 
1452037_at Mgat2 mannoside acetylglucosaminyltransferase 2 
1415897_a_at Mgst1 microsomal glutathione S-transferase 1 
1416733_at Mkln1 
muskelin 1, intracellular mediator containing 
kelch motifs 
1430635_at Mlana melan-A 
1448139_at Mlc1 
megalencephalic leukoencephalopathy with 
subcortical cysts 1 homolog (human) 
1433811_at Mllt6 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 
6 
1420092_at Morc3 Microrchidia 3 
1432216_s_at Mpp7 
membrane protein, palmitoylated 7 (MAGUK 
p55 subfamily member 7) 
1455179_at Mpp7 
membrane protein, palmitoylated 7 (MAGUK 
p55 subfamily member 7) 
1437622_x_at Mrpl28 mitochondrial ribosomal protein L28 
1427158_at Mrps30 mitochondrial ribosomal protein S30 
1453030_at Msl2 male-specific lethal 2 homolog (Drosophila) 
1436704_x_at Mthfd1 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent), methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthase 
1419272_at Myd88 
myeloid differentiation primary response gene 
88 
1424933_at Myo5c myosin VC 
1423590_at Napsa napsin A aspartic peptidase 
1444086_at Nckap5 NCK-associated protein 5 
1448934_at Ndufa10 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 10 
1417285_a_at Ndufa5 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 5 
1448427_at Ndufa6 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 6 (B14) 
1447919_x_at Ndufab1 
NADH dehydrogenase (ubiquinone) 1, 
alpha/beta subcomplex, 1 
1455911_x_at Ndufb11 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 11 
1451109_a_at Nedd4 
neural precursor cell expressed, 
developmentally down-regulated 4 
1428248_at Nfx1 nuclear transcription factor, X-box binding 1 
1448465_at Nipsnap1 4-nitrophenylphosphatase domain and non-
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neuronal SNAP25-like protein homolog 1 (C. 
elegans) 
1417278_a_at Nkd1 naked cuticle 1 homolog (Drosophila) 
1429819_at Nmnat1 nicotinamide nucleotide adenylyltransferase 1 
1456573_x_at Nnt nicotinamide nucleotide transhydrogenase 
1455768_at Npc2 Niemann Pick type C2 
1434270_at Npcd  
neuronal pentraxin chromo domain /// neuronal 
pentraxin receptor 
1452107_s_at Npnt nephronectin 
1421429_a_at Npnt nephronectin 
1424412_at Ogfrl1 opioid growth factor receptor-like 1 
1418529_at Osgep O-sialoglycoprotein endopeptidase 
1450969_at Pccb 
propionyl Coenzyme A carboxylase, beta 
polypeptide 
1435741_at Pde8b phosphodiesterase 8B 
1437989_at Pde8b phosphodiesterase 8B 
1423648_at Pdia6 protein disulfide isomerase associated 6 
1427550_at Peg10 paternally expressed 10 
1449442_at Pex11a peroxisomal biogenesis factor 11 alpha 
1448995_at Pf4 platelet factor 4 
1451149_at Pgm2 phosphoglucomutase 2 
1428714_at Pgrmc2 progesterone receptor membrane component 2 
1435003_at Pi4ka 
phosphatidylinositol 4-kinase, catalytic, alpha 
polypeptide 
1437999_x_at Pigq 
phosphatidylinositol glycan anchor biosynthesis, 
class Q 
1438652_x_at Pigq 
phosphatidylinositol glycan anchor biosynthesis, 
class Q 
1435596_at Pion pigeon homolog (Drosophila) 
1416387_at Pip4k2c 
phosphatidylinositol-5-phosphate 4-kinase, type 
II, gamma 
1421834_at Pip5k1b 
phosphatidylinositol-4-phosphate 5-kinase, type 
1 beta 
1424442_a_at Pja2 praja 2, RING-H2 motif containing 
1448786_at Plbd1 phospholipase B domain containing 1 
1423372_at Pole4 
polymerase (DNA-directed), epsilon 4 (p12 
subunit) 
1449648_s_at Polr1c polymerase (RNA) I polypeptide C 
1417041_at Polr1c polymerase (RNA) I polypeptide C 
1452596_at Polr2k 
polymerase (RNA) II (DNA directed) polypeptide 
K 
1448379_at Pot1a protection of telomeres 1A 
1452831_s_at Ppat 
phosphoribosyl pyrophosphate 
amidotransferase 
1454848_at Ppp1r12c protein phosphatase 1, regulatory (inhibitor) 
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subunit 12C 
1440285_at Ppp1r9a 
protein phosphatase 1, regulatory (inhibitor) 
subunit 9A 
1425542_a_at Ppp2r5c 
protein phosphatase 2, regulatory subunit B 
(B56), gamma isoform 
1452788_at Ppp2r5e 
protein phosphatase 2, regulatory subunit B 
(B56), epsilon isoform 
1418036_at Prim2 DNA primase, p58 subunit 
1439549_at Prrg3 
proline rich Gla (G-carboxyglutamic acid) 3 
(transmembrane) 
1418320_at Prss8 protease, serine, 8 (prostasin) 
1450696_at Psmb9 
proteasome (prosome, macropain) subunit, beta 
type 9 (large multifunctional peptidase 2) 
1433503_at Ptgr2 prostaglandin reductase 2 
1423414_at Ptgs1 prostaglandin-endoperoxide synthase 1 
1436448_a_at Ptgs1 prostaglandin-endoperoxide synthase 1 
1438670_at Ptpn1 
protein tyrosine phosphatase, non-receptor type 
1 
1450819_at Pvrl1 poliovirus receptor-related 1 
1437993_x_at Qdpr quinoid dihydropteridine reductase 
1417829_a_at Rab15 RAB15, member RAS oncogene family 
1423083_at Rab33b RAB33B, member of RAS oncogene family 
1416591_at Rab34 RAB34, member of RAS oncogene family 
1424331_at Rab40c Rab40c, member RAS oncogene family 
1424188_at Rabgap1 RAB GTPase activating protein 1 
1443877_a_at Rapgef6 
Rap guanine nucleotide exchange factor (GEF) 
6 
1422449_s_at Rcn2 reticulocalbin 2 
1450107_a_at Renbp renin binding protein 
1451236_at Rerg RAS-like, estrogen-regulated, growth-inhibitor 
1427580_a_at Rian RNA imprinted and accumulated in nucleus 
1426504_a_at Rnf121 ring finger protein 121 
1452769_at Rnf145 ring finger protein 145 
1429321_at Rnf149 ring finger protein 149 
1426414_a_at Rnf7 ring finger protein 7 
1438626_x_at Rpl14 ribosomal protein L14 
1448398_s_at Rpl22 ribosomal protein L22 
1439780_at Rpl7l1 ribosomal protein L7-like 1 
1422552_at Rprm 
reprimo, TP53 dependent G2 arrest mediator 
candidate 
1455364_a_at Rps7 ribosomal protein S7 
1417096_at Rrp15 
ribosomal RNA processing 15 homolog (S. 
cerevisiae) 
1415823_at Scd2 stearoyl-Coenzyme A desaturase 2 
1449686_s_at Scp2 sterol carrier protein 2, liver 
	  	   179	  
1429446_at Sdccag1 serologically defined colon cancer antigen 1 
1456120_at Secisbp2l SECIS binding protein 2-like 
1450642_at Secisbp2l SECIS binding protein 2-like 
1448110_at Sema4a 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A 
1449202_at Sema4g 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4G 
1448903_at Sep15 selenoprotein 
1449040_a_at Sephs2 selenophosphate synthetase 2 
1420010_at Serinc4 serine incorporator 4 
1455546_s_at Sf3a2 splicing factor 3a, subunit 2 
1418639_at Sftpc surfactant associated protein C 
1417560_at Sfxn1 sideroflexin 1 
1415892_at Sgpl1 sphingosine phosphate lyase 1 
1457867_at Sgpp2 sphingosine-1-phosphate phosphotase 2 
1417600_at Slc15a2 
solute carrier family 15 (H+/peptide transporter), 
member 2 
1424730_a_at Slc15a2 
solute carrier family 15 (H+/peptide transporter), 
member 2 
1416854_at Slc34a2 
solute carrier family 34 (sodium phosphate), 
member 2 
1416949_s_at Slc39a7 
solute carrier family 39 (zinc transporter), 
member 7 
1416832_at Slc39a8 
solute carrier family 39 (metal ion transporter), 
member 8 
1460565_at Slc41a1 solute carrier family 41, member 1 
1435008_at Slc9a6 
solute carrier family 9 (sodium/hydrogen 
exchanger), member 6 
1425108_a_at Smagp small cell adhesion glycoprotein 
1424760_a_at Smyd2 SET and MYND domain containing 2 
1433674_a_at Snhg1 
small nucleolar RNA host gene (non-protein 
coding) 1 
1436040_at Snhg12 small nucleolar RNA host gene 12 
1417695_a_at Soat1 sterol O-acyltransferase 1 
1417696_at Soat1 sterol O-acyltransferase 1 
1423215_at Spcs2 
signal peptidase complex subunit 2 homolog (S. 
cerevisiae) 
1460243_at Sptlc2 
serine palmitoyltransferase, long chain base 
subunit 2 
1435937_at Sptlc2 
serine palmitoyltransferase, long chain base 
subunit 2 
1427902_at Srrm2 serine/arginine repetitive matrix 2 
1439095_at Srsf11 serine/arginine-rich splicing factor 11 
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1427333_s_at Srsf15 serine/arginine-rich splicing factor 15 
1452616_s_at Ssbp1 single-stranded DNA binding protein 1 
1420928_at St6gal1 beta galactoside alpha 2,6 sialyltransferase 1 
1418075_at St6galnac4 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-
2,6-sialyltransferase 4 
1460700_at Stat3 signal transducer and activator of transcription 3 
1428917_at Stx17 syntaxin 17 
1415891_at Suclg1 
succinate-CoA ligase, GDP-forming, alpha 
subunit 
1427896_at Suds3 
suppressor of defective silencing 3 homolog (S. 
cerevisiae) 
1424604_s_at Sumf1 sulfatase modifying factor 1 
1422457_s_at Sumo3 
SMT3 suppressor of mif two 3 homolog 3 
(yeast) 
1424255_at Supt5h suppressor of Ty 5 homolog (S. cerevisiae) 
1441927_at Syt7 synaptotagmin VII 
1440819_s_at Szt2 seizure threshold 2 
1434238_at Taf2 
TAF2 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor 
1455733_at Taok3 TAO kinase 3 
1420196_s_at Tbc1d14 TBC1 domain family, member 14 
1449772_at Tbc1d14 TBC1 domain family, member 14 
1416060_at Tbc1d15 TBC1 domain family, member 15 
1426644_at Tbc1d20 TBC1 domain family, member 20 
1434224_at Tbl2 transducin (beta)-like 2 
1451838_a_at Tc2n tandem C2 domains, nuclear 
1439045_x_at Tc2n tandem C2 domains, nuclear 
1437463_x_at Tgfbi transforming growth factor, beta induced 
1428521_at Thap3 
THAP domain containing, apoptosis associated 
protein 3 
1448517_at Timm22 
translocase of inner mitochondrial membrane 22 
homolog (yeast) 
1439454_x_at Tm2d2 TM2 domain containing 2 
1424707_at Tmed10 
transmembrane emp24-like trafficking protein 10 
(yeast) 
1427314_at Tmed7 
transmembrane emp24 protein transport domain 
containing 7 
1426436_at Tmem159 transmembrane protein 159 
1451133_s_at Tmem168 transmembrane protein 168 
1453480_at Tmem213 transmembrane protein 213 
1417611_at Tmem37 transmembrane protein 37 
1421127_at Tmem42 transmembrane protein 42 
1424042_at Tmem5 transmembrane protein 5 
1418124_at Tmem85 transmembrane protein 85 
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1417866_at Tnfaip1 
tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
1422924_at Tnfsf9 
tumor necrosis factor (ligand) superfamily, 
member 9 
1435055_a_at Tom1 target of myb1 homolog (chicken) 
1417754_at Topors topoisomerase I binding, arginine/serine-rich 
1436049_at Tox4 TOX high mobility group box family member 4 
1423602_at Traf1 TNF receptor-associated factor 1 
1416170_at Trap1 TNF receptor-associated protein 1 
1456225_x_at Trib3 tribbles homolog 3 (Drosophila) 
1424611_x_at Trub2 
TruB pseudouridine (psi) synthase homolog 2 
(E. coli) 
1424610_at Trub2 
TruB pseudouridine (psi) synthase homolog 2 
(E. coli) 
1416908_s_at Tsn translin 
1430310_at Tspan11 tetraspanin 11 
1416484_at Ttc3 tetratricopeptide repeat domain 3 
1452782_a_at Txn2 thioredoxin 2 
1417202_s_at Uba3 ubiquitin-like modifier activating enzyme 3 
1426398_at Ube2w ubiquitin-conjugating enzyme E2W (putative) 
1453097_a_at Ubtf 
upstream binding transcription factor, RNA 
polymerase I 
1425020_at Ubxn2a UBX domain protein 2A 
1450968_at Uqcrfs1 
ubiquinol-cytochrome c reductase, Rieske iron-
sulfur polypeptide 1 
1423817_s_at Use1 
unconventional SNARE in the ER 1 homolog (S. 
cerevisiae) 
1455812_x_at Vasn vasorin 
1452770_at Vkorc1 vitamin K epoxide reductase complex, subunit 1 
1430801_at Vps13b vacuolar protein sorting 13B (yeast) 
1422634_a_at Vsig2 V-set and immunoglobulin domain containing 2 
1451754_a_at Wdr45 WD repeat domain 45 
1459985_at Wdr61 WD repeat domain 61 
1423923_a_at Wdr8 WD repeat domain 8 
1438709_at Wipi1 
WD repeat domain, phosphoinositide interacting 
1 
1433676_at Wnk1 WNK lysine deficient protein kinase 1 
1427196_at Wnk4 WNK lysine deficient protein kinase 4 
1417437_at Xrcc6 
X-ray repair complementing defective repair in 
Chinese hamster cells 6 
1424196_at Yipf1 Yip1 domain family, member 1 
1420668_a_at Yipf2 Yip1 domain family, member 2 
1434277_a_at Ypel2 yippee-like 2 (Drosophila) 
1435824_at Yy1 YY1 transcription factor 
1438443_at Zbtb20 zinc finger and BTB domain containing 20 
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1452084_at Zcchc17 zinc finger, CCHC domain containing 17 
1423646_at Zdhhc3 zinc finger, DHHC domain containing 3 
1436081_a_at Zfp414 zinc finger protein 414 
1447775_x_at Zfp622 zinc finger protein 622 
1436537_at Zfp629 zinc finger protein 629 
1417849_at Zfp704 zinc finger protein 704 
1434682_at Zfp770 zinc finger protein 770 
1453140_at Zfp871 zinc finger protein 871 
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Table A7: Genes Down in shTaz Cells 
F.p.value Name 
CK1750 
shGFP 
CK1750 
shTaz  
SC241 
shGFP 
SC241 
shTaz  
Tmet 
shGFP 
Tmet 
shTaz  
0.03788 Wwtr1  8.73 8.02 8.06 6.92 8.28 6.08 
0.01116 Zfp442  5.29 4.88 6.06 4.99 6.24 4.66 
0.03684 BC003266  6.09 5.30 6.48 6.08 6.45 4.70 
0.01137 Rps6ka2  7.56 6.97 8.20 7.32 7.97 6.54 
0.00139 Scara3  8.69 7.97 9.01 7.66 8.76 8.01 
0.02016 Ltbp4  6.96 6.37 7.38 6.40 6.71 5.71 
0.0464 Mrm1  4.00 3.55 4.97 4.06 5.13 3.95 
0.0021 Snord111  3.13 2.52 3.57 2.60 3.40 2.50 
0.00561 
Mbnl2  // 
Mbnl2  5.35 5.00 5.62 4.75 5.88 4.71 
0.04965 Abcd4  5.71 5.28 6.17 5.59 5.81 4.48 
0.04085 Aldh7a1  7.45 7.47 7.88 6.88 7.76 6.41 
0.017 Kctd5  7.31 6.70 7.56 7.04 7.39 6.26 
0.01783 Rpl37  4.42 3.93 4.80 4.28 4.83 3.59 
0.04609 Mapk12  5.55 5.57 6.25 5.48 6.47 5.04 
0.04859 
D17Wsu10
4e  5.93 5.84 6.48 5.92 6.68 5.19 
0.01877 Nudt21  8.53 8.29 8.77 8.21 9.10 7.81 
0.04542 Agpat4  4.89 4.76 4.80 4.32 5.40 3.95 
0.04748 Sgsh  6.26 6.26 6.30 5.41 6.67 5.50 
0.04068 
Ero1l  // 
Ero1l  5.88 5.93 6.58 5.41 6.20 5.29 
0.03014 Tanc1  6.65 6.58 6.91 6.14 6.94 5.78 
0.01177 Trim62  3.62 3.09 3.89 3.11 3.44 2.76 
0.04005 Gm8894  7.87 7.05 8.09 7.69 8.44 7.68 
0.03504 Hgsnat  7.34 7.12 7.23 6.76 7.59 6.33 
0.02248 Irak4  6.32 5.60 6.12 5.90 6.19 5.18 
0.04403 Rxrb  6.15 5.52 6.28 6.03 6.16 5.09 
0.01623 S100a13  7.05 6.06 6.79 6.43 7.14 6.57 
0.03185 
Rps5  // 
Rps5  8.08 7.96 8.61 7.85 8.87 7.86 
0.03451 Farsa  7.68 7.27 7.54 7.22 8.32 7.15 
0.01561 Madd  5.77 5.31 6.03 5.61 6.12 5.13 
0.03882 Mrpl38  8.93 8.65 9.26 8.81 9.21 8.08 
0.02796 Fzd4  5.32 4.75 5.50 5.13 5.33 4.41 
0.04361 Slc35c2  7.02 6.64 6.88 6.66 7.14 5.93 
0.04353 Klk1b26  3.00 2.27 3.44 3.01 3.22 2.57 
0.04365 Clcn3  5.73 5.53 5.65 5.28 6.02 4.80 
0.03656 Fbxw4  6.05 5.83 6.48 5.81 6.14 5.28 
0.03817 Rps7  6.65 6.36 6.63 6.39 7.14 5.92 
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0.04879 Zscan21  5.16 4.82 5.00 4.64 5.05 4.01 
0.03277 Tmem38a  5.40 5.02 5.38 5.05 6.02 4.99 
0.04888 Telo2  5.44 5.08 5.81 5.52 6.02 4.95 
0.01691 E4f1  5.42 5.17 5.73 4.81 5.40 4.84 
0.02097 Snord66  4.81 4.63 4.93 4.08 4.89 4.23 
0.02038 Fbxl4  5.07 4.47 5.29 4.82 4.98 4.38 
0.03229 Rap2c  6.96 6.45 6.97 6.82 7.37 6.36 
0.02385 Shroom4  5.62 5.53 5.98 5.30 6.05 5.16 
0.0457 Mir1249  3.07 2.84 3.76 2.93 3.23 2.65 
0.02639 Olfr1337  3.94 3.35 4.27 3.70 3.84 3.38 
0.02649 Kcnk9  3.54 2.79 3.61 2.95 3.58 3.36 
0.0202 Flt4  4.02 3.41 3.97 3.58 4.32 3.75 
0.02806 
Ywhag  // 
Ywhag  6.90 6.45 6.98 6.67 6.92 6.10 
0.03018 Gm5124  4.02 3.62 3.93 3.16 4.07 3.69 
0.01981 Hcrtr1  3.55 3.18 3.88 3.42 3.87 3.16 
0.04182 
Sys1  // 
Sys1  4.27 3.70 4.44 3.75 3.83 3.57 
0.02145 Wdr4  4.79 4.52 5.04 4.61 5.03 4.26 
0.04116 Fbxo44  4.12 3.50 4.10 3.82 3.84 3.28 
0.03681 Gm19316  6.04 5.64 5.91 5.60 6.47 5.72 
0.02812 Phb  4.72 4.23 4.81 4.60 4.92 4.17 
0.01787 Cyp4a10  2.58 2.20 2.67 2.36 2.79 2.04 
0.01648 
Mir5102  // 
Mir5102  5.19 4.64 5.14 4.90 5.38 4.74 
0.04247 Fdxr  4.22 4.15 4.77 3.93 4.47 3.96 
0.03302 Timm8a1  5.52 4.73 5.45 5.22 5.39 5.03 
0.02533 Igfbp2  4.21 3.88 4.24 3.95 4.29 3.59 
0.02112 Tnfrsf10b  7.61 7.27 7.50 7.13 7.80 7.19 
0.03774 Cdk6  8.65 8.40 8.56 8.32 8.94 8.13 
0.02075 Piga  4.77 4.40 4.89 4.49 4.74 4.22 
0.0452 Gm13558  2.70 2.13 2.67 2.08 2.25 2.15 
0.04835 Zdhhc21  6.04 5.41 6.06 5.88 5.95 5.53 
0.03407 Mir684-1  5.77 5.53 6.01 5.55 6.12 5.62 
0.03718 Fam96b  5.72 5.55 6.05 5.56 5.91 5.41 
0.0396 Kif1a  3.36 2.92 3.22 2.85 3.05 2.69 
0.04105 Bbs10  3.98 3.56 4.20 3.89 4.16 3.72 
0.04815 Hoga1  4.27 3.74 4.39 4.16 4.39 3.98 
0.04988 Asph  6.62 6.05 6.28 6.20 6.41 5.90 
0.0441 Zbtb6  5.76 5.34 5.91 5.61 6.02 5.60 
0.04751 
LOC100504
825  5.12 4.94 5.09 4.76 5.42 4.80 
0.02345 Spats2  7.44 7.03 7.56 7.19 7.50 7.15 
0.04856 Sowahc  5.92 5.49 5.71 5.55 6.11 5.58 
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0.03853 Opn4  4.02 3.89 4.26 3.78 4.19 3.69 
0.04701 Cntnap5b  2.45 2.35 2.79 2.26 2.74 2.28 
0.03746 Wdr36  8.47 8.23 8.38 7.96 8.43 7.99 
0.049 Atp13a2  5.72 5.44 5.62 5.41 5.72 5.11 
0.04178 Fzd5  6.31 5.97 6.32 6.15 6.45 5.86 
0.04749 Mtmr9  8.22 7.92 8.28 8.10 8.46 7.86 
0.04929 Lrrc10  4.11 3.91 4.46 3.98 4.29 3.91 
0.03425 Igkv1-133  2.14 1.87 2.25 1.89 2.38 1.94 
0.04982 
Chsy1  // 
Chsy1  4.89 4.52 4.90 4.70 5.10 4.66 
0.03873 Il17a  3.26 2.94 3.18 2.88 3.29 2.96 
0.04701 DXBay18  3.68 4.01 3.75 3.98 3.72 4.04 
0.04649 DXBay18  2.89 3.27 2.89 3.17 2.93 3.17 
0.03987 Xlr5b  2.17 2.53 2.27 2.52 2.18 2.50 
0.04519 Olfr1358  2.52 2.77 2.45 2.69 2.39 2.86 
0.04631 Rasgrp4  2.16 2.53 2.14 2.45 2.30 2.59 
0.03346 Gpr158  2.33 2.67 2.28 2.56 2.26 2.62 
0.04079 Opn5  2.31 2.66 2.47 2.69 2.37 2.79 
0.0479 Rcsd1  2.06 2.26 2.11 2.40 1.89 2.41 
0.04099 Otos  3.34 3.69 3.45 3.62 3.23 3.73 
0.0382 
Beta-s  // 
Hbb-b2  // 
Hbb-b1  1.93 2.35 1.94 2.13 1.83 2.24 
0.04229 Grin3a  2.60 2.94 2.64 2.90 2.70 3.16 
0.04698 Krt6b  2.85 3.14 2.97 3.21 2.90 3.44 
0.04863 Zfp354b  1.85 2.29 2.14 2.28 1.99 2.46 
0.03856 Pdzd4  3.70 4.07 3.50 3.87 3.61 3.95 
0.03549 Adam26a  1.73 2.12 1.86 2.07 1.82 2.28 
0.03241 Rcsd1  3.92 4.19 4.00 4.39 3.97 4.38 
0.03367 Cd4  2.58 3.03 2.81 3.15 2.70 3.01 
0.04312 Gm13871  3.23 3.36 3.00 3.40 3.02 3.59 
0.04545 Hsf4  4.48 4.88 4.78 4.96 4.57 5.08 
0.04192 Barx2  2.99 3.59 3.31 3.56 3.22 3.48 
0.03751 Sds  // Sds  2.37 2.77 2.53 2.79 2.55 3.00 
0.03434 Atp1b2  2.88 3.41 2.94 3.12 2.91 3.32 
0.0395 Ms4a10  3.57 3.79 3.66 3.97 3.37 3.96 
0.02482 Olfr466  2.12 2.55 2.26 2.46 2.14 2.64 
0.04009 Olfr919  2.27 2.78 2.48 2.80 2.61 2.94 
0.04883 Slc44a5  2.06 2.63 2.38 2.41 2.11 2.67 
0.04536 
LOC100861
890  2.54 2.94 2.81 3.13 2.79 3.24 
0.04037 
Pstpip2  // 
Pstpip2  2.43 2.90 2.49 2.87 2.74 3.07 
0.01649 Rpe65  2.12 2.50 2.04 2.50 2.14 2.48 
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0.03319 B4galt4  4.34 4.84 4.25 4.81 4.53 4.65 
0.04148 Gm8777  2.02 2.42 2.32 2.58 2.18 2.69 
0.01992 BC106175  3.20 3.64 3.19 3.47 3.15 3.62 
0.03683 Mir5100  3.75 3.93 3.79 4.17 3.57 4.21 
0.03143 Vmn1r234  2.37 2.65 2.53 2.90 2.38 2.93 
0.03637 Mettl7a3  2.17 2.48 2.31 2.84 2.26 2.62 
0.03003 Gm12108  3.41 3.63 3.44 3.79 3.19 3.83 
0.0457 Ugt2b1  2.54 2.79 2.30 2.67 2.10 2.70 
0.02516 Gm6362  2.10 2.68 2.34 2.70 2.36 2.62 
0.02561 Vmn1r24  2.06 2.59 2.14 2.37 2.17 2.64 
0.01934 Klrb1c  1.99 2.44 2.06 2.55 2.20 2.48 
0.0303 Tmem217  2.37 2.82 2.37 2.98 2.65 2.83 
0.03951 Gm20599  2.26 2.76 2.59 2.70 2.18 2.79 
0.04715 AY358078  4.68 4.91 4.35 4.74 4.49 5.11 
0.04732 Olfr119  1.98 2.29 2.06 2.26 1.97 2.70 
0.03487 Ighg  4.33 4.57 4.20 4.51 3.93 4.63 
0.01568 Adcy4  3.09 3.61 3.23 3.58 3.09 3.49 
0.02543 Ucp3  3.18 3.35 3.06 3.58 3.10 3.67 
0.03939 Oas1f  2.13 2.66 2.38 2.58 2.39 2.94 
0.04261 Unc93a  3.58 3.75 3.53 3.90 3.48 4.23 
0.04552 Psmb11  2.74 2.95 2.67 2.95 2.58 3.39 
0.03074 Tmem215  2.80 3.15 2.75 3.08 2.84 3.47 
0.03036 Mcpt9  2.20 2.54 2.29 2.67 2.35 2.94 
0.03059 
Gsdmd  // 
Gsdmd  3.67 4.38 3.88 4.22 4.08 4.36 
0.03305 Gm5576  3.33 3.53 3.05 3.47 2.90 3.60 
0.02832 Vmn1r72  2.06 2.35 1.90 2.23 1.89 2.60 
0.04367 Gm5329  2.99 3.55 2.74 3.44 3.05 3.13 
0.03192 Arhgef6  1.92 2.25 1.98 2.35 2.04 2.68 
0.04234 
Mir3098  // 
Mir3098  2.13 2.53 2.18 2.83 2.53 2.82 
0.02413 Olfr448  1.72 2.23 1.95 2.21 1.92 2.51 
0.02239 Gm3591  2.64 3.02 2.64 3.06 2.78 3.36 
0.02201 Slc29a3  3.88 4.23 3.84 4.11 3.68 4.44 
0.02496 Kcnj16  2.67 3.00 2.71 3.04 2.66 3.39 
0.01173 Lypd6  3.29 3.75 3.45 3.76 3.22 3.86 
0.01412 Gm15688  3.07 3.71 3.01 3.44 3.13 3.48 
0.01605 Mir1905  3.78 4.16 3.89 4.21 3.71 4.44 
0.03432 Ccdc62  3.00 3.37 2.85 3.08 2.71 3.54 
0.04842 Pomc  2.59 3.20 2.64 3.46 2.99 2.99 
0.01666 Vmn1r78  1.90 2.59 1.86 2.28 2.00 2.32 
0.03009 Gm6531  2.93 3.28 3.01 3.39 3.05 3.77 
0.02956 Mir713  2.66 3.36 3.04 3.26 3.01 3.57 
0.03385 Gm10139  4.85 5.20 4.88 5.10 4.71 5.61 
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// Gm10139  
0.02289 Olfr429  2.43 2.81 2.30 2.58 2.07 2.90 
0.03084 Gm5325  6.36 6.92 6.35 6.53 6.32 7.08 
0.01736 Epha5  2.88 3.10 2.80 3.36 2.76 3.49 
0.04574 Gckr  2.53 2.89 2.73 2.96 2.58 3.49 
0.02395 Snhg11  3.34 3.59 2.84 3.65 3.16 3.60 
0.02956 Ighg  2.62 3.40 2.55 2.97 2.88 3.20 
0.04761 Lce1a2  3.14 3.81 3.22 3.52 3.53 4.10 
0.03797 Gm10166  4.79 5.26 4.60 4.93 4.25 5.00 
0.0497 Isg15  3.59 4.19 3.26 3.57 3.38 4.03 
0.02733 Gm4559  3.96 4.31 4.15 4.75 3.82 4.42 
0.04153 Oca2  2.82 3.30 2.82 3.03 2.84 3.71 
0.04818 Xpnpep2  3.68 3.90 3.90 4.33 3.33 4.24 
0.03085 Olfr113  2.64 3.02 2.90 3.42 2.46 3.13 
0.0424 Mycs  2.74 3.04 2.69 3.22 2.93 3.68 
0.04904 Yy2  5.65 5.89 5.23 5.63 5.31 6.24 
0.04738 Gm5751  2.36 3.03 1.98 2.45 2.07 2.52 
0.03643 AU021034  3.97 4.48 3.89 4.21 4.09 4.84 
0.03953 Gm10125  3.60 4.21 3.23 3.63 3.34 3.93 
0.01267 Zfp352  2.69 3.33 2.86 3.08 2.69 3.44 
0.04138 Acnat1  2.60 2.87 2.75 3.10 2.56 3.54 
0.04336 Ipo4  3.75 4.28 3.35 3.93 3.89 4.41 
0.02641 Dkk1  3.41 3.63 3.49 3.94 3.10 4.06 
0.03129 Rab4a  3.70 4.09 3.51 3.79 3.42 4.39 
0.04716 Gm6337  2.26 2.56 2.57 3.19 2.45 3.17 
0.01189 Ggt5  2.55 2.88 2.51 3.00 2.44 3.27 
0.03251 Vmn2r5  2.26 2.48 2.08 2.65 2.24 3.10 
0.03376 Gm10827  3.57 3.90 3.54 3.96 3.62 4.53 
0.00967 Slc22a2  3.14 4.01 3.37 3.80 3.42 3.79 
0.04602 Gm4701  2.21 3.11 2.66 2.76 2.68 3.35 
0.03724 Npm1  5.78 6.17 5.39 6.00 5.84 6.54 
0.02261 Tnfaip8l3  3.36 3.67 3.31 3.85 3.39 4.25 
0.02687 Mir1960  2.80 3.23 2.89 3.30 2.94 3.82 
0.04059 Mir212  4.16 4.79 3.63 4.27 4.09 4.54 
0.03401 Cox6a2  3.33 4.16 3.56 3.57 3.23 4.12 
0.02923 Exoc7  2.14 2.60 2.08 2.46 2.20 3.12 
0.04435 Fbxw28  2.07 2.49 1.82 2.22 2.05 2.99 
0.02517 Ffar1  3.19 3.44 2.96 3.45 2.96 3.98 
0.01448 Atp5j2  3.10 3.57 3.15 3.46 2.69 3.70 
0.03415 Setbp1  5.47 6.38 5.36 5.87 5.90 6.28 
0.01045 Sh3rf3  2.78 3.38 2.59 3.08 2.78 3.50 
0.04049 Zp3  3.38 3.59 3.20 3.66 3.19 4.33 
0.01514 
Mir669h  // 
Mir669h  2.43 2.63 2.09 3.06 2.12 2.78 
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0.02798 Foxb1  3.42 3.45 3.09 3.87 2.95 3.98 
0.01765 Timm8a2  4.75 5.17 4.40 4.95 4.58 5.46 
0.00463 
Gvin1  // 
Gvin1  3.50 4.33 3.68 4.09 3.66 4.27 
0.0259 Islr  3.20 3.61 3.50 4.23 3.12 3.86 
0.02854 Rnase11  2.30 3.11 2.59 2.73 2.52 3.44 
0.01203 Tmem90a  3.51 4.28 3.56 3.91 3.21 3.96 
0.0345 Zcchc7  6.58 6.99 6.14 6.54 6.04 7.13 
0.03878 Tpsab1  2.27 2.83 2.56 3.48 2.28 2.71 
0.01755 Svop  3.31 3.67 3.55 4.12 3.16 4.14 
0.04184 Galr3  3.50 3.54 3.23 4.28 3.48 4.30 
0.02265 
Mir669m-1  
// Mir669m-
1  4.40 5.22 4.65 4.73 4.24 5.28 
0.01503 
Gm10503  
// Gm10503  3.13 3.93 3.33 3.56 3.23 4.19 
0.04265 Gm6613  3.27 3.48 3.10 3.88 3.39 4.40 
0.02625 F2rl3  2.99 4.15 3.59 3.90 3.67 4.19 
0.03744 
Tgtp2  // 
Tgtp1  2.21 2.91 2.39 2.62 2.43 3.51 
0.00377 
Vmn2r41  // 
Vmn2r40  3.08 3.69 2.93 3.78 3.28 3.84 
0.02935 Olfr488  1.95 2.53 1.70 2.06 1.80 2.90 
0.04933 Aph1c  4.19 4.19 3.52 4.88 4.13 4.82 
0.00662 Gm19451  3.79 4.61 4.08 4.39 3.86 4.81 
0.02197 Figf  3.82 4.77 4.02 4.17 3.45 4.48 
0.02823 Phf11  3.86 4.11 3.12 3.89 3.04 4.28 
0.01408 Apol7e  2.21 3.17 2.14 2.61 2.42 3.34 
0.02622 Ppnr  5.17 5.68 4.43 5.27 4.92 5.97 
0.0099 
Gm609  // 
Gm609  1.96 2.78 2.23 2.95 2.45 3.38 
0.03977 Fcrl1  2.82 3.20 3.22 4.34 2.88 3.86 
0.01712 Stk39  5.28 6.23 5.22 5.48 4.80 6.19 
0.01341 Sgk3  4.72 4.88 3.98 5.18 4.01 5.30 
0.04852 Gm17783  2.62 3.07 2.81 3.62 2.99 4.50 
0.02882 Olfr310  4.11 4.35 3.18 4.66 3.49 6.01 
0.00136 Gfra2  4.08 5.90 3.86 5.22 3.81 5.02 	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Table A8: GSEA in shGFP vs shTaz Cells 
NAME SIZE ES NES NOM p-val FDR q-val 
MITOCHONDRION 315 -0.58 -2.48 0.00 0.00 
MITOCHONDRIAL_PART 137 -0.61 -2.41 0.00 0.00 
MITOCHONDRIAL_ENVELOPE 93 -0.65 -2.37 0.00 0.00 
MITOCHONDRIAL_MEMBRANE_P
ART 50 -0.71 -2.36 0.00 0.00 
MITOCHONDRIAL_INNER_MEMB
RANE 63 -0.67 -2.34 0.00 0.00 
ORGANELLE_INNER_MEMBRAN
E 71 -0.65 -2.31 0.00 0.00 
MITOCHONDRIAL_MEMBRANE 82 -0.64 -2.31 0.00 0.00 
ENVELOPE 164 -0.58 -2.31 0.00 0.00 
ORGANELLE_ENVELOPE 164 -0.58 -2.30 0.00 0.00 
ORGANELLE_MEMBRANE 289 -0.54 -2.29 0.00 0.00 
LIGASE_ACTIVITY 93 -0.59 -2.19 0.00 0.00 
INTRACELLULAR_TRANSPORT 268 -0.52 -2.19 0.00 0.00 
MITOCHONDRION_ORGANIZATI
ON_AND_BIOGENESIS 44 -0.68 -2.18 0.00 0.00 
BIOSYNTHETIC_PROCESS 445 -0.50 -2.17 0.00 0.00 
CELLULAR_BIOSYNTHETIC_PRO
CESS 304 -0.51 -2.16 0.00 0.00 
HELICASE_ACTIVITY 50 -0.63 -2.13 0.00 0.00 
ENDOMEMBRANE_SYSTEM 214 -0.52 -2.13 0.00 0.00 
ENDOPLASMIC_RETICULUM 271 -0.51 -2.14 0.00 0.00 
NUCLEOBASENUCLEOSIDE_AND
_NUCLEOTIDE_METABOLIC_PR
OCESS 48 -0.63 -2.10 0.00 0.00 
RESPONSE_TO_OXIDATIVE_STR
ESS 44 -0.64 -2.11 0.00 0.00 
ATP_DEPENDENT_HELICASE_A
CTIVITY 26 -0.72 -2.12 0.00 0.00 
GOLGI_APPARATUS 213 -0.51 -2.12 0.00 0.00 
RNA_PROCESSING 164 -0.51 -2.05 0.00 0.00 
GOLGI_APPARATUS_PART 96 -0.55 -2.04 0.00 0.00 
ORGANIC_ACID_METABOLIC_PR
OCESS 166 -0.51 -2.05 0.00 0.00 
TRANSLATION 173 -0.50 -2.03 0.00 0.00 
RNA_BINDING 245 -0.49 -2.03 0.00 0.00 
ELECTRON_CARRIER_ACTIVITY 70 -0.57 -2.02 0.00 0.00 
CARBOXYLIC_ACID_METABOLIC
_PROCESS 164 -0.51 -2.02 0.00 0.00 
NUCLEOSIDE_TRIPHOSPHATAS
E_ACTIVITY 198 -0.49 -2.01 0.00 0.00 
CELLULAR_LOCALIZATION 352 -0.47 -2.01 0.00 0.00 
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VESICLE_MEMBRANE 30 -0.66 -2.01 0.00 0.00 
ESTABLISHMENT_OF_CELLULAR
_LOCALIZATION 334 -0.47 -2.01 0.00 0.00 
LIGASE_ACTIVITY_FORMING_CA
RBON_NITROGEN_BONDS 65 -0.57 -2.01 0.00 0.00 
NUCLEOLUS 110 -0.53 -2.00 0.00 0.00 
NUCLEOTIDE_METABOLIC_PRO
CESS 38 -0.62 -2.00 0.00 0.00 
PROTEASOME_COMPLEX 22 -0.70 -1.98 0.00 0.00 
RRNA_METABOLIC_PROCESS 16 -0.76 -1.98 0.00 0.00 
MITOCHONDRIAL_RESPIRATOR
Y_CHAIN 23 -0.69 -1.98 0.00 0.00 
AMINO_ACID_AND_DERIVATIVE_
METABOLIC_PROCESS 98 -0.53 -1.97 0.00 0.00 
PYROPHOSPHATASE_ACTIVITY 211 -0.48 -1.96 0.00 0.00 
PROTEIN_FOLDING 53 -0.59 -1.97 0.00 0.00 
ORGANELLE_ORGANIZATION_A
ND_BIOGENESIS 449 -0.45 -1.96 0.00 0.00 
CELLULAR_CATABOLIC_PROCE
SS 196 -0.48 -1.97 0.00 0.00 
TRANSLATION_FACTOR_ACTIVIT
Y_NUCLEIC_ACID_BINDING 36 -0.62 -1.96 0.00 0.00 
PROTON_TRANSPORTING_TWO
_SECTOR_ATPASE_COMPLEX 15 -0.76 -1.96 0.00 0.00 
NUCLEOBASENUCLEOSIDENUC
LEOTIDE_KINASE_ACTIVITY 25 -0.67 -1.96 0.00 0.00 
CYTOPLASMIC_VESICLE_PART 28 -0.65 -1.94 0.00 0.00 
CYTOPLASMIC_VESICLE_MEMB
RANE 28 -0.65 -1.94 0.00 0.00 
HYDROLASE_ACTIVITY_ACTING
_ON_ACID_ANHYDRIDES 213 -0.47 -1.94 0.00 0.00 
MEMBRANE_ENCLOSED_LUMEN 427 -0.45 -1.94 0.00 0.00 
ALCOHOL_METABOLIC_PROCES
S 81 -0.53 -1.93 0.00 0.00 
ORGANELLE_LUMEN 427 -0.45 -1.93 0.00 0.00 
RRNA_PROCESSING 15 -0.77 -1.93 0.00 0.00 
MEMBRANE_COAT 17 -0.71 -1.92 0.00 0.00 
AMINO_ACID_METABOLIC_PROC
ESS 77 -0.53 -1.93 0.00 0.00 
CATABOLIC_PROCESS 206 -0.47 -1.93 0.00 0.00 
ATP_DEPENDENT_RNA_HELICA
SE_ACTIVITY 16 -0.73 -1.92 0.00 0.00 
LIPID_BIOSYNTHETIC_PROCESS 92 -0.52 -1.92 0.00 0.00 
MACROMOLECULE_BIOSYNTHE
TIC_PROCESS 308 -0.45 -1.92 0.00 0.00 
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RIBONUCLEOPROTEIN_COMPLE
X_BIOGENESIS_AND_ASSEMBLY 83 -0.52 -1.91 0.00 0.00 
STRUCTURAL_CONSTITUENT_O
F_RIBOSOME 78 -0.54 -1.91 0.00 0.00 
NITROGEN_COMPOUND_BIOSY
NTHETIC_PROCESS 23 -0.67 -1.91 0.00 0.00 
TRANSLATION_INITIATION_FACT
OR_ACTIVITY 23 -0.68 -1.91 0.00 0.00 
GTPASE_ACTIVITY 88 -0.52 -1.90 0.00 0.00 
CYTOSOL 190 -0.47 -1.91 0.00 0.00 
CELLULAR_RESPONSE_TO_STI
MULUS 18 -0.71 -1.91 0.00 0.00 
PROTEIN_TRANSPORT 152 -0.48 -1.90 0.00 0.00 
NITROGEN_COMPOUND_METAB
OLIC_PROCESS 149 -0.48 -1.90 0.00 0.00 
RNA_HELICASE_ACTIVITY 23 -0.67 -1.90 0.00 0.00 
NUCLEOTIDE_BIOSYNTHETIC_P
ROCESS 16 -0.73 -1.90 0.00 0.00 
MACROMOLECULE_LOCALIZATI
ON 221 -0.46 -1.89 0.00 0.00 
NUCLEAR_MEMBRANE_PART 42 -0.58 -1.89 0.00 0.00 
INTRACELLULAR_PROTEIN_TRA
NSPORT 141 -0.48 -1.89 0.00 0.00 
COATED_MEMBRANE 17 -0.71 -1.89 0.00 0.00 
LIPID_METABOLIC_PROCESS 284 -0.45 -1.89 0.00 0.00 
PROTEIN_COMPLEX_ASSEMBLY 156 -0.47 -1.89 0.00 0.00 
VESICLE_MEDIATED_TRANSPO
RT 180 -0.47 -1.89 0.00 0.00 
RNA_DEPENDENT_ATPASE_ACT
IVITY 17 -0.70 -1.88 0.00 0.00 
COATED_VESICLE_MEMBRANE 17 -0.69 -1.88 0.00 0.00 
MACROMOLECULAR_COMPLEX_
ASSEMBLY 265 -0.45 -1.88 0.00 0.00 
CELLULAR_COMPONENT_ASSE
MBLY 283 -0.44 -1.87 0.00 0.00 
PHOSPHOLIPID_BIOSYNTHETIC_
PROCESS 37 -0.60 -1.87 0.00 0.00 
NUCLEAR_ENVELOPE_ENDOPL
ASMIC_RETICULUM_NETWORK 90 -0.51 -1.87 0.00 0.00 
ENDOPLASMIC_RETICULUM_PA
RT 91 -0.50 -1.87 0.00 0.00 
TRANSLATION_REGULATOR_AC
TIVITY 37 -0.58 -1.87 0.00 0.00 
CELLULAR_LIPID_METABOLIC_P
ROCESS 224 -0.45 -1.87 0.00 0.00 
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RNA_EXPORT_FROM_NUCLEUS 18 -0.70 -1.87 0.00 0.00 
MEMBRANE_LIPID_BIOSYNTHET
IC_PROCESS 45 -0.58 -1.87 0.00 0.00 
NUCLEAR_LUMEN 360 -0.44 -1.86 0.00 0.00 
APOPTOTIC_NUCLEAR_CHANGE
S 19 -0.68 -1.85 0.00 0.00 
MITOCHONDRIAL_TRANSPORT 19 -0.69 -1.86 0.00 0.00 
VITAMIN_METABOLIC_PROCESS 17 -0.70 -1.85 0.00 0.00 
ESTABLISHMENT_OF_PROTEIN_
LOCALIZATION 180 -0.46 -1.86 0.00 0.00 
HYDROLASE_ACTIVITY_HYDROL
YZING_O_GLYCOSYL_COMPOU
NDS 32 -0.61 -1.85 0.00 0.00 
UNFOLDED_PROTEIN_BINDING 41 -0.58 -1.86 0.00 0.00 
OXIDOREDUCTASE_ACTIVITY 255 -0.45 -1.86 0.00 0.00 
HYDROLASE_ACTIVITY_ACTING
_ON_GLYCOSYL_BONDS 41 -0.58 -1.85 0.00 0.00 
PROTEIN_LOCALIZATION 202 -0.45 -1.85 0.00 0.00 
REGULATION_OF_I_KAPPAB_KI
NASE_NF_KAPPAB_CASCADE 88 -0.50 -1.85 0.00 0.00 
GOLGI_MEMBRANE 44 -0.56 -1.85 0.00 0.00 
COATED_VESICLE 45 -0.56 -1.84 0.00 0.00 
CARBOHYDRATE_METABOLIC_P
ROCESS 168 -0.46 -1.85 0.00 0.00 
VESICLE_COAT 16 -0.72 -1.84 0.00 0.00 
ENZYME_BINDING 169 -0.46 -1.84 0.00 0.01 
RIBONUCLEOPROTEIN_COMPLE
X 139 -0.47 -1.84 0.00 0.01 
PROTEIN_TARGETING 107 -0.48 -1.84 0.00 0.01 
GLYCEROPHOSPHOLIPID_BIOSY
NTHETIC_PROCESS 28 -0.62 -1.84 0.00 0.01 
NUCLEOBASENUCLEOSIDENUC
LEOTIDE_AND_NUCLEIC_ACID_T
RANSPORT 29 -0.60 -1.84 0.00 0.01 
CARBON_CARBON_LYASE_ACTI
VITY 17 -0.69 -1.83 0.00 0.01 
ENDOPLASMIC_RETICULUM_ME
MBRANE 81 -0.51 -1.83 0.00 0.01 
GOLGI_VESICLE_TRANSPORT 48 -0.55 -1.83 0.00 0.01 
POSITIVE_REGULATION_OF_I_K
APPAB_KINASE_NF_KAPPAB_CA
SCADE 83 -0.50 -1.83 0.00 0.01 
CELLULAR_CARBOHYDRATE_M
ETABOLIC_PROCESS 120 -0.47 -1.82 0.00 0.01 
CYTOPLASM_ORGANIZATION_A 15 -0.71 -1.82 0.00 0.01 
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ND_BIOGENESIS 
PROGRAMMED_CELL_DEATH 402 -0.42 -1.82 0.00 0.01 
POSITIVE_REGULATION_OF_TR
ANSPORT 22 -0.65 -1.81 0.00 0.01 
ENERGY_DERIVATION_BY_OXID
ATION_OF_ORGANIC_COMPOUN
DS 36 -0.57 -1.81 0.00 0.01 
REGULATION_OF_APOPTOSIS 319 -0.43 -1.81 0.00 0.01 
DNA_METABOLIC_PROCESS 242 -0.43 -1.80 0.00 0.01 
AROMATIC_COMPOUND_METAB
OLIC_PROCESS 25 -0.61 -1.80 0.00 0.01 
APOPTOTIC_PROGRAM 57 -0.52 -1.80 0.00 0.01 
ATPASE_ACTIVITY 109 -0.47 -1.79 0.00 0.01 
RIBOSOME_BIOGENESIS_AND_A
SSEMBLY 18 -0.67 -1.79 0.00 0.01 
COFACTOR_BIOSYNTHETIC_PR
OCESS 21 -0.64 -1.79 0.00 0.01 
FATTY_ACID_OXIDATION 16 -0.67 -1.79 0.01 0.01 
REGULATION_OF_PROGRAMME
D_CELL_DEATH 320 -0.42 -1.79 0.00 0.01 
APOPTOSIS_GO 401 -0.42 -1.79 0.00 0.01 
PHOSPHOTRANSFERASE_ACTIV
ITY_PHOSPHATE_GROUP_AS_A
CCEPTOR 18 -0.68 -1.79 0.00 0.01 
RUFFLE 31 -0.59 -1.79 0.00 0.01 
NUCLEAR_PORE 31 -0.58 -1.79 0.00 0.01 
I_KAPPAB_KINASE_NF_KAPPAB
_CASCADE 107 -0.47 -1.79 0.00 0.01 
ACTIN_CYTOSKELETON 115 -0.47 -1.78 0.00 0.01 
NEGATIVE_REGULATION_OF_AP
OPTOSIS 143 -0.46 -1.78 0.00 0.01 
ENZYME_INHIBITOR_ACTIVITY 108 -0.47 -1.78 0.00 0.01 
ACID_AMINO_ACID_LIGASE_ACT
IVITY 54 -0.52 -1.78 0.00 0.01 
TRANSFERASE_ACTIVITY_TRAN
SFERRING_PHOSPHORUS_CON
TAINING_GROUPS 410 -0.41 -1.77 0.00 0.01 
DAMAGED_DNA_BINDING 20 -0.65 -1.77 0.00 0.01 
NUCLEOTIDE_EXCISION_REPAI
R 19 -0.65 -1.77 0.00 0.01 
NEGATIVE_REGULATION_OF_PR
OGRAMMED_CELL_DEATH 144 -0.45 -1.77 0.00 0.01 
KINASE_ACTIVITY 356 -0.41 -1.76 0.00 0.01 
NUCLEAR_MEMBRANE 50 -0.53 -1.76 0.00 0.01 
LIPOPROTEIN_METABOLIC_PRO 30 -0.58 -1.76 0.00 0.01 
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CESS 
MRNA_PROCESSING_GO_00063
97 70 -0.50 -1.76 0.00 0.01 
TRANSFERASE_ACTIVITY_TRAN
SFERRING_ONE_CARBON_GRO
UPS 36 -0.56 -1.76 0.00 0.01 
TRANSLATIONAL_INITIATION 37 -0.56 -1.76 0.00 0.01 
REGULATION_OF_ENDOCYTOSI
S 15 -0.68 -1.76 0.01 0.01 
LIPID_TRANSPORT 27 -0.60 -1.75 0.00 0.01 
REGULATION_OF_TRANSPORT 62 -0.51 -1.75 0.00 0.01 
RESPONSE_TO_ENDOGENOUS_
STIMULUS 184 -0.43 -1.75 0.00 0.01 
NUCLEAR_EXPORT 31 -0.58 -1.75 0.00 0.01 
GTP_BINDING 43 -0.54 -1.75 0.00 0.01 
PROTEOLYSIS 176 -0.43 -1.75 0.00 0.01 
DNA_HELICASE_ACTIVITY 25 -0.60 -1.75 0.01 0.01 
NEGATIVE_REGULATION_OF_CE
LLULAR_COMPONENT_ORGANIZ
ATION_AND_BIOGENESIS 27 -0.60 -1.75 0.00 0.01 
NITROGEN_COMPOUND_CATAB
OLIC_PROCESS 29 -0.58 -1.75 0.00 0.01 
HETEROCYCLE_METABOLIC_PR
OCESS 23 -0.61 -1.74 0.00 0.01 
GUANYL_NUCLEOTIDE_BINDING 44 -0.52 -1.74 0.00 0.01 
MEMBRANE_ORGANIZATION_AN
D_BIOGENESIS 127 -0.44 -1.74 0.00 0.01 
GOLGI_ASSOCIATED_VESICLE 28 -0.59 -1.74 0.01 0.01 
RNA_SPLICING 86 -0.47 -1.74 0.00 0.01 
AMINE_METABOLIC_PROCESS 136 -0.45 -1.74 0.00 0.01 
CYTOSKELETAL_PROTEIN_BIND
ING 151 -0.44 -1.73 0.00 0.01 
MRNA_METABOLIC_PROCESS 81 -0.48 -1.73 0.00 0.01 
CELLULAR_RESPIRATION 19 -0.64 -1.73 0.01 0.01 
MITOCHONDRIAL_MATRIX 45 -0.53 -1.73 0.00 0.01 
ACTIN_BINDING 68 -0.49 -1.73 0.00 0.01 
ISOMERASE_ACTIVITY 34 -0.56 -1.72 0.00 0.01 
ATPASE_ACTIVITY_COUPLED 90 -0.47 -1.73 0.00 0.01 
NUCLEAR_TRANSPORT 85 -0.47 -1.72 0.00 0.01 
POSITIVE_REGULATION_OF_SIG
NAL_TRANSDUCTION 120 -0.45 -1.72 0.00 0.01 
NUCLEOLAR_PART 18 -0.64 -1.72 0.00 0.01 
AMINE_CATABOLIC_PROCESS 27 -0.57 -1.72 0.01 0.01 
RIBONUCLEOTIDE_METABOLIC_
PROCESS 15 -0.67 -1.72 0.01 0.01 
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RAS_GTPASE_BINDING 25 -0.59 -1.72 0.01 0.01 
PHOSPHOINOSITIDE_BIOSYNTH
ETIC_PROCESS 22 -0.61 -1.71 0.00 0.02 
MICROTUBULE_ASSOCIATED_C
OMPLEX 39 -0.53 -1.71 0.00 0.02 
MITOCHONDRIAL_LUMEN 45 -0.53 -1.71 0.00 0.02 
KINASE_BINDING 67 -0.49 -1.71 0.00 0.02 
HYDROLASE_ACTIVITY_ACTING
_ON_CARBON_NITROGEN_NOT_
PEPTIDEBONDS 43 -0.53 -1.71 0.00 0.02 
INORGANIC_CATION_TRANSME
MBRANE_TRANSPORTER_ACTIV
ITY 54 -0.50 -1.71 0.00 0.02 
MACROMOLECULE_CATABOLIC_
PROCESS 125 -0.45 -1.71 0.00 0.02 
SMALL_NUCLEAR_RIBONUCLEO
PROTEIN_COMPLEX 21 -0.61 -1.71 0.01 0.02 
ACETYLGLUCOSAMINYLTRANSF
ERASE_ACTIVITY 16 -0.65 -1.71 0.01 0.02 
REGULATION_OF_CELLULAR_P
ROTEIN_METABOLIC_PROCESS 156 -0.43 -1.70 0.00 0.02 
OXIDOREDUCTASE_ACTIVITY_G
O_0016616 47 -0.51 -1.70 0.00 0.02 
UBIQUITIN_PROTEIN_LIGASE_A
CTIVITY 46 -0.52 -1.70 0.00 0.02 
REGULATION_OF_INTRACELLUL
AR_TRANSPORT 25 -0.58 -1.70 0.01 0.02 
NUCLEAR_ENVELOPE 72 -0.47 -1.70 0.00 0.02 
PROTEIN_AMINO_ACID_O_LINKE
D_GLYCOSYLATION 18 -0.63 -1.70 0.01 0.02 
LYASE_ACTIVITY 53 -0.51 -1.69 0.00 0.02 
NEGATIVE_REGULATION_OF_DE
VELOPMENTAL_PROCESS 189 -0.42 -1.69 0.00 0.02 
CELLULAR_MACROMOLECULE_
CATABOLIC_PROCESS 94 -0.45 -1.69 0.00 0.02 
PORE_COMPLEX 36 -0.54 -1.69 0.00 0.02 
OUTER_MEMBRANE 24 -0.58 -1.69 0.01 0.02 
RAS_PROTEIN_SIGNAL_TRANSD
UCTION 65 -0.48 -1.69 0.00 0.02 
NUCLEOCYTOPLASMIC_TRANSP
ORT 84 -0.46 -1.69 0.00 0.02 
LIPOPROTEIN_BIOSYNTHETIC_P
ROCESS 24 -0.58 -1.69 0.01 0.02 
GENERATION_OF_PRECURSOR
_METABOLITES_AND_ENERGY 111 -0.44 -1.68 0.00 0.02 
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REGULATION_OF_TRANSLATION
AL_INITIATION 30 -0.55 -1.68 0.01 0.02 
SIGNAL_SEQUENCE_BINDING 15 -0.67 -1.68 0.01 0.02 
CHROMOSOME_ORGANIZATION
_AND_BIOGENESIS 119 -0.44 -1.68 0.00 0.02 
PURINE_NUCLEOTIDE_BINDING 197 -0.41 -1.68 0.00 0.02 
PURINE_RIBONUCLEOTIDE_BIN
DING 191 -0.41 -1.68 0.00 0.02 
MICROSOME 32 -0.55 -1.68 0.01 0.02 
ELECTRON_TRANSPORT_GO_00
06118 44 -0.52 -1.68 0.00 0.02 
ORGANELLE_OUTER_MEMBRAN
E 24 -0.58 -1.67 0.01 0.02 
VESICULAR_FRACTION 34 -0.53 -1.67 0.00 0.02 
PROTEIN_HETERODIMERIZATIO
N_ACTIVITY 74 -0.46 -1.67 0.01 0.02 
CARBOXYLIC_ACID_TRANSPOR
T 39 -0.52 -1.67 0.01 0.02 
ER_GOLGI_INTERMEDIATE_COM
PARTMENT 22 -0.58 -1.67 0.01 0.02 
ACTIN_FILAMENT_BINDING 22 -0.59 -1.67 0.01 0.02 
REGULATION_OF_PROTEIN_ME
TABOLIC_PROCESS 165 -0.42 -1.67 0.00 0.02 
RESPONSE_TO_DNA_DAMAGE_
STIMULUS 150 -0.42 -1.66 0.00 0.02 
REGULATION_OF_NUCLEOCYTO
PLASMIC_TRANSPORT 22 -0.59 -1.66 0.01 0.02 
CELLULAR_COMPONENT_DISAS
SEMBLY 33 -0.54 -1.66 0.00 0.02 
PROTEIN_KINASE_BINDING 59 -0.48 -1.66 0.00 0.02 
NUCLEOTIDE_BINDING 209 -0.40 -1.66 0.00 0.02 
SMALL_CONJUGATING_PROTEI
N_LIGASE_ACTIVITY 48 -0.50 -1.66 0.00 0.02 
SMALL_GTPASE_MEDIATED_SIG
NAL_TRANSDUCTION 85 -0.46 -1.66 0.00 0.02 
DNA_DIRECTED_RNA_POLYMER
ASE_COMPLEX 15 -0.64 -1.65 0.01 0.02 
SECONDARY_ACTIVE_TRANSME
MBRANE_TRANSPORTER_ACTIV
ITY 42 -0.51 -1.65 0.00 0.02 
OXIDOREDUCTASE_ACTIVITY_A
CTING_ON_THE_CH_CH_GROUP
_OF_DONORS 20 -0.59 -1.66 0.01 0.02 
CARBOHYDRATE_KINASE_ACTI
VITY 15 -0.64 -1.65 0.01 0.02 
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AMINO_ACID_CATABOLIC_PROC
ESS 25 -0.57 -1.66 0.01 0.02 
GLUCOSE_METABOLIC_PROCES
S 26 -0.55 -1.66 0.00 0.02 
REGULATION_OF_MAP_KINASE_
ACTIVITY 62 -0.47 -1.65 0.00 0.02 
RNA_POLYMERASE_COMPLEX 15 -0.64 -1.65 0.01 0.02 
MEMBRANE_LIPID_METABOLIC_
PROCESS 95 -0.45 -1.65 0.00 0.02 
UBIQUITIN_LIGASE_COMPLEX 26 -0.56 -1.65 0.01 0.02 
RESPONSE_TO_UV 26 -0.56 -1.65 0.01 0.02 
REGULATION_OF_DEVELOPMEN
TAL_PROCESS 415 -0.38 -1.65 0.00 0.02 
REGULATION_OF_CELL_CYCLE 171 -0.41 -1.65 0.00 0.02 
RESPONSE_TO_TEMPERATURE
_STIMULUS 16 -0.63 -1.65 0.02 0.02 
PHOSPHOLIPID_METABOLIC_PR
OCESS 70 -0.46 -1.65 0.00 0.02 
ORGANIC_ACID_TRANSPORT 40 -0.51 -1.65 0.01 0.02 
STEROID_METABOLIC_PROCES
S 58 -0.48 -1.65 0.01 0.02 
NUCLEAR_DNA_DIRECTED_RNA
_POLYMERASE_COMPLEX 15 -0.64 -1.64 0.02 0.02 
INTERPHASE 67 -0.47 -1.64 0.00 0.02 
ENZYME_REGULATOR_ACTIVITY 308 -0.39 -1.64 0.00 0.02 
NUCLEOTIDYLTRANSFERASE_A
CTIVITY 47 -0.49 -1.64 0.00 0.02 
NEGATIVE_REGULATION_OF_G
ROWTH 38 -0.52 -1.64 0.01 0.02 
NUCLEAR_CHROMOSOME 51 -0.49 -1.64 0.00 0.02 
GLYCOPROTEIN_METABOLIC_P
ROCESS 88 -0.44 -1.64 0.00 0.02 
STRUCTURAL_MOLECULE_ACTI
VITY 218 -0.40 -1.64 0.00 0.02 
COFACTOR_BINDING 21 -0.59 -1.63 0.01 0.03 
ENDOSOME 63 -0.47 -1.63 0.01 0.03 
PROTEIN_KINASE_CASCADE 276 -0.39 -1.63 0.00 0.03 
NEGATIVE_REGULATION_OF_CE
LLULAR_PROTEIN_METABOLIC_
PROCESS 44 -0.49 -1.63 0.01 0.03 
PHOSPHOINOSITIDE_METABOLI
C_PROCESS 29 -0.54 -1.63 0.01 0.03 
CELLULAR_LIPID_CATABOLIC_P
ROCESS 31 -0.53 -1.63 0.01 0.03 
DNA_REPAIR 117 -0.42 -1.63 0.00 0.03 
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RIBONUCLEASE_ACTIVITY 19 -0.60 -1.62 0.02 0.03 
SMALL_PROTEIN_CONJUGATIN
G_ENZYME_ACTIVITY 48 -0.48 -1.62 0.01 0.03 
PROTEOGLYCAN_METABOLIC_P
ROCESS 21 -0.58 -1.62 0.02 0.03 
IDENTICAL_PROTEIN_BINDING 290 -0.38 -1.62 0.00 0.03 
CLATHRIN_COATED_VESICLE 36 -0.52 -1.62 0.01 0.03 
REGULATION_OF_ACTION_POT
ENTIAL 17 -0.60 -1.62 0.02 0.03 
CELLULAR_PROTEIN_COMPLEX
_ASSEMBLY 31 -0.54 -1.61 0.01 0.03 
HOMEOSTASIS_OF_NUMBER_O
F_CELLS 19 -0.59 -1.61 0.02 0.03 
DNA_DIRECTED_RNA_POLYMER
ASEII_HOLOENZYME 63 -0.46 -1.61 0.00 0.03 
POSITIVE_REGULATION_OF_CA
TALYTIC_ACTIVITY 155 -0.41 -1.61 0.00 0.03 
ANTIOXIDANT_ACTIVITY 17 -0.60 -1.61 0.02 0.03 
PROTEIN_AMINO_ACID_LIPIDATI
ON 22 -0.57 -1.61 0.02 0.03 
POSITIVE_REGULATION_OF_MA
P_KINASE_ACTIVITY 42 -0.50 -1.61 0.00 0.03 
INTRAMOLECULAR_OXIDOREDU
CTASE_ACTIVITY 18 -0.59 -1.61 0.02 0.03 
REGULATION_OF_PROTEIN_MO
DIFICATION_PROCESS 42 -0.49 -1.60 0.01 0.03 
DNA_REPLICATION 95 -0.43 -1.60 0.00 0.03 
CYTOSKELETON 329 -0.38 -1.60 0.00 0.03 
POSITIVE_REGULATION_OF_TR
ANSFERASE_ACTIVITY 79 -0.44 -1.60 0.00 0.03 
PROTEIN_RNA_COMPLEX_ASSE
MBLY 64 -0.46 -1.60 0.01 0.03 
AEROBIC_RESPIRATION 15 -0.64 -1.60 0.03 0.03 
CELLULAR_CARBOHYDRATE_CA
TABOLIC_PROCESS 22 -0.58 -1.60 0.01 0.03 
REGULATION_OF_PROTEIN_AMI
NO_ACID_PHOSPHORYLATION 29 -0.55 -1.59 0.01 0.03 
INTERPHASE_OF_MITOTIC_CEL
L_CYCLE 61 -0.47 -1.59 0.01 0.03 
OXIDOREDUCTASE_ACTIVITY_A
CTING_ON_CH_OH_GROUP_OF_
DONORS 53 -0.47 -1.59 0.01 0.03 
OXIDOREDUCTASE_ACTIVITY_A
CTING_ON_THE_ALDEHYDE_OR
_OXO_GROUP_OF_DONORS 22 -0.57 -1.59 0.02 0.03 
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CHROMATIN_MODIFICATION 53 -0.47 -1.59 0.01 0.03 
POST_TRANSLATIONAL_PROTEI
N_MODIFICATION 457 -0.37 -1.59 0.00 0.03 
GLYCOPROTEIN_BIOSYNTHETIC
_PROCESS 72 -0.45 -1.59 0.01 0.03 
GLYCEROPHOSPHOLIPID_META
BOLIC_PROCESS 43 -0.49 -1.59 0.01 0.03 
PHOSPHOTRANSFERASE_ACTIV
ITY_ALCOHOL_GROUP_AS_ACC
EPTOR 322 -0.37 -1.59 0.00 0.03 
NUCLEOPLASM 266 -0.38 -1.59 0.00 0.03 
NEGATIVE_REGULATION_OF_PR
OTEIN_METABOLIC_PROCESS 46 -0.48 -1.58 0.01 0.04 
PHOSPHORYLATION 297 -0.37 -1.58 0.00 0.04 
REGULATION_OF_CATALYTIC_A
CTIVITY 260 -0.38 -1.58 0.00 0.04 
COFACTOR_METABOLIC_PROC
ESS 51 -0.47 -1.58 0.01 0.04 
METHYLTRANSFERASE_ACTIVIT
Y 35 -0.51 -1.58 0.01 0.04 
CELL_CYCLE_GO_0007049 298 -0.37 -1.58 0.00 0.04 
DRUG_BINDING 16 -0.61 -1.57 0.02 0.04 
DNA_CATABOLIC_PROCESS 23 -0.56 -1.57 0.02 0.04 
HISTONE_MODIFICATION 22 -0.56 -1.58 0.03 0.04 
TRANSCRIPTION_FACTOR_BINDI
NG 292 -0.37 -1.57 0.00 0.04 
MITOTIC_CELL_CYCLE 151 -0.40 -1.57 0.00 0.04 
LEADING_EDGE 47 -0.47 -1.57 0.01 0.04 
REGULATION_OF_MOLECULAR_
FUNCTION 306 -0.37 -1.57 0.00 0.04 
PROTEIN_N_TERMINUS_BINDIN
G 36 -0.50 -1.57 0.02 0.04 
HYDROGEN_ION_TRANSMEMBR
ANE_TRANSPORTER_ACTIVITY 23 -0.55 -1.57 0.03 0.04 
RESPONSE_TO_HORMONE_STI
MULUS 30 -0.52 -1.57 0.01 0.04 
MITOCHONDRIAL_OUTER_MEMB
RANE 18 -0.58 -1.57 0.03 0.04 
CELL_CYCLE_PHASE 165 -0.39 -1.57 0.00 0.04 
ESTABLISHMENT_AND_OR_MAI
NTENANCE_OF_CHROMATIN_AR
CHITECTURE 74 -0.43 -1.56 0.00 0.04 
ACTIVE_TRANSMEMBRANE_TRA
NSPORTER_ACTIVITY 115 -0.40 -1.56 0.01 0.04 
BIOPOLYMER_CATABOLIC_PRO 106 -0.41 -1.56 0.01 0.04 
	  	   200	  
CESS 
REGULATION_OF_PROTEIN_IMP
ORT_INTO_NUCLEUS 16 -0.60 -1.56 0.04 0.04 
REGULATION_OF_CELLULAR_C
OMPONENT_ORGANIZATION_AN
D_BIOGENESIS 120 -0.41 -1.56 0.00 0.04 
SPLICEOSOME 49 -0.47 -1.56 0.01 0.04 
MONOVALENT_INORGANIC_CAT
ION_TRANSMEMBRANE_TRANS
PORTER_ACTIVITY 30 -0.51 -1.56 0.02 0.04 
POSITIVE_REGULATION_OF_PH
OSPHATE_METABOLIC_PROCES
S 26 -0.53 -1.56 0.03 0.04 
CHROMOSOME 119 -0.41 -1.55 0.01 0.04 
CARBOHYDRATE_CATABOLIC_P
ROCESS 23 -0.55 -1.55 0.02 0.04 
TRANSITION_METAL_ION_BINDI
NG 96 -0.42 -1.55 0.01 0.04 
ADENYL_NUCLEOTIDE_BINDING 158 -0.39 -1.55 0.00 0.04 
TRANSFERASE_ACTIVITY_TRAN
SFERRING_GLYCOSYL_GROUPS 105 -0.41 -1.55 0.00 0.04 
ONE_CARBON_COMPOUND_ME
TABOLIC_PROCESS 26 -0.53 -1.55 0.03 0.04 
CELL_STRUCTURE_DISASSEMB
LY_DURING_APOPTOSIS 18 -0.58 -1.55 0.03 0.04 
RECEPTOR_MEDIATED_ENDOC
YTOSIS 32 -0.51 -1.55 0.02 0.04 
PHOSPHORIC_MONOESTER_HY
DROLASE_ACTIVITY 110 -0.41 -1.55 0.01 0.04 
PERINUCLEAR_REGION_OF_CY
TOPLASM 50 -0.47 -1.55 0.02 0.04 
REGULATION_OF_PROTEIN_KIN
ASE_ACTIVITY 143 -0.39 -1.55 0.00 0.04 
NUCLEOPLASM_PART 203 -0.39 -1.54 0.00 0.04 
REGULATION_OF_SIGNAL_TRAN
SDUCTION 211 -0.37 -1.54 0.00 0.04 
ADENYL_RIBONUCLEOTIDE_BIN
DING 152 -0.39 -1.54 0.00 0.05 
FATTY_ACID_METABOLIC_PROC
ESS 52 -0.46 -1.54 0.02 0.05 
PEROXISOME 45 -0.46 -1.54 0.02 0.05 
REGULATION_OF_CELL_GROWT
H 44 -0.47 -1.54 0.01 0.05 
LIPID_CATABOLIC_PROCESS 34 -0.50 -1.54 0.02 0.05 
INDUCTION_OF_APOPTOSIS_BY
_EXTRACELLULAR_SIGNALS 27 -0.53 -1.53 0.04 0.05 
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CHROMATIN 35 -0.49 -1.53 0.02 0.05 
AMINO_ACID_TRANSPORT 26 -0.51 -1.53 0.03 0.05 
SECRETORY_PATHWAY 82 -0.42 -1.53 0.01 0.05 
ATP_BINDING 145 -0.39 -1.53 0.00 0.05 
PEPTIDYL_AMINO_ACID_MODIFI
CATION 60 -0.44 -1.53 0.01 0.05 
RESPONSE_TO_DRUG 19 -0.55 -1.53 0.04 0.05 
ACTIN_FILAMENT_BASED_PROC
ESS 111 -0.41 -1.53 0.01 0.05 
MICROBODY 45 -0.46 -1.52 0.02 0.05 
      
      
NAME SIZE ES NES NOM p-val FDR q-val 
CYTOKINE_ACTIVITY 93 0.51 2.15 0.00 0.00 
CHEMOKINE_RECEPTOR_BINDI
NG 32 0.65 2.16 0.00 0.00 
CHEMOKINE_ACTIVITY 31 0.66 2.18 0.00 0.00 
G_PROTEIN_COUPLED_RECEPT
OR_BINDING 43 0.56 2.05 0.00 0.01 
HEMATOPOIETIN_INTERFERON_
CLASSD200_DOMAIN_CYTOKINE
_RECEPTOR_BINDING 23 0.60 1.87 0.01 0.04 
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Transcription Factors Differentially Expressed in Lung and Lung Stem Cells 
 
 
Statistical and Bioinformatics Analysis was performed by the Center for 
Computational Cancer Biology (CCCB) at Dana-Farber Cancer Institute. 
Array quality was assessed using the R/Bioconductor package (Gentleman et al., 
2004). All arrays passed visual inspection and no technical outliers were identified. Raw 
CEL files were processed using the robust multiarray average (RMA) algorithm (Irizarry 
et al., 2003). To identify genes correlating with the phenotypic groups, we used limma 
(Smyth, 2004) to fit a statistical linear model to the data and then tested for differential 
gene expression in the contrasts of interest. Results were adjusted for multiple testing 
using the Benjamini and Hochberg (BH) method (Benjamini and Hochberg, 1995), and 
significance was determined using a False-Discovery-Rate cutoff of less than 5%.  
First, transcription factors were found from the differentially expressed gene lists. 
Then, separate transcription factor analyses were performed by first filtering the 
normalized expression values based on GO annotations (Ashburner et al., 2000) to 
include only genes belonging to that particular class.  A statistical linear model was then 
fit to the filtered dataset and then tested for differential gene expression in the contrasts 
of interest. 
Next, quantitative real-time PCR was performed in wildtype lung samples of 
Sca1+ (BASC-enriched) and Sca1- (AT2 cell-enriched) cells, or in wildtype Sca1-low 
(BASC-enriched) and Sca1-high (mesenchymal-enriched) populations. Whole lung or 
CD31-CD45- (epithelial-enriched) cells served as controls. qPCR results shown are 
those that verified the array findings. 
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The following array comparisons from our lab’s generated datasets were performed: 
o WT lung Sca1+ high vs Sca1+ low   
o WT lung Sca1+ vs Sca1-     
o WT lung Sca1low vs Sca1- 
o Kras;p53-flox Sca1+ vs Kras;p53-flox Sca1-  
 
The following array comparisons from published datasets were performed: 
o Mouse adult lung vs other adult tissues   
o Mouse adult lung vs embryonic lung (E13.5)   
o Human fetal lung vs other fetal tissues    
o Human adult lung vs other adult tissues   
o Human adult lung vs fetal lung    
 
Mouse embryonic lung (E 13.5) (Naxerova et al., 2008): GSE11539 
Mouse adult lung and other adult tissues (Thorrez et al., 2008):  GSE9954  
Human adult lung and other adult tissues, human fetal lung and other fetal tissues (Su 
et al., 2004): GSE1133  
 
Table A9: Transcription factors up in lung vs. other organs 
Gene Name Arrays Literature  
Dmtf1 
up in human adult lung vs 
other 
deleted in NSCLCs, Myb-like, tumor 
suppressor, activation of Arf by Ras/Raf 
signaling is indirectly mediated by Dmp1, 
macrophage differentiation 
Pa2g4 (Ebp1) 
up in WT Sca1low vs neg, up 
in mouse adult lung vs other 
enriched in lung  branching regions- distal 
lung mesenchyme 
Pou2f2 (Oct2) up in human fetal lung vs other lineage specificity of B cells 
Six6 up in human fetal lung vs other 
expressed in embryonic lung nuclear 
extracts 	  	  
Table A10: Transcription factors up epithelial lung cells vs BASCs 
Gene Name Arrays Literature  
Etv5 (Erm) up in wt Sca1 neg, Kras;p53 
Sca1 neg 
Expressed in spermatogonial stem cells, 
Lung AT1 and AT2 cell differentiation 
Pbx2 up in wt Sca1 neg, Kras;p53 
Sca1 neg 
 
Pre B-cell leukemia TF2, forms 
transcription complex in myeloid cells- 
lineage differentiation, Up in lung cancer 
Usf2 up in wt Sca1 neg, Kras;p53 
Sca1 neg 
Induces SP-A expression in development, 
Up in lung squamous cell carcinoma 
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Table A11: Transcription factors up in BASC populations vs. other lung 
populations 
Gene Name Arrays Literature  
Cbx2 (M33) 
up in WT Sca1low vs neg, 
down in WT Sca1high vs low 
In PRC1 complex with Bmi1, Polycomb 
gene (PRC1 complex), expansion of T 
and B cell precursors 
Hopx (Hop) 
up in WT Sca1low vs neg, 
down in WT Sca1high vs low 
Acts downstream of Ttf-1, negatively 
regulates surfactant production. Loss of 
hopx causes defective AT2 
development, increased surfactant, 
disrupted alveolar formation 
Myb 
up in Sca1 low, Kras;p53 Sca1 
pos 
Promotes proliferation and inhibits 
differentiation in hematopoietic stem and 
progenitor cells, regulates colon and 
neural stem cells, colon and breast 
cancer, Up in lung adenocarcinoma 
Nfe2l3 (Nrf3) 
up in WT Sca1low vs neg, 
down in WT Sca1high vs low 
Role in placental gene expression and 
development, Reactive oxygen species 
balancing and in muscle precursor 
migration during early embryo 
development, Role in SMC differentiation 
from stem cells toward vascular lineage 
Six4 
up in WT Sca1low vs neg, 
down in WT Sca1high vs low 
Differentiation of neuronal, retinal cells. 
Also in tooth mammary, uterine buds, 
limb buds 
Sox2 
Up in Kras;p53 Sca1pos vs 
neg, Down in Wt Sca1 high vs 
low,  
Sox21 
up in Sca1 low, Wt Sca1 pos, 
Kras;p53 Sca1 pos 
Expressed in hair follicle progenitors 
neural stem and progenitor cells, 
overlapping expression/ counteracts 
Sox2, Expressed in lung neuroendocrine 
cells, Antibodies expressed in SCLC, 
squamous cell carcinoma 
Tbx5 
up in WT Sca1low vs neg, 
down in WT Sca1high vs low 
lung mesenchyme, induces 
mesenchymal Fgf10- production of 
branching signals, target of Hif1a, 
upregulated by Nkx2.5, forelimb bud 
formation, cardiac morphogenesis 	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Table A12: Additional transcription factors found using separate linear model 
Gene Name Arrays Literature  
Erg 
Up in WT Sca1 pos vs neg, 
WT Sca1 low vs neg, down 
in WT Sca1 high vs low 
ETS family, expressed in lung- 
antiinflammatory effects, 
overexpressed in lung tumors, 
regulator of differentiation of early 
hematopoietic cells, required for the 
differentiation of embryonic stem cells 
along the endothelial lineage, 
requirement in normal HSC and 
megakaryocyte homeostasis 
Glis 3 
Up in Kras;p53 Sca1pos vs 
neg, Down in Wt Sca1 high 
vs low,  
Plays a role in cell lineage 
specification, particularly in the 
development of pancreatic beta cells, 
also regulates insulin gene expression 
Hey1 
Up in Kras;p53 Sca1 pos vs 
neg, WT Sca1 low vs Sca1 
neg, Down in WT Sca1 high 
vs low 
Inhibits myogenesis, Notch mediator, 
enriched in lung endothelial cells, 
highly expressed in lung cancer cell 
lines 
Klf7 
Up in Kras;p53 Sca1pos vs 
neg, WT Sca1 pos vs neg, 
WT Sca1 low vs Sca1 neg 
Regulates differentiation of 
neuroectodermal and mesodermal cell 
lineages, mice without Klf7 die at birth 
and display hypoplastic olfactory bulbs 
which lack peripheral innervation, 
iportant for neuronal morphogenesis, 
required for TrkA gene expression 
Prrx1 
Up in Kras;p53 Sca1pos vs 
neg, WT Sca1 pos vs neg, 
WT Sca1 low vs Sca1 neg 
Required for pulmonary vascular 
development, localizes to 
differentiating endothelial cells (ECs) 
within the fetal lung mesenchyme 
Purb  
Up in Kras;p53 Sca1 pos vs 
neg, WT SCa1 low vs Sca1 
neg, Down in WT Sca1 high 
vs low 
Represses smooth muscle alpha-actin 
gene transcription 
Runx1 
Up in Kras;p53 Sca1 pos vs 
neg, WT SCa1 low vs Sca1 
neg, Down in WT Sca1 high 
vs low Hematopoetic transcription factor 
Sox18 
Up in Kras;p53 Sca1 pos vs 
neg, WT SCa1 low vs Sca1 
neg, Down in WT Sca1 high 
vs low 
Very abundant in lung tissue, key 
regulator of murine and human blood 
vessel formation, directly targets and 
trans-activates VCAM-1 expression, 
expression led to the enhanced 
proliferation of early hematopoietic 
precursors while blocking their 
maturation 
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Tbx1 
Up in Kras;p53 Sca1pos vs 
neg, Down in Wt Sca1 high 
vs low,  
Regulates proliferation and 
differentiation of multipotent heart 
progenitors, regulates Vegfr3 and is 
required for lymphatic vessel 
development, expressed in the 
developing lung epithelium 
Tcerg1 
Up in Kras;p53 Sca1 pos vs 
neg, WT SCa1 low vs Sca1 
neg, Down in WT Sca1 high 
vs low   
Tead2 (Etf) 
Up in WT Sca1 pos vs neg, 
WT Sca1 low vs neg, down 
in WT Sca1 high vs low 
Enriched in lung during development 
and adult, YAP/Hippo pathway, neural 
tube closure, regulates Pax3 
Ttf-1 (Nkx2-
1) 
Down in Kras;p53 Sca1pos 
vs neg 
Regulates differentiation of lung 
epithelial cells during development, lost 
in lung adenocarcinoma metastasis 
Zeb1 
Up in Kp53 pos vs neg, Up in 
WT Sca1pos vs neg,  
EMT regulator (repressses Ecad), 
Knockdown suppresses anchorage-
independent growth of lung cancer cell 
lines, associated with poor prognosis 
and EGFR resistance in lung cancer, 
promotes metastasis 
Zfp423 
Up in WT Sca1 pos vs neg, 
WT Sca1 low vs neg, down 
in WT Sca1 high vs low 
Transcriptional regulator of 
preadipocyte determination, 
deregulated expression contributes to 
CML, required for normal cerebellar 
development, controls proliferation and 
differentiation of neural precursors in 
cerebellar vermis formation 	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Figure A-1: Expression of Transcription Factors in BASCs and AT2 cells. A. 
Quantitative real-time PCR analysis of relative Etv5 mRNA levels in whole lung cells, 
lung epithelial cells (CD31-CD45-), BASCs (CD31-CD45-Sca1+), or AT2 cells (CD31-
CD45-Sca1-). Each set (1-2) represents samples from a separate sort and mouse.  B. 
Quantitative real-time PCR analysis of relative Ttf-1 mRNA levels in lung epithelial cells 
(CD31-CD45-), BASCs (CD31-CD45-Sca1+), or AT2 cells (CD31-CD45-Sca1-). Each 
set (1-2) represents samples from a separate sort and mouse.  C. Quantitative real-time 
PCR analysis of relative Sox21 mRNA levels in whole lung cells, lung epithelial cells 
(CD31-CD45-), BASCs (CD31-CD45-Sca1+), or AT2 cells (CD31-CD45-Sca1-). D. 
Quantitative real-time PCR analysis of relative Sox2 mRNA levels in whole lung cells, 
lung epithelial cells (CD31-CD45-), BASCs (CD31-CD45-Sca1+), or AT2 cells (CD31-
CD45-Sca1-). Each set (1-2) represents samples from a separate sort and mouse.  E. 
Quantitative real-time PCR analysis of relative Six4 mRNA levels in whole lung cells or 
BASCs (CD31-CD45-Sca1low), or mesenchymal cells (CD31-CD45-Sca1high). Each set 
(1-3) represents samples from a separate mouse.  F. Quantitative real-time PCR 
analysis of relative Myb mRNA levels in whole lung cells, BASCs (CD31-CD45-Sca1low), 
or mesenchymal cells (CD31-CD45-Sca1high). Each set (1-3) represents samples from a 
separate mouse.  Error bars represent the standard deviation of the mean. 
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Figure A-1: (continued)	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Testing of CCSP and SPC knock-in mice for lineage tracing 
 Two mice strains were created with the intent to be able to do lineage tracing of 
the BASC population. The first strain uses tamoxifen-inducible Flp recombinase (Flp-
ER) to restricted to Clara cells and BASCs: the “CKI 1” strain contrains a FlpER- IRES-
GFP allele knocked in to the endogenous CCSP locus. For the strain named “CKI 2,” a 
Frt-Stop-Frt-Cre-ERT2-IRES-mCherry cassette was knocked in to the endogenous SPC 
locus, a BASC-specific component when used in combination with CCSP-FlpER. In 
mice containing both CKI 1 and CKI 2 alleles (CCSP-FlpER-IRES-GFP; SPC-Frt-Stop-
Frt-CreER-IRES-mCherry mice), only SPC-expressing cells will transcribe Cre-ERT2 
after Flp-mediated recombination. This would enable spatial (BASC-specific) and 
temporal (in adult vs. all of development) regulation of Cre expression.  
 In CKI 1 mice, qPCR analysis showed that knock-in mice had expression of Flp 
and reduced expression levels of CCSP as expected (qPCR was performed by Dave 
Raiser). However, after many experiments testing several doses or methods (IP 
injection or oral gavage) of tamoxifen delivery, both tissue staining and FACS 
experiments failed to show expression of Flp dependent fluorescent reporters. This 
indicated that the CKI 1 mice were not functioning as expected. In CKI2 mice, 1 
experiment was done to test the leakiness of the SPC-FSF-CreER by giving CKI2; LSL-
YFP mice (with no Flip driver) tamoxifen by IP injection. YFP expression was not 
detected. A final set of experiments was done combining both CKI 1 and CKI 2 alleles 
along with Kras and LSL-YFP. YFP expression was not detected in these mice 3-4 
months after IP tamoxifen injection, and no tumors were formed, indicating that one or 
both knock-in alleles was not functioning properly. CKI2 mice were then further tested 
by Kristen Leeman using B-actin Flp mice and AdFlpO virus. 
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Figure A-2: Diagrams of knock-in mice and reporters tested. A. CKI 1: CCSP-
FlpER- IRES-GFP. B. CKI 2: SPC-Frt-Stop-Frt -CreER- IRES-mCherry. C. Fela: 
Rosa26-Frt-Stop-Frt-LoxP-GFP-Stop-LoxP-βGal D. Frepe: Rosa26-Frt-Stop-Frt-LoxP- 
mCherry-Stop-LoxP-GFP
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Figure A-2: (continued) 
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Figure A-3: Testing CKI 1 mice. A. Quantitative real-time PCR analysis of relative Flp 
mRNA levels in CKI1 mice compared to non-CKI 1littermate controls. Error bars 
represent the standard deviation of the mean. B. Quantitative real-time PCR analysis of 
relative CCSP mRNA levels in CKI1 mice compared to non-CKI 1 littermate controls. 
Error bars represent the standard deviation of the mean. C.-E. Immunofluorescent 
staining for CCSP (red) and YFP/GFP (green) in lung slides from C. wildtype 129 mice 
(negative control) D. CC10Cre-ER; LSL-YFP mice (positive control) E. tamoxifen-
treated CKI 1.1; Fela mice F.-H. Representative FACS analysis for GFP expression in 
CD31-CD45- lung cells from F. wildtype 129 mice (negative control)  G. B-actin-GFP 
mice (positive control) H. tamoxifen-treated CKI 1.1; Fela mice I. Table showing 
tamoxifen doses, delivery method and reporter mice tested.
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Figure A-3: (continued) 
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Figure A-4: Testing CKI1 and CKI2 mice. A.-E. FACS analysis of YFP expression in 
CD31-CD45- EpCAM+ lung cells from A. untreated CKI2 mice (negative control) B. 
untreated CKI2; LSL-YFP mice (negative control) C. untreaed B-actin-Flp; CKI2; LSL-
YFP mice (negative control) D. tamoxifen treated CKI2 mice (negative control for YFP) 
E. tamoxifen treated CKI2; LSL-YFP mice. Results are from one experiment. F.-H. 
FACS analysis of YFP expression in CD31-CD45- EpCAM+ lung cells from F. CC10-
CreER; LSL-YFP mice (positive control) G. corn oil-treated CKI; CKI2; Kras; LSL-YFP 
mice (negative control) H. tamoxifen treated CKI; CKI2; Kras; LSL-YFP mice. Results 
are representative from two experiments.
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Figure A-4: (continued) 
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